











This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
• This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
• A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
• This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
• The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
• When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given. 
 
 
The regulation of endometrial 
regeneration; mechanisms contributing to 
repair and restoration of tissue integrity 
following menses 
 




Medical Research Council 
Centre for Reproductive Health 
The Queen’s Medical Research Institute 
47 Little France Crescent 
Edinburgh, EH16 4TJ 
 
Thesis submitted to the University of Edinburgh for the 





This thesis was composed by the author and the studies presented in this thesis were the 
unaided work of the author, except where acknowledgement is made by reference. The work 












I cannot have had a better supervisor than Professor Philippa Saunders, and I can’t thank you 
enough for your support, patience, guidance and most of all your endless enthusiasm for my 
PhD project, especially on those occasions when I had none. Thank you for giving me the 
opportunity to be part of such a great team. Thank you to my second supervisor Professor 
Hilary Critchley for your input and encouragement over the last three years. 
A big part of my PhD was spent in the Animal House and my time there was made easier by 
the presence of Alison Murray. I will forever be indebted to you, not only for teaching me all 
I’ll ever need to know about mice, but for being a constant source of encouragement and 
enthusiasm when things didn’t go quite right, in and outside of work. Thank you for picking 
me up and keeping me going. 
The Saunders Lab group are a fantastic group of people to be around on a daily basis; 
Frances Collins, Arantza Esnal, James Martin, Erin Greaves, Douglas Gibson and Yannis 
Simitsidellis, I thank each and every one of you for all your support over the last three years 
whether it be technical support, scientific input or just providing me with a bank of great 
memories.  
I would like to acknowledge the technical help of Forbes Howie, as well as Mike Millar who 
carried out the automated immunohistochemistry. Thank you to Jessica Scanlon who carried 
out qRTPCR for some of the candidate genes. Thank you to all the staff in the animal unit. 
To the other PhD students/postdocs/staff that have been part of the CRH during my time 
here, thanks for being a supportive and understanding group! To the girls who started with 
me; Karen Kilcoyne, Fiona Connolly and Lorraine Frew, thank you for the laughs and most 
of all the fun away from the lab. A big thank you goes to my officemates, Karen and Doug, 
without you two my PhD would have been a hell of a lot harder. Thank you for everything, 
your support and friendship has been incredible. 
I’d like to thank my family for their continued support; they might not have always 
understood what it was I did or why my moods were almost always governed by how well 
my science was going, but they dealt with my ups and downs as best as they could. Thank 
you to the Inverleith HC Ladies 1s for giving me a reason to leave the lab and for all the fun 
and laughter over the years. Finally, to the girls; Savannah, Katie, Kat, Lyn, Laura, Moira 
and Mhairi who have been behind me every step of the way, pushing me towards the end 
point, I can’t thank you enough for everything you have done for me.  
I would like to dedicate this thesis to the memory of Dr. Sarju Patel, who sadly passed away 
before I even began my PhD. Whilst I was still an undergraduate, Sarj told me I should do a 
PhD as it would be the best thing I would ever do. Perhaps, in time, I might just agree with 





The human endometrium is a dynamic, multi-cellular tissue that lines the inside of the 
uterine cavity. During a woman’s reproductive lifespan the endometrium is subjected to 
cyclical episodes of proliferation, angiogenesis, differentiation/decidualisation, shedding 
(menstruation), repair and regeneration in response to fluctuating levels of oestrogen and 
progesterone secreted by the ovaries. The endometrium displays unparalleled, tightly 
regulated, tissue remodelling resulting in a healed, scar-free tissue following menses or 
parturition. Mechanisms responsible for initiation of menses have been well documented: 
following progesterone withdrawal there is an increase in inflammatory mediators, focal 
hypoxia and induction and activation of matrix-degrading enzymes. In contrast, the 
molecular and cellular changes responsible for rapid, regulated, tissue repair at a time when 
oestrogen and progesterone are low are poorly understood.  
Histological studies using human menstrual phase endometrium have revealed that tissue 
destruction and shedding occur in close proximity to re-epithelialisation/repair. It has been 
proposed that re-epithelialisation involves proliferation of glandular epithelial cells in the 
remaining basal compartment; there is also evidence for a contribution from the underlying 
stroma. A role for androgens in the regulation of apoptosis of endometrial stromal cells has 
been proposed but the impact of androgens on tissue repair has not been investigated. Studies 
using human xenografts and primates have been used to model some aspects of the impact of 
progesterone withdrawal but simultaneous shedding (menses) and repair have not been 
modelled in mice; the species of choice for translational biomedical research.  
In the course of the studies described in this thesis, the following aims have been addressed:  
1. To establish a model of menses in the mouse which mimics menses in women, 
namely; simultaneous breakdown and repair, overt menstruation, immune cell 
influx, tissue necrosis and re-epithelialisation. 
2. To use this model to determine if the stromal cell compartment contributes to 
endometrial repair.  
3. To examine the impact of androgens on the regulation of menses (shedding) and 
repair. 
An informative mouse model of endometrial breakdown that was characterised by overt 
menses, as well as rapid repair, was developed. Immunohistological evidence for extensive 
tissue remodelling including active angiogenesis, transient hypoxia, epithelial cell-specific 




during an “early window of breakdown and repair” (4 to 24 hours after progesterone 
withdrawal). Novel data included identification of stromal cells that expressed epithelial cell 
markers, close to the luminal surface following endometrial shedding, suggesting a role for 
mesenchymal to epithelial transition (MET) in re-epithelialisation of the endometrium. In 
support of this idea, array and qRTPCR analyses revealed dynamic changes in expression of 
mRNAs encoded by genes known to be involved in MET during the window of breakdown 
and repair. Roles for hypoxia and tissue-resident macrophages in breakdown and tissue 
remodelling were identified.  
Treatment of mice with dihydrotestosterone to mimic concentrations of androgens circulated 
in women at the time of menses had an impact on the timing and duration of endometrial 
breakdown. Array analysis revealed altered expression of genes implicated in MET and 
angiogenesis/inflammation highlighting a potential, previously unrecognised role for 
androgens in regulation of tissue turnover during menstruation.  
In summary, using a newly refined mouse model new insights were obtained, implicating 
androgens and stromal MET in restoration of endometrial tissue homeostasis during 
menstruation. These findings may inform development of new treatments for disorders 
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Chapter 1 Literature Review 
1.1 Neonatal and postnatal development of the female 
reproductive tract 
The foundations of the human reproductive tract are laid down between the third and eighth 
weeks of gestation, at a time when the embryo undergoes a dramatic transformation from a 
flat plate of cells to recognisable human structures, including; arms, legs and a face.  
Humans have a simple uterus, consisting of a single uterine cavity, formed from the fusion of 
the basement membranes of the two Müllerian ducts during Carnegie stages 22-23 
(approximately 8 weeks of gestation) (1–3). The uterus then grows intensively between 
weeks 16 and 24 of gestation (4), where the mesenchyme differentiates into the endometrial 
stroma and the myometrium by week 22 of gestation. Superficial glands differentiate from 
the simple, columnar, luminal epithelium to primordial, glandular epithelial buds (1). 
Proliferation of cells in the endometrial glands is initiated after birth and continues until the 
onset of puberty, glands extend from the luminal epithelium towards the myometrium (5–7).  
In both male and female embryos the primordial germ cells migrate to the genital ridge 
before populating the developing gonads around 5 and 6 weeks of gestation (8–12). Sexual 
differentiation occurs around week 7 (8, 13–15) and thereafter ovarian development is 
characterised by germ cell proliferation and differentiation into clusters of oocytes, a process 
which continues until the 22
nd
 week of gestation where the oocytes enter meiotic arrest (16–
20).  
1.2 Hypothalamic-pituitary-ovarian axis 
The female reproductive system is tightly regulated by the hypothalamic pituitary ovarian 
(HPO) axis.  The HPO axis is usually characterised by a linearly organised set of endocrine 
regulated tissues with a hierarchy, composed of; a subset of hypothalamic neurons, that 
express the peptide gonadotrophin releasing hormone (GnRH) (21–23), gonadotrope cells of 
the anterior pituitary and the ovary (composed of two endocrine structures, the follicular 
complex and the corpus luteum) (24) as depicted in Figure 1-1. Activation of this system 
commences during puberty, independent of gonadal input (25, 26) and is associated with the 
onset of pulsatile secretion of GnRH from the hypothalamus. GnRH binds to GnRH 
receptors (GnRHRs) on the surface of the gonadotropes (27, 28) in the pituitary, triggering 
the synthesis and secretion of the gonadotrophins, follicle stimulating hormone (FSH) and 
luteinising hormone (LH).  LH and FSH act on the ovary to stimulate the synthesis of the 
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steroid hormones oestrogens, progestagens and androgens; this will be discussed further in 
section 1.3.  
 
Figure 1-1: Hypothalamic pituitary ovarian axis. The HPO axis is an integrated set of endocrine 
regulated tissues governed by positive and negative feedback loops. Gonadotrophin releasing 
hormone (GnRH) stimulates the pituitary to secrete luteinising hormone (LH) and follicle stimulating 
hormone (FSH) which act on the ovary to drive steroid hormone synthesis.  Adapted from (29).  
GnRH pulsatility varies across the menstrual cycle (30–32). Pulse frequencies regulate 
gonadotrophin release from the pituitary, a process which is critical for the controlled 
generation of an LH surge ensuring correct timing of ovulation (33, 34).  
The HPO axis is governed by both positive and negative feedback regulatory loops (35–38). 
In the female, the effects of the gonadal steroids are dependent upon the stage of the 
menstrual cycle. Oestrogens exert both negative and positive effects on the hypothalamus. 
Animal studies, using ovariectomised mice, have indicated that oestrogens are able to 
suppress the release of gonadotrophin releasing hormone (GnRH) from the hypothalamus 
during the follicular phase of the menstrual cycle (39). However, studies in ovariectomised 
pigs show that, during the pre-ovulatory phase oestrogens exert a positive effect on both the 
hypothalamus and the pituitary (34, 40). 
The increase in circulating concentrations of oestrogen levels during the late follicular 
phases, associated with growth of antral follicles (41), positively stimulates increased 
secretion of GnRH from the hypothalamus and increased LH secretion from the pituitary 
(42). Following ovulation, progesterone is released by the corpus luteum which negatively 
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regulates the HPO axis at all levels. Following the demise of the corpus luteum, oestrogen 
and progesterone concentrations fall and negative feedback of FSH is removed (reviewed in 
(43)). 
1.3 Ovarian steroid biosynthesis  
Sex steroids play a key role in the growth and differentiation of the human endometrium. In 
women, circulating steroids are derived from the ovary and the adrenal gland. In 1974, 
Abraham demonstrated that ovarian activity was responsible for fluctuations in the 
circulating concentrations of oestrogen and progesterone during the normal menstrual cycle 
(44). Blood plasma concentrations of FSH, LH, oestradiol, progesterone and testosterone 
fluctuate across the menstrual cycle and are known to vary between women, therefore mean 
serum concentrations are shown in Table 1-1.  
 
Table 1-1: Mean serum concentrations (±SEM) of gonadotrophins luteinising hormone (LH) and 
follicle stimulating hormone (FSH) and the steroid hormones oestradiol (E2), progesterone (P), 
testosterone (T) and androstenedione (A).  Steroid hormone concentrations are shown in picograms 
per millilitre (pg/ml), n=12. Adapted from (45). 
The ovary is composed of two endocrine structures; the follicular complex and the corpus 
luteum (24). The ovary serves two functions; oogenesis and steroidogenesis. The cellular 
components of the follicular complex drive steroid hormone production that feeds back to 
the hypothalamus and pituitary whilst also driving local follicle maturation (46). 
The gonadotrophins LH and FSH act on the ovary to stimulate synthesis of the steroid 
hormones, the most important of which are; testosterone (T), oestradiol (E2) and 
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progesterone (P4). These steroid hormones are synthesised de novo from free cholesterol 
(reviewed in (47, 48)), which is transported from the liver (49) via the blood to the cytosol of 
thecal cells in the ovary. Biosynthesis of oestrogen and progesterone requires an enzyme 
cascade with proteins expressed in both theca and granulosa cells (50, 51), this “two-cell, 
two-gonadotrophin” model is depicted in Figure 1-2.  
 
Figure 1-2: Two-cell, two-gonadotrophin model.  Steroid hormones testosterone, progesterone and 
oestradiol are synthesised from cholesterol, via side chain cleavage of cholesterol by CYP11A1 to 
pregnenolone. Steroid dehydrogenase enzyme activity converts pregnenolone to androstenediol or 
progesterone. Androstenedione crosses the basement membrane into granulosa cells where it is 
converted to oestradiol by aromatase (CYP19).  CYP11A1; cholesterol side chain cleavage 
cytochrome P450, CYP17; 17α hydroxylase/C17-20 lyase cytochrome P450, CYP19; aromatase, 
17βHSD; 17β hydroxysteroid dehydrogenase, 3βHSD; 3β hydroxysteroid dehydrogenase, cAMP; 
adenosine 3’,5’-cyclic monophosphate, PKA; protein kinase A, FSH; follicle stimulating hormone, 
FSHR; follicle stimulating hormone receptor, LH; luteinising hormone, LHR; luteinising hormone 
receptor. Adapted from (52, 53). 
In brief, LH stimulates biosynthesis of androgens in the theca cells of developing follicles. 
Binding of LH to a membrane bound G protein coupled receptor (GPCR), LHR, stimulates a 
second message cascade involving cyclic adenosine monophosphate (cAMP) (54), which in 
turn stimulates transcription of the CYP11A gene. The CYP11a enzyme acts by side chain 
cleavage, to convert cholesterol to pregnenolone (55). Androstenediol is synthesised by 
multiple intermediates under the control of 17α hydroxylase (CYP17, encoded by the gene 
CYP17A1) and 17β hydroxysteroid dehydrogenase (17βHSD) (56, 57).  
FSH binds to the FSHR (58), which like LHR is also a membrane bound GPCR, on 
granulosa cells of secondary follicles to initiate a signalling cascade involving cAMP to 
stimulate aromatase (CYP19) expression (59). CYP19 aromatises theca cell-produced 
androstenedione, which has crossed the basement membrane (60), to oestradiol. Oestradiol is 
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then released into the blood stream to act in an endocrine manner on the endometrium and 
other oestrogen-target tissues.  
Oestrogen is the primary hormone synthesised in the ovary during the follicular phase of the 
cycle, however the pre-ovulatory surge of LH and FSH drives theca and granulosa cell 
differentiation to form the corpus luteum (61). The first observation of corpora lutea was in 
the mid-1600s, however the importance of the corpus luteum and its function as an endocrine 
gland was not confirmed until 1903 by Fraenkel (62) who observed that removal of the 
corpora lutea resulted in embryo resorption in rabbits.  
Corpus lutea formation alters the steroidogenic pathway so that progesterone, not androgens, 
becomes the main steroid hormone produced by these cells during the secretory phase of the 
menstrual cycle (61). This is achieved by increased expression of CYP11A1 and 3βHSD to 
firstly convert cholesterol to pregnenolone then to progesterone, and a decrease in expression 
of 17α hydroxylase and 17β hydroxysteroid dehydrogenase (63, 64) to reduce oestradiol 
synthesis.  
During the luteal phase of the cycle the size of the corpus luteum increases until it has 
reached maximal levels of progesterone secretion, this level is maintained during the mid-
luteal phase, coinciding with the implantation of a blastocyst. In a conceptus cycle, the 
corpus luteum is indispensable for establishment of pregnancy (65), whereas in non-
conceptus cycle the corpus luteum will undergo luteolysis (structural and functional 
degradation) (66), resulting in a decrease in oestradiol and progesterone production (65, 67). 
Suppression of FSH is removed upon progesterone withdrawal and a new cycle of follicle 
growth and steroid hormone production is initiated (68, 69). 
1.4 The human endometrium 
The human endometrium is a highly complex and dynamic tissue that lines the inside of the 
uterine cavity. During a woman’s reproductive lifespan the endometrium is subjected to 
cyclical episodes of proliferation, differentiation, decidualisation, shedding (menstruation), 
repair and regeneration in response to fluctuating levels of steroid hormones produced from 
the ovaries (70–77). The endometrium displays unparalleled, controlled, tissue remodelling, 
resulting in a healed, scar-free tissue following menses or parturition (78–80). Taking into 
account the declining age of menarche (81), the development of contraception, smaller 
family sizes and the choice to delay pregnancy until a later age, the average woman 
undergoes 400 menstrual cycles during her reproductive lifespan (82). 
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Co-ordinated cell-cell interactions within the endometrium during the menstrual cycle are 
pivotal to maintaining female fertility. Remodelling of the tissue is essential for maintaining 
the receptivity of the endometrium to the possible implantation of a blastocyst (83). In the 
absence of an implanted blastocyst, regression of the corpus luteum is followed by a 
decrease of progesterone secretion (61, 83–86) that initiates the onset of focal and ischaemic 
necrosis resulting in shedding of the endometrium (menstruation) and the beginning of a new 
cycle with the opportunity to re-establish a “receptive” endometrium.  
1.4.1 Endometrial composition 
The endometrium is morphologically divided into two layers; the upper luminal functional 
layer and the lower basal layer, adjacent to the myometrium (87–89). The functional layer 
comprises the upper two thirds of the proliferated endometrium, and it is this layer that is 
shed during menstruation. It is in the functional layer where the majority of tissue 
remodelling occurs under tight regulation of the sex steroid hormones oestrogen (secreted 
from the granulosa cells of the developing ovarian follicles) during the proliferative phase 
and progesterone (produced from thecal cells of the corpus luteum following ovulation) 
during the secretory phase. One feature of the functional layer is a striking increase in its 
depth, with an average thickness of 7mm during the mid-secretory phase, a 14 fold increase 
in thickness from an initial post-menstruation depth of 0.5mm (90). 
Both layers of the endometrium are multi-cellular with well-defined stromal and epithelial 
compartments. The luminal surface of the functional layer is lined by a single layer of 
epithelial cells. Embedded within the stroma are glands that are lined with columnar 
epithelium, extending away from the surface epithelium. Stromal fibroblasts and an 
extensive vascular compartment are characterised by endothelial cells surrounded by 
perivascular cells that express contractile proteins such as smooth muscle actin (91–93). The 
endometrium is also host to a fluctuating immune cell population. T-lymphocytes, 
eosinophils, mast cells, uterine natural killer cells (uNK) and macrophages are all present 
through-out the cycle, whilst an influx of leukocytes during the secretory and menstrual 
phases of the cycle has also been identified (reviewed by (94, 95) and further discussed in 
section 1.6.3.3.1). 
1.5 Steroid hormones and their receptors in the human 
endometrium  
It is well established from studies in women and a range of animal models that oestrogens 
and progestagens are essential for endometrial function; however there is emerging evidence 
of a role for androgens in regulating cellular function of the endometrium (96).  
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Mouse models are often used to study the human endometrium due to the similarity in 
endometrial structure; the mouse endometrium also displays cyclical changes in cell 
morphology (97) and steroid receptor expression (98) that parallel those documented in 
human endometrium during the normal menstrual cycle. Mice are a particularly useful 
resource due to the availability of transgenics, specifically cell-specific knock out models, 
which will be discussed in this section.  The use of mouse models to study the dynamics of 
endometrial function will be discussed further in section 1.9.  
1.5.1 Steroid hormone receptor structure 
Classical actions of sex steroids are mediated via their steroid hormones receptors, which 
belong to a superfamily of receptors known as nuclear receptors (NR). NRs are an abundant 
class of transcriptional regulators; ligand binding to NRs has effects on growth, development 
and homeostasis (99). Analysis of NRs has revealed a common structural organisation of 6 
homologous domains (100), named A-F depicted in Figure 1-3.  
 
Figure 1-3: Protein structure of the main steroid receptors, oestrogen receptors alpha and beta 
(ERα/ERβ), progesterone receptors A and B (PR-A/PR-B) and androgen receptors A and B (AR-
A/AR-B).  AF; activation function. Amino acid lengths for each domain are shown below each 
protein. Adapted from (101–103). 
The N terminal A/B domain differs in length between NR superfamily members and is the 
least conserved domain of the NR protein. Activation function (AF) sites are located in the 
A/B region. DNA binding is encoded in domain C (104, 105), which is the most conserved 
region of the superfamily. Domain E is the hormone binding domain which upon ligand 
binding participates in dimerisation, translocation and transcriptional activation (106). 
Domain E also contains the binding site for the heat shock protein hsp90, a chaperone 
protein (107, 108). This ligand binding domain also contains an additional AF domain, AF-2, 
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responsible for ligand-dependent activation of the receptor. PR-B contains a third AF in its 
upstream sequence (109), whilst AR contains AF-5 in its N terminal domain, to allow for 
ligand-independent binding (101, 110). 
1.5.2 Oestrogens in normal endometrial function 
Oestrogens regulate the essential processes of normal endometrial function including; 
proliferation of the functional layer and extensive angiogenesis (111). Oestradiol (E2) is the 
dominant oestrogen and can be synthesised in the ovary, (as described in section 1.3). 
However, there is new evidence for local biosynthesis of oestrogens in the normal, cycling 
endometrium (112) which complements that from studies in disorders including 
endometriosis (113–115).  
Two phases of oestrogen elevation are observed across the menstrual cycle (Table 1-1 and 
Figure 1-4, E2); the first peak occurs during the late follicular phase prior to ovulation and 
the LH surge where oestradiol levels rise from around 80pg/ml in the mid follicular phase to 
approximately 231pg/ml.  The second elevation is observed in the mid luteal phase, where 
E2 peaks around 147pg/ml, studies in mice and women have supported a role for oestrogens 
during embryo implantation (116–120). 
Oestrogens exert their effects on two oestrogen receptors; oestrogen receptor alpha (ERα) 
and oestrogen receptor beta (ERβ). Both belong to the steroid receptor super-family of 
nuclear receptors encoded by genes ESR1 and ESR2 and are located on chromosomes 6q25.1 
and 14q23.2 respectively (106).  
In the human endometrium, both ERα and ERβ are temporally and spatially regulated in 
multiple cell types (98). In the functional layer of the endometrium, ERα and ERβ are both  
expressed in stromal cells and glandular epithelial cells (121). Studies using mice with cell-
specific deletion of ERα (ERKO) have identified a key role for stromal ERα in mediating 
oestrogen-dependent epithelial cell proliferation (122). However ERβ, not ERα, is expressed 
in endothelial cells that line the blood vessels (123). ERα and ERβ have been 
immunolocalised to the perivascular stromal cell (123). Splice variant isoforms of ESR2, 
which lack a ligand binding domain, have been detected in normal endometrium and in 
endometrial cancer (124).  The expression of both ERα and ERβ fluctuate through-out the 
menstrual cycle and are discussed further in section 1.6.  
1.5.3 Progesterone in normal endometrial function 
Progesterone concentrations increase significantly during the secretory phase from 
1144pg/ml in the late follicular phase to a peak of around 16,241pg/ml in the mid secretory 
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phase (Table 1-1, P). Progesterone acts via the progesterone receptor (PR), of which there 
are two main isoforms; PR-A and PR-B (125), encoded by a single gene (PGR) located on 
chromosome 11q22 (126).  
Progesterone plays a role in limiting oestrogen-mediated mitogenesis by promoting 
differentiation of stromal cells (127, 128). For example, progesterone, acting via its cognate 
receptor inhibits the transcription of the ESR1 gene (129). Progesterone also stimulates 
expression of 17β hydroxysteroid dehydrogenase-2 (17βHSD2) which converts oestradiol to 
oestrone, an oestrogen which has a weaker affinity for the oestrogen receptor (130). In a 
murine model, when PR was blocked by administration of the antagonist, RU486, a 
significant decrease in vascular function was noted (131).  
Notably, expression of the PR gene and its isoforms are controlled by both oestrogen and 
progesterone. During the proliferative phase oestrogen stimulates transcriptional activity of 
the PR gene; however maximal activation of the PR protein is observed during the secretory 
phase when bioavailable concentrations of the ligand progesterone are at their greatest (132). 
PR-A is the predominant isoform during the secretory phase, immunolocalised to the stroma 
and perivascular cells, but absent from the endothelium (98).  Selective uterine PR knockout 
mice (PRKO), for both isoforms, exhibit extensive hyperplasia due to unopposed actions of 
oestrogen (133). Interestingly, in the uterine cell-selective PR-A knockout (PRAKO), PR-B 
was sufficient to maintain epithelial mitogenesis (134), indicating that PR-A isoforms are 
involved in both the opposition of PR-B signalling and oestrogen-dependent proliferation 
during the secretory phase. 
Early studies with selective uterine and ovarian PR knockout mice (PRKO) found that 
endometrial tissues exhibited a failure in stromal cell decidualisation and were also infertile 
due to deficient luteinisation of follicle theca and granulosa cells at ovulation (133). More 
recent studies have highlighted that PR-A is indispensible for decidualisation of the 
functional endometrium during the secretory phase (96, 135), a process essential for 
establishment of pregnancy. Artificial stimulation to induce decidualisation in uterine 
PRAKO mice failed to induce a decidual response (135). This evidence highlights a key role 
for progesterone and the PR in normal endometrial function. 
1.5.4 Androgens in normal endometrial function  
Whilst the impact of oestrogens and progestagens on endometrial function has been 
extensively studied, little attention has been paid to androgens and their actions on the 
endometrium.  
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Adult women synthesise about half their circulating androgens in the adrenal and in the 
ovary, with the other half being synthesised in peripheral sites like the skin (136, 137).  
Although testosterone is often classed as the “male hormone”, because of its key role in the 
maintenance of the male phenotype, measurement of circulating concentrations of active 
androgenic ligands reveal that normal women synthesise androgens at a level which is 
approximately 60% of that of an adult male (138). 
Abraham, in 1974, determined the circulating concentrations of androgens (and their 
metabolites) across the menstrual cycle by taking daily blood samples from 6 women of 
reproductive age (44). To investigate the relative contributions of the adrenals and ovaries to 
total serum concentrations blood samples were taken during one normal cycle, then the same 
women were given a dose of dexamethasone to suppress adrenal production of androgens 
during the next cycle (44). Abraham observed that ovarian-derived testosterone, 
androstenedione and dehydroepiandrosterone (DHEA) were maximal during mid-cycle (late 
proliferative/early secretory phase), whereas concentrations of circulating 
dihydrotestosterone (DHT) and DHEA sulphate (DHEAS) were maintained across the cycle 
and were apparently unaffected by menstrual phase. Adrenal contributions of testosterone, 
androstenedione, DHEA and DHEAS were constant through-out the cycle. More recently, 
these fluctuations in androgens across the cycle have been confirmed and a decrease in 
circulating androgens is reported in women with advanced reproductive age (139, 140).     
Androgens exert their effects on the androgen receptor (AR) located on the X chromosome 
at the Xq11-12 locus (141), that consists of 8 exons which encode a protein of 919 amino 
acids. In the absence of ligand, the AR is bound by heat shock proteins that dissociate upon 
ligand binding. AR monomers are then transported to the nucleus where they dimerise.  The 
AR has been shown to mediate a range of cellular processes including proliferation, 
differentiation and apoptosis (142). 
The androgen receptor has been immunolocalised to the nuclei of stromal cell fibroblasts of 
both the functional and basal layer during the proliferative phase (143). However, this 
expression gradually decreases over the cycle, until a complete lack of expression is 
observed in the functional layer by day 23 during the late secretory phase (reviewed in (98)). 
This has been supported by in vitro studies, where AR protein levels are suppressed by 
progesterone in a model of stromal cell decidualisation  (96). Using gene data sets, 
downstream androgen target genes have been shown to have a greater expression during the 
proliferative phase than in the mid secretory phase (144). This would suggest that that AR 
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expression is mediated by the fluctuating levels of oestrogen and progesterone through-out 
the menstrual cycle (145). 
The impact of androgens on endometrial function has been investigated.  It has been reported 
that androgens alone cannot initiate a decidual response in primary endometrial stromal cells 
in vitro. However, AR has been shown to regulate expression of genes involved in the 
maintenance of decidualisation which suggests a role for AR in embryo implantation (96). 
The inability of AR to initiate decidualisation further underlines the importance of 
progesterone and PR in regulating endometrial receptivity. Furthermore, in a murine model, 
androgens (more specifically, DHT) were able to maintain decidualisation of the 
endometrium after the withdrawal of progesterone support (146). Despite being able to 
maintain the decidual response in vivo, DHT was unable to support foetal development 
during pregnancy after the removal of progesterone on day 6 of gestation, further evidence 
for the importance of progesterone in the establishment of pregnancy (146).  
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1.6 Cyclical changes in the pattern of steroid receptor 
expression and changes in cellular morphology of the 
endometrium across the menstrual cycle 
The classical morphological changes that occur in the endometrium in response to ovarian 
steroids were first described by Hitschmann and Adler in 1908 (147). Subsequent studies 
have described the endometrial morphology of each phase of the menstrual cycle in detail 
(87, 88, 148–153). A diagrammatic representation of the key changes in the morphology of 
the functional layer, along with fluctuations in ovarian steroids, is illustrated in Figure 1-4.  
 
 
Figure 1-4: Cyclical changes in cellular composition of the functional layer of the human 
endometrium.  The E2 dominant proliferative phase precedes the P4 dominant secretory phase. E2 
acting via ERα stimulates cellular proliferation and angiogenesis during days 4-14 of the cycle. 
Following ovulation the corpus luteum secretes progesterone that in turn mediates the 
differentiation (decidualisation) of stromal cells in preparation for pregnancy. In the absence of a 
blastocyst, falling concentrations of progesterone precipitates a cascade of morphological changes 
culminating in sloughing of the functional layer at the time of menses. In the presence of a blastocyst 
(pregnancy), progesterone concentrations are maintained (P, dotted blue line) and further 
decidualisation occurs in the functional layer. Image courtesy of Professor. P. Saunders, unpublished.  
Histological evaluation and dating of endometrium during each phase of the menstrual cycle 
is based on a detailed set of criteria which was first reported in 1950 by Noyes et al. This 
method classifies the cycle into early, mid and late proliferative; early, mid and late 
secretory; and menstrual phases (89). The following descriptions of the dynamic and 
temporal changes in cell function of endometrial proliferation and differentiation are based 
on an average menstrual cycle length of 28 days. 
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1.6.1 Proliferative phase 
During the oestrogen-dominant proliferative phase rising concentrations in serum oestradiol 
(Figure 1-4; green line; E2), secreted from granulosa cells, stimulate the growth of the 
functional layer, promoting epithelial and stromal cell proliferation and regrowth of 
endometrial blood vessels through endothelial cell proliferation (70, 97, 123, 154–156).  
Ovarian production of oestrogens begins on approximately day 4 of an average cycle. 
Oestrogens display different impacts on stromal and epithelial compartments of the 
endometrium. For example, oestradiol up-regulates the production of insulin-like growth 
factor-1 (IGF-1) by stromal cells which promotes proliferation of stromal and epithelial cells 
(157). Epidermal growth factor (EGF) is a potent mitogenic factor, present in the uterine 
cavity (158). Increasing serum concentrations of oestradiol stimulates the expression of the 
epidermal growth factor receptor (EGFR) on endometrial epithelial cells, allowing increased 
ligand binding of EGF (158–160) depicted in Figure 1-5, A. By the mid-proliferative phase 
(days 8-10) proliferation of cells in both the epithelial and stromal cell compartments results 
in lengthening of the basal glands and an expansion of the extracellular matrix in the stromal 
cell compartment (161). Occurring in parallel to these changes, an increase in the number of 
cilia and microvilli on epithelial cells (161) is observed (Figure 1-5,B). These cilia and 
microvilli aid distribution of glandular secretions during the secretory phase (148, 162, 163).  
Intra-nuclear concentrations of ERα are maximal during the proliferative phase. ERα has 
been immunolocalised to both the stromal cells and the luminal and glandular epithelium but 
not in the endothelium (98, 164) (Figure 1-5, C). The full length wild type receptor (ERβ1) 
and a truncated splice variant (ERβ2) are present in the glandular epithelium, the stroma and 
endothelium of the proliferative endometrium (123) (Figure 1-5, D). However, the impact of 
ERβ2 in the endometrium is not well understood. Oestrogen primes the endometrium for the 
morphological changes that will take place during the secretory phase by inducing 
expression of the oestrogen-dependent gene PR (70, 165, 166).  
In the late proliferative phase (11-14 days) pseudostratification of the nuclei of the luminal 
epithelium cells is thought to contribute to the intra-glandular secretions which occur during 
the secretory phase to coincide with blastocyst implantation (89). Epithelial mitosis 
decreases so that proliferation of the functional layer gives way to stromal cell differentiation 
and decidualisation (161). Notably, PR expression in the glandular epithelium decreases 
(167). 




Figure 1-5: Proliferative phase of the human endometrium.  A; Oestrogen acts on the epithelium 
and stroma (red arrows) to stimulate up-regulation of the production of growth factors (bold black 
arrows) such as insulin-like growth factor (IGF-1) to promote stromal and epithelial cell proliferation. 
Up-regulation of EGFR by oestradiol allows epidermal growth factor (EGF) to bind and promote 
epithelial cell proliferation. B; SEM image of the proliferative phase endometrium. Arrows show cilia 
projecting from the luminal epithelium. C; In the functional layer ERα is immunolocalised to nuclei of 
the glandular epithelium (G) and stroma (S) but is not found in the endothelium (arrowheads). D; 
ERβ is immunolocalised to the nuclei of glandular epithelial cells (G), stromal cells (S) and is found in 
the endothelium (arrows). (Adapted from, (123, 168, 169)). 
1.6.2 Secretory phase 
Humans display haemochorial placentation during pregnancy, a key feature of this type of 
placenta is trophoblast invasion and direct contact with the maternal blood supply. It is 
believed that in order to avoid excessive invasion of the trophoblast, the human endometrium 
has evolved to accommodate spontaneous and extensive decidualisation typified by 
differentiation of stromal fibroblasts. It has been reported that incomplete or insufficient 
decidualisation results in infertility (170).  
Spontaneous decidualisation of the endometrium during the secretory phase occurs in 
preparation for blastocyst implantation. Implantation is a highly co-ordinated event between 
both the developing embryo and the endometrium (171), with each secreting a number of 
factors to aid adhesion, invasion and development (172, 173). The endometrium is only 
receptive to the blastocyst for a limited period of time (173), known as the “window of 
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receptivity”; therefore it is critical that regulatory molecules are tightly co-ordinated. The 
“window” is thought to “open” around day 20, when pinopode formation is observed by 
SEM (174); pinopode formation is dependent upon steroid hormone control (175) and is 
thought to aid blastocyst implantation (174). Immunolocalisation studies for integrins α4 and 
β3, adhesion molecules present during secretory phase in human tissues, have shown that the 
window stays open until around day 23 (174). Gene expression profiles using endometrial 
biopsies from the proliferative and secretory phase have identified a panel of genes that may 
be responsible for the regulation of preparation of pregnancy (176, 177).  
During the secretory phase, the endometrium is exposed to rising levels of progesterone 
(Figure 1-4; blue line; P4) secreted from the hormone producing cells of the corpus luteum. 
Progesterone secretion results in cessation of endometrial epithelial cell proliferation and 
expression of ERα is down-regulated in both the epithelial and stromal cell compartments 
(178) (Figure 1-6, B). ERβ is maintained in the stroma during the secretory phase but is 
insufficient in regulating expression of IGF-1 and other factors (Figure 1-6, C) (123).  
Rising levels of progesterone, results in increased expression of PR-A in the stromal cell 
compartment (Figure 1-6, D) (167). During decidualisation, stromal fibroblasts accumulate 
collagen (179) and laminin (180), whilst undergoing cellular enlargement to become pre-
decidual or decidual cells. Decidualised cells secrete insulin-like growth factor binding 
protein 1 (IGFBP-1) (Figure 1-6, A) which in turn mediates progesterone-regulated 
decidualisation (181, 182). During the mid-secretory phase, (day 23) stromal cells initially 
undergo decidualisation just below the luminal epithelium and around spiral arterioles (183), 
where progesterone drives the expression of angiopoietin 1, which is a blood vessel 
stabilisation agent to block excessive angiogenesis (184). Decidualisation then spreads in a 
“wave-like” motion through-out the endometrium, so that by day 24 (during the late 
secretory phase of the human cycle); peak secretory activity is observed (Figure 1-6, E). 
During the late secretory phase, stromal oedema is apparent and the tissue is infiltrated by 
immune cells including uterine natural killer cells (uNK), macrophages and T cells (83, 185).  




Figure 1-6: Secretory phase of the human endometrium. A; Increasing concentrations of 
progesterone mediate stromal cell decidualisation via a number of factors including; secretion of 
insulin-like growth factor binding protein (IGFBP), which decrease stromal cell proliferation. B; In the 
functional layer ERα is down-regulated in the glandular epithelium (G), stroma (s) and is absent from 
the endothelium (arrowheads). C; ERβ1 is down-regulated in the glandular epithelium (G), but is 
maintained in the stroma (S) and in the endothelium (arrows). D; PR is expressed in the stroma and 
the glandular epithelium of the decidualised, mid-secretory phase endometrium. E; SEM image of 
the secretory phase endometrium, tall, columnar epithelia are evident. (Adapted from, (123, 148, 
168)). 
1.6.3 Menstrual phase 
In the absence of a developing blastocyst, and therefore the absence of the embryonic signal 
chorionic gonadotrophin, the corpus luteum regresses resulting in a rapid fall in ovarian-
derived steroids and functional progesterone withdrawal  (61,63, reviewed by 82). The 
menstrual phase of the cycle is characterised by the sloughing of the functional layer into the 
uterine lumen. The shed tissue is then expelled from the uterine cavity via the vagina. 
Menstrual bleeding itself is the first outward sign of menses; however it is now appreciated 
that this is the culmination of a cascade of cellular and vascular changes that are initiated 
following the failure of conception, a summary of this cascade is shown in Figure 1-8.  
1.6.3.1 Current concepts of endometrial breakdown 
Our current understanding of the cellular changes associated with menstruation is based on 
the observations by Markee in the 1940s. Markee’s studies using auto-transplanted 
endometrium in the anterior chamber of the eye of rhesus monkeys allowed observations of 
endometrial function. Markee reported that endometrial bleeding was induced by reduced 
blood flow to the upper two thirds of the endometrium, followed by a shrinkage in tissue 
density, then vasoconstriction of the spiral arterioles (186). It has been documented that 
vasoconstriction is associated with local ischaemia, loss of cell-cell adhesion molecules and 
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focal disruptions to the endothelium which culminate in a loss of tissue integrity and 
degradation of the endometrium (84, 169, 187).  
Data obtained from detailed high powered analysis of endometrial tissue has revealed that 
endometrial shedding is a piecemeal process, as shown in Figure 1-7, with areas of shed 
endometrium (white arrow, exposed basal layer) adjacent to unshed endometrium (black 
arrow, intact epithelium) (148).  
Loss of endometrial integrity has been widely investigated; prostaglandins, enzymatic 
digestion, matrix metalloproteinases (MMPs), leukocytes, macrophages and fibrinolysis are 
all implicated in playing a role in tissue breakdown and degradation of only the upper layer 
of the tissue and the interaction of these factors are shown in Figure 1-8. In normal women, 
these events are tightly controlled to prevent excessive blood loss and the onset of anaemia.  
 
Figure 1-7: Menstrual phase of the human endometrium.  SEM image of the endometrium during 
menses. The endometrium sheds in pieces; areas of unshed endometrium (black arrow) are 
observed adjacent to a denuded area of the basal layer (white arrow). Exposed basal glands are 
observed (arrowhead) (adapted from (148)).  
1.6.3.2 Hypoxia as a regulating factor during menses 
Vasoconstriction of the spiral arterioles prior to the onset of endometrial breakdown is likely 
to result in local hypoxia in the functional layer of the human endometrium. Initial evidence 
was proved by the auto-transplantation model used in the rhesus monkey by Markee (186) 
and reinforced in a mouse model of endometrial breakdown, where the authors reported low 
oxygen tension within the tissue using a marker of hypoxia (pimonidazole) (188).  
Hypoxia inducible factor (HIF1α) is a nuclear protein that regulates a cell’s response to 
hypoxia. In normoxic conditions the protein is rapidly degraded, however when oxygen 
levels fall the protein is stabilised and the two HIF subunits (HIF1α and HIF1β) dimerise to 
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initiate transcription of target genes (189). HIF1α protein and mRNA has been identified in 
the human endometrium during the late secretory and menstrual phases (190), however 
expression of the protein is independent of mRNA expression consistent with post-
transcriptional regulation being key to its function (189).  
Hypoxia has been shown to regulate genes involved in angiogenesis (191–193). For 
example, exposure of endometrial stromal cells to low oxygen tensions in vitro is reported to 
increase concentrations of vascular endothelial growth factor (VEGF) mRNA (193) and 
decrease expression of the chemokine CXCL12 (191). In a mouse model of breakdown, 
VEGF has been shown to be essential for re-epithelialisation and angiogenesis of the 
endometrium following tissue breakdown (188) suggesting that the transient induction of 
hypoxia, at menses, may provide a key regulatory step in stimulating the rapid repair of the 
tissue and restoration of tissue homeostasis.  
1.6.3.3 Menstruation as an inflammatory event 
It was Finn, in 1986, who first linked the events of menstruation to those of an inflammatory 
response (194). It has been proposed that progesterone maintains uterine quiescence by 
acting as an anti-inflammatory mediator during the menstrual cycle, in part by, inhibiting the 
production of pro-inflammatory prostaglandins (PGs) (195–198). For example, in women in 
vivo, it has been reported that progesterone increases the expression of prostaglandin 
metabolising enzyme 15 hydroxy-prostaglandin dehydrogenase (PGDH) whilst 
simultaneously suppressing the production of the inducible factor COX-2 in secretory phase 
endometrium (199). It has also been shown in vitro, in human myometrial cells, that 
progesterone suppresses inter-leukin β (IL-β) derived activation of COX-2, the enzyme that 
converts arachidonic acid to prostaglandins. Inhibition of IL-β mediated COX-2 suppression 
is removed upon progesterone withdrawal (200). This allows prostaglandin F2α (PGF2α) 
facilitated vasoconstriction of the spiral arterioles and smooth muscle contraction to aid 
shedding, whilst prostaglandin E2 (PGE2) mediates vasodilation (200). PGE2 has also been 
shown to regulate the expression of hypoxia inducible factor (HIF1α) in Ishikawa cells (an 
immortalised endometrial epithelial cell line) in vitro (190), which in turn up-regulates 
angiogenic factors which may be involved in vessel stabilisation following tissue 
degradation (as outlined in Figure 1-8, depicted by the green arrows). 
Further anti-inflammatory effects of progesterone include stabilisation of lysosomal 
membranes and stimulating fibrinolysis. From scanning electron microscopy studies, it has 
become evident that during the secretory phase progesterone acts to stabilise lysosomal 
membranes. However, as progesterone concentrations fall lysosomes release lytic enzymes 
Chapter 1. Literature Review. 
19 
 
and acid phosphatases (129, 201) that digest intracellular bridges (as outlined in Figure 1-8, 
depicted by the pink arrows). A loss of progesterone also stimulates fibrinolysis, where 
plasminogen is converted to plasmin to aid the breakdown of fibrin in the endothelium of 
blood vessels (202), so that clotting of the menstrual blood is inhibited (203). Fibrinolysis is 
an important process in preventing the organisation of fibrin into scar tissue (80, 204), 
essential to the scar-free healing observed in the endometrium with every menstrual cycle. 
1.6.3.3.1 Immune cell influx 
As inflammatory mediators, prostaglandins are known to regulate the activity of cytokines 
and chemokines that play a role in leukocyte recruitment to the endometrium through-out the 
menstrual cycle (205, 206) (as outlined in Figure 1-8, depicted by the blue arrows). From 
immunohistochemistry studies, it is proposed that leukocytes comprise up to 40% of the 
endometrial tissue at the pre-menstrual phase (185). Of the different leukocyte populations 
present, neutrophils and macrophages appear to be recruited to the endometrium from the 
blood stream (207–209). In comparison, the majority of the uNK cell population arises from 
proliferation in situ with the remainder recruited from blood stream (210–213). 
Immunolocalisation for macrophages reveals that they make up approximately 6-15% of the 
endometrium during the menstrual phase (214) and are proposed to play multiple roles in the 
regulation of endometrial function; initiation of breakdown, repair and remodelling and 
preparation for pregnancy. Immunolocalisation studies on fixed tissues and in vitro organ 
culture of endometrial tissues from each phase of the menstrual cycle have revealed that 
macrophages release matrix metalloproteinases (215) (as outlined in Figure 1-8, depicted by 
the purple arrows) and hydrolytic enzymes (216) to assist in breaking down collagens and 
extracellular matrix, respectively, in the endometrium at the time of menses.  
Neutrophils are the dominant leukocyte involved in inflammatory processes, with increased 
numbers localised to the endometrium during breakdown as observed in a mouse model of 
menstruation, and peak numbers observed during repair (217). In vitro culture of human 
peripheral blood neutrophils and endometrial stromal fibroblasts, revealed that neutrophils 
activate the secretion MMPs, important mediators of tissue breakdown (as outlined in Figure 
1-8, depicted by the purple arrows) (207). In a mouse model of breakdown, neutralisation of 
neutrophils by antibody administration resulted in a delay of repair of the endometrium 
(218).  
1.6.3.3.2 Matrix metalloproteinases 
Matrix metalloproteinases are zinc-dependent endopeptidases that cleave almost all extra-
cellular components. The integral role that MMPs play in endometrial tissue breakdown was 
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first described in vitro, in human endometrial explants cultures (219). In the absence of 
exogenous steroids, tissue necrosis was reported microscopically and increased 
concentrations of MMPs were observed in the culture media. Administration of inhibitors of 
MMPs were observed to prevent the lysis of extra-cellular matrix components in vitro (219).  
The expression of MMPs varies across the menstrual cycle; at menses (consistent with a time 
of progesterone withdrawal) there is a stark increase in protein expression of MMP-1, -3,-7, -
9, -11 and -12 (220–228).  Oestradiol and progesterone have been shown to suppress the 
expression of MMP-1, -3, -7 in culture tissue explants (219), supporting a role for ovarian 
steroid regulation of MMPs at all stages the menstrual cycle (221, 223, 229). In a mouse 
model of breakdown, immunolocalisation of MMP-3, -7 and -9 were found to increase in the 
stroma (MMP-3, -9) and in the epithelium (MMP-7) at the time of tissue breakdown (230), 
consistent with findings in the human (220, 221, 223, 227). Notably, MMP-3 and -7 were 
localised close to areas of repairing epithelium and MMP-7 and -9 were co-localised with 
neutrophils (230). In contrast to findings in women, administration of MMP inhibitors in the 
mouse model did not have any adverse effect on breakdown of the tissue (230), suggesting 
that in the mouse MMPs may not be the main contributor to endometrial breakdown.  
  




Figure 1-8: Summary of the cascade of events of endometrial breakdown following progesterone 
withdrawal.  Corpus luteum regression results in falling serum progesterone concentrations. This 
results in a cascade of events culminating in endometrial breakdown. Three main pathways are 
thought to be involved; 1. An increase in COX-2 and prostaglandin synthesis leads to increased 
PGF2α causing vasoconstriction and up-regulation of hypoxia inducible factor. COX-2 and PG 
synthesis also results in increased PGE2 expression (green arrows); 2. An increase in lysosomal 
leakiness results in hydrolytic breakdown of the tissue (pink arrows); 3. An increase in production of 
chemokines and immune cell influx (blue arrows). ↑; increase, ↓; decrease, PGF2α; prostaglandin 
F2 alpha, PGE2; prostaglandin E2, MMPs; matrix metalloproteinases. (Adapted from (72, 83, 187)). 
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1.7 Endometrial repair and regeneration  
The morphological changes that occur during the proliferative, secretory and menstrual 
phases have been studied by a number of investigators using human tissue, primate and 
rodent models (72, 132, 148, 169, 201, 231–238), whereas little attention has been paid to 
endometrial repair.  
One striking observation made using human tissue samples was that initial “repair” of the 
human endometrium is a rapid process, occurring within 48 hours of shedding (237). Elegant 
scanning electron microscopy (SEM) studies by Ferenczy, in 1975, observed that repair of 
the human endometrium began on days 2-3 of the menstrual cycle and was completed by 
days 4-5, as evidenced by a fully reconstructed epithelial cell layer (201, 237). Surprisingly, 
repair was only observed in areas where the basal glands were exposed to the luminal 
environment. A recent SEM study by Garry et al., (169) has shown that shedding is a 
piecemeal process, as evidenced by areas of new epithelium present before shedding is 
complete. Taken together these observations suggest a co-existence of breakdown and repair 
processes, which imply a complex regulatory pathway. Therefore, it is important to 
remember that whilst the menstrual phase, and outward bleeding observed by women, may 
last up to 5 days or longer, repair processes are already initiated at the start of this process 
something which is clearly important in limiting the severity of blood loss.   
Repair of the endometrium appears to occur in a steroid depleted micro-environment, with 
low levels of circulating oestrogen and progesterone following the regression of the corpus 
luteum and prior to significant oestrogen secretion from growing follicles in the ovary. 
Oestrogen does not appear to be required for the initiation of, or the process of, repair as 
demonstrated in animal models of endometrial repair (239, 240). For example, an in vivo 
study using a mouse model of breakdown and repair has shown that, in the absence of 
oestrogen, epithelial, stromal and endothelial cell repair can occur when all exogenous 
steroids are removed by the administration of letrozole (an aromatase inhibitor), at the time 
of progesterone withdrawal. Removal of oestrogen did not affect the complete repair of the 
endometrium following shedding, which was observed within 48 hours (239). Furthermore, a 
xenograft model using human proliferative phase endometrial explants has also shown that 
oestrogen is not essential for tissue restoration. Proliferative phase explants were grafted sub-
cutaneously onto ovariectomised immunodeficient mice and exposed to exogenous oestrogen 
and progesterone for 28 days to mimic a human cycle. After steroid removal, tissue 
destruction was observed. Following breakdown of the tissue on day 31, explants were 
observed to return to a proliferative phase-like morphology by day 35 in the absence of any 
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exogenous steroidal support. Repair of the explants in a steroid-depleted micro-environment 
was confirmed by measuring the circulating concentrations of oestrogens and progesterone 
in the blood sera (240). A role for oestrogen during endometrial repair has yet to be 
demonstrated in women.  
1.7.1 Epithelial cell proliferation contributes to endometrial repair 
The mechanisms that drive endometrial repair after breakdown of the tissue during menses 
are still a hotly debated topic; epithelial repair has been well described from a morphological 
view (201, 237) but is still poorly understood from a molecular viewpoint. The most 
accepted view of repair is that of Novak and Te Linde, who in 1924, proposed that the new 
luminal epithelium arises from the preserved glandular epithelium of residual glands in the 
remaining basal layer (241). Histological examination of specimens of menstrual phase 
tissue, have revealed continuous epithelial extensions arising from basal glands (237) 
supporting the idea that luminal epithelial cells are derived from the glandular epithelium.  
However, an investigation into the mitotic activity of epithelial cells by Baggish et al., in 
1967, supports a different view. One where stromal cells undergo cellular transformation to 
become new surface epithelial cells (242). This hypothesis is supported by recent work by 
Garry et al., (148, 169) who showed, by SEM, isolated groups of epithelial cells that were 
not associated with or located near the exposed ends of the basal glands. These authors also 
report little proliferation of epithelial cells during the repair phase, calling into question the 
earlier model. The contribution of the stromal cell compartment to epithelial repair has not 
been widely studied.  
1.7.2 Endometrial regeneration by stem cells 
The regenerative capacity of the endometrium has also been linked to the presence of adult 
“stem” (progenitor) cells within the tissue, a concept which was first proposed by 
Prianishnikov in 1978 (243). Unlike pluripotent foetal stem cells, stem cell progenitors, 
believed to exist in many adult tissues, are not identified nor defined by the expression of 
stem cell marker proteins, rather by their functional properties. One example of a tissue that 
has been identified to have residual adult stem cells is the intestine. The intestine and its 
niche, the intestinal crypt, have been intensively studied, due to the highly regenerative 
capacity of the intestine; in an in vivo study, where proliferating crypt cells were destroyed, it 
was discovered that the mouse intestinal epithelium regenerates every three days (244). 
Studies of the intestine have reported that adult stems and their niche are capable of 
substantial self-renewal, of differentiation into functional mature progeny and have a high 
proliferative potential (245–249). 
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Due to the highly regenerative capacity of the endometrium, it has been proposed that 
endometrial progenitor stem cells may reside in the base of the glands in the basal layer, due 
to the monoclonality of the epithelial cells in these glands (250). It is postulated that a rare 
stem cell population, which might be located in a niche composed of surrounding stromal 
cells, could give rise to a population of endometrial progenitor cells that will further 
differentiate into specific endometrial cell types (251). The notion of an adult stem cell niche 
is not a new concept, having first been described in relation to haematopoietic progenitors by 
Schofield in 1978 (252). It has been proposed that adult stem cells exist within a tightly 
controlled micro-environment to ensure they remain undifferentiated but are able to undergo 
lineage commitment when under special circumstances, such as stress (253). The stem cell 
niche has been identified in several adult tissues; these include the neural stem cell niche, the 
epidermal hair follicle niche, the haematopoietic niche and the intestinal crypt stem cell 
niche (247, 254–256). Each stem cell niche will vary slightly in its cell composition and 
location, with each being uniquely controlled in order to regenerate their respective organ. 
Evidence for endometrial progenitors includes establishment of colonies from single cell 
suspensions of endometrial tissue taken during hysterectomy. These single cell populations 
proliferate and can form  cells with epithelial and stromal cell characteristics in culture 
(257); these studies indicated a need for stromal-epithelial cell interaction to maintain clonal 
growth.  
“Side populations” of progenitor stem cells have been isolated from human tissues. Side 
population cells are distinct from the main population of somatic cells in that they display 
stem cell-like characteristics, one being their ability to efflux dyes, such as Hoechst 33342, 
through the activity of the ATP-binding cassette pumps localised to their plasma membrane 
(258). Endometrial side populations for both epithelial and stromal cells have been isolated 
from living tissues (259) and are capable of reconstructing the human endometrium, when 
placed under the kidney capsule of mice (260). 
A second potential site for an endometrial stem cell population is in a perivascular location 
within the basal layer. In 2007, Schwab and Gargett identified a population of cells in the 
human endometrium that displayed similar characteristics to mesenchymal stem cells 
(MSC). Using two markers; CD146 and platelet derived growth factor receptor β (PDGFRβ) 
they identified putative pericytes (261), it is postulated that this MSC-like population 
contributes to the regeneration of both the stromal cell and endothelial cell compartments of 
the endometrium with each menstrual cycle. More recently, in 2012, Masuda et al., (262) 
have identified W5C5, a single marker that was able to isolate multipotent and self-renewing 
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MSCs from the endometrium. When exposed to myogenic or angiogenic conditioned media 
in vitro, these cells were able to differentiate into smooth muscle cells and endothelial cells 
respectively. When placed under the kidney capsule of ovariectomised immunodeficient 
mice, cells formed stromal cell-like connective tissues, with the support of exogenous 
oestrogen (262). 
A contribution of bone marrow progenitors to the endometrium has also been investigated, 
following on from a demonstration that haematopoietic stem cells are able to differentiate 
into hepatocytes (263), neurons (264) and skin (265). In 2004 and later in 2007, the first 
evidence for a bone marrow contribution to the endometrium was provided. Using a mouse 
model where bone marrow from male donors was injected into the uterus of recipient mice 
(266, 267), Y chromosome positive stromal and epithelial cells were observed in the uterus 6 
months after bone marrow transplant. This study is supported by work from Cervello et al., 
(268) who examined the endometrium of women who had undergone a bone marrow 
transplant for haematological malignancy and had received male-derived bone marrow. The 
authors observed Y chromosome positive epithelial and stromal cells in the endometrium of 
these women, however the numbers of cells were very low (0.45%-2.62%). Furthermore, the 
authors found that the male-derived donor cells were a time-limited population that did not 
contribute to the endometrial side population (268).   
1.8 Disorders associated with endometrial function 
1.8.1 Heavy menstrual bleeding 
Abnormal uterine bleeding, characterised by heavy and prolonged periods, affects up to one-
third of women of child bearing age, leading to social and physical morbidity (269). The 
mean blood loss per cycle in a normal woman is approximately 30ml (270); however women 
with heavy menstrual bleeding (HMB) report a mean blood loss of 60-80ml (271) whereas 
excessive HMB blood loss is reported as greater than 100ml (272). 
It is unknown what causes heavy menstrual bleeding; whether it is caused by a delay in 
repair of the endometrium resulting in a longer bleed or if women with HMB have a thicker, 
decidualised endometrium resulting in an excess of tissue to be shed. Studies using 
menstrual effluent from women with HMB and women with normal blood loss have shown a 
role for prostaglandins in HMB. For example, increased concentrations of mRNAs for COX-
1 and COX-2, enzymes that promote the synthesis of prostaglandins, were observed in 
menstrual effluent (273). HMB is also associated with a shift in the PGF2α/PGE2 ratio, with 
increased concentrations of PGE2 observed in menstrual effluent (274), which may have an 
effect on vessel stabilisation during the repair phase. Furthermore, concentrations of VEGFa 
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and active MMP mRNAs were lower in the effluent of women with HMB (275), which may 
contribute to a delay in epithelial repair. Hypoxia mediated HIF1α regulated VEGF 
production has been shown in ex vivo endometrial tissue cultures, and is thought to 
contribute to repair of the endometrium (192, 193). It is postulated that a defective hypoxic 
response may contribute to HMB. Therefore it is imperative to understand the mechanisms 
that drive the repair phase of the endometrium, in order to develop a therapeutic option for 
treating HMB. 
1.8.2 Endometrial cancer 
Endometrial cancer is the most common gynaecological condition in the developed world, 
and postmenopausal women account for 90% of diagnosed patients (Cancer Research, UK, 
(276)). Endometrial cancers are divided into two types; type 1 is the oestrogen-dependent 
endometrioid adenocarcinomas whilst type 2 is oestrogen-independent and carries a poor 
prognosis due to their intense metastatic phenotype (277–279). 
The mechanisms that lead to endometrial cancer are poorly understood; however it is thought 
that progressive genetic abnormalities (280–283) eventually lead to disruptions in cellular 
processes that cause increased cell proliferation, a decrease in apoptosis and aberrant 
angiogenesis (284). It has also been proposed that aberrant inflammatory processes may 
contribute to endometrial adenocarcinoma (285). Therefore, understanding the mechanisms 
that control these processes (proliferation, inflammation, apoptosis and angiogenesis) during 
endometrial repair may provide an insight to the aberrant mechanisms in the development of 
cancer. 
1.8.3 Endometriosis 
Endometriosis is the growth of endometrial glands and stroma in sites outside of the uterus, 
typically on the peritoneum or the ovary (286, 287), and affects 1 in 10 women of 
reproductive age. Despite the disease first being described in the 1700s, the cause of this 
condition remains unknown. Endometriosis can cause chronic pelvic pain in some patients, 
although a direct relationship between pain severity and lesion characteristics has been 
difficult to demonstrate (288–291). 
The most widely accepted theory of why endometriosis develops suggests that endometrial 
tissue fragments are flushed into the peritoneum at the time of menses and survive by 
developing a local blood supply (292). The presence of endometriotic tissue in areas outside 
of the peritoneal cavity (293, 294) and in males (295) appears to contradict this mechanism, 
and it has been suggested that there are different types of endometriosis that originate from 
different cell types. For example, there is emerging evidence that endometrial progenitors 
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shed during menses may contribute to lesion development at ectopic sites (296). Alternative 
theories include aberrant actions of peritoneal mesothelial cells and stem cells arising from 
the fallopian tube (reviewed by (297)).  
Endometriotic lesions have heterogeneous morphology containing a stromal cell 
compartment and a glandular epithelium, as well as blood vessels, which closely interact 
with the mesothelium of the peritoneum to establish blood flow (298) and to ensure lesion 
development. Lesion development and endometrial repair are likely to share common 
mechanisms (proliferation, stromal cell organisation, angiogenesis) and therefore studying 
the repair phase may contribute to the understanding of this disease. 
1.8.4 Polycystic ovarian syndrome 
Polycystic ovarian syndrome (PCOS) is a complex gynaecological condition that affects 
approximately 5-20% of the population (299–304). The disease is characterised by endocrine 
symptoms including amenorrhoea (the absence of menses) and hyperandrogenism that 
causes outward symptoms including acne and hirsutism (299, 300). It is also linked to 
metabolic symptoms (305, 306) including peripheral insulin resistance (307) and obesity 
(308). 
Hyperandrogenism in PCOS patients is caused by elevated LH (but not elevated FSH) (309). 
LH acts on LH receptors expressed on thecal cells stimulating overproduction of  
androstenedione, stimulating growth of an increased number of follicles and eventual atresia 
of these follicles which leads to the “cysts” like structures observed by ultrasound (310).  
1.8.5 A potential role for androgens in endometrial pathologies 
Androgens are not subject to the same fluctuations seen in oestradiol and progesterone 
(Table 1-1) (44) and therefore it is possible, that at the time of menses, that androgens may 
contribute to repair of endometrium by an oestrogen-independent mechanism. A role for 
androgens in endometrial function has not yet been fully elucidated. In a recent study, 
Marshall et al., has identified a group of androgen-regulated genes in primary human 
endometrial stromal fibroblasts that appeared to play a role in protecting cells from apoptosis 
(cell death) and also mediated stromal cell migration (144). This suggests that androgens 
could play a previously unexplored role in the regulation of endometrial tissue repair.  
Notably, aberrations in ovarian androgen production, such as in PCOS, have been shown to 
result in infertility. Androgens have been implicated in the development of endometrial 
cancers in post-menopausal women, due to androgens being aromatised to oestrogens to 
create a hyperoestrogenic state (311). Furthermore, androgens have been shown to promote 
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the metastatic potential of stromal fibroblasts cells in vitro in a model of prostate cancer 
(312) and could potentially promote prostate cancer cell growth by increasing expression of 
stromal fibroblast VEGF, as evidenced in vitro (313). Therefore, further investigation into 
androgen actions in the endometrium may elucidate mechanisms that could be targeted for 
the treatment of endometrial disorders. 
1.9 Studying the endometrium 
Modelling the dynamic changes observed in the human endometrium through-out the 
menstrual cycle in animals is challenging because only a few Old World Primates (314, 315) 
and bat species (316) undergo menstruation. Other mammals, such as rodents, who display 
cyclical changes in ovarian-derived steroids, do not exhibit endometrial shedding following 
progesterone withdrawal, rather a process of re-absorption and stromal cell compartment re-
organisation (317). 
1.9.1 Animal models of menstruation 
The endometrium is a multi-cellular tissue with a complex stromal cell compartment that 
interacts with the epithelial cell compartments. Therefore using individual single cell culture 
techniques do not enable a full understanding of tissue function, as cell-cell interactions 
cannot be investigated. Animal models of endometrial function have been developed and 
successfully used to investigate the mechanisms of progesterone withdrawal and subsequent 
breakdown of the tissue in vivo (231, 233, 234). More recently, models have been used to 
delineate contributing factors to endometrial repair (188, 217, 239, 318–320). Xenograft 
models, using human endometrial tissue explants and immunodeficient mice, have allowed 
investigation of endometrial function ex vivo (260, 321–324). 
1.9.2 Xenograft models 
In vitro cultures of single cell suspensions or endometrial explants have limitations in that 
they do not have their own blood supply and the immune cell dynamics cannot be studied. 
Xenograft models using human endometrium, transplanted under the skin or under the 
kidney capsule of ovariectomised mice, maintain tissue integrity, whilst recreating the 
steroid micro-environment. Mice are treated with exogenous oestradiol and progesterone to 
mimic the human cycle. In response to  progesterone withdrawal, endometrial explants 
undergo responses characteristic of menses, including tissue breakdown and immune cell 
influx (240). Xenograft models have been used to study a role for hypoxia during breakdown 
(321), immune cell dynamics (240, 325), and the regulation of MMPs during tissue 
remodelling (325). 
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1.9.3 Non-human primate models 
Menstruating non-human primates, including the macaque, have been used to study 
endometrial function. Like women, macaques display an average 28 day menstrual cycle and 
have a similar uterus. As in women, their endometrium can also be morphologically 
characterised into functional and basal layers (326).  
Artificial menstruation can also be induced in ovariectomised rhesus macaques (Macaca 
mulatta) (231). Sequential treatment with oestradiol for 14 days recreates the proliferative 
phase of the cycle and subsequent treatment with oestradiol plus progesterone mimics the 
secretory phase of the cycle. Removal of progesterone after 14 days induces a “menses like” 
event that mimics that of women. 
This model has been used to study the mechanisms responsible for the induction of 
endometrial breakdown, including a role for MMPs during breakdown (231) and a role for 
fibronectin and integrins in endometrial repair (327). A role for VEGF in endometrial repair 
has also been highlighted using this model (328). VEGFa mRNA concentrations were 
observed to increase 2 days after progesterone withdrawal, during endometrial breakdown. A 
further increase in VEGF expression and in the expression of VEGF receptors 1 and 2 was 
observed during the window of repair (328).  
Slayden and Brenner, have identified a critical window of progesterone withdrawal in these 
animals (329) where menstruation could be reversed if progesterone was withdrawn and then 
replaced within 36 hours. This study supports the hypothesis by Kelly et al., who postulate 
that menstruation occurs in two phases (164). The first phase, where falling progesterone 
concentrations result in increased production in prostaglandins and vasoconstriction can be 
reversed if progesterone is replaced. This suggests that this phase is primarily controlled by 
progesterone mediating its effects through the progesterone receptor. However, the second 
phase of menstruation (tissue breakdown and sloughing) cannot be reversed irrespective of 
progesterone replacement as the factors that drive these mechanisms are postulated to be 
progesterone-independent (164).  
A second non-human primate model involves sub-cutaneous auto-grafting of macaque 
endometrium (231). Ovariectomised animals are treated for 14 days with oestradiol, then 
with oestradiol and progesterone for 8 days. Endometrial grafts were then removed from the 
uterus, stripped of their functional layer and distributed across the abdominal surface in sub-
cutaneous pockets. Animals received oestradiol and progesterone for one month then the 
progesterone pellet was removed and replaced in two week cycles to recreate recurring 
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menstrual cycles. These grafts undergo repair, growth and shedding in response to 
exogenous steroid hormones (231).  
1.9.4 Murine models of breakdown and repair 
1.9.4.1 Using the mouse to model human endometrial function 
As in women, the murine endometrium is subject to cyclical fluctuations in concentrations of 
ovarian steroids as depicted in Figure 1-9, over a 4 day oestrous cycle. In similarity to 
women, the mouse undergoes endometrial proliferation during the oestrogen dominant 
proestrous and oestrous phases. Serum progesterone concentrations increase following 
ovulation however, the murine endometrium does not undergo spontaneous decidualisation 
in the absence of a blastocyst, nor does it breakdown at the end of each cycle following the 
withdrawal of progesterone (330). Despite these shortcomings, the availability of inbred 
strains and transgenic lines, including those with cell-specific deletions of genes, make mice 
an attractive model.   
The mouse endometrium is similar to the human endometrium in that it can be divided into 
three layers; the myometrium, the compacted basal layer and the loosely compacted 
functional stromal compartment (Figure 1-10, A). Like the human endometrium the 
functional layer of the mouse endometrium contains a loosely packed stromal cell 
compartment containing endothelial cells and a luminal and glandular epithelium as depicted 
in Figure 1-10, B.  
 




Figure 1-9: Comparison of murine and human steroid hormone fluctuations across a 4 day oestrous 
cycle (mouse) and a 28 day menstrual cycle (human). Both species are exposed to rising 
concentrations of oestrogens during the follicular phase, with a peak prior to ovulation. Serum 
progesterone concentrations increase during the luteal phase, adapted from (168, 330).  
 
 
Figure 1-10: The murine endometrium. A; The endometrium is divided into three layers; the 
myometrium, the basal layer and the functional layer. B; the functional stroma contains a glandular 
and luminal epithelium and endothelial cells. L; lumen, LE; luminal epithelium, G; glandular 
epithelium, BL; basal layer, FS; functional stroma, M; myometrium; arrows indicate endothelial cells. 
Author’s own image. 
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1.9.4.2 Artificial induction of decidualisation and subsequent breakdown in an 
ovariectomised mouse model 
Finn and Pope recognised the need for a small animal model of menses and were the first to 
describe the artificial induction of decidualisation and menstruation in an ovariectomised 
albino mouse (234). Finn and Keen had previously developed the artificial decidualisation of 
the rat endometrium by oil injection in 1967 (331), having identified a defined treatment 
regime of exogenous steroids to prime the rat endometrium for decidualisation. Finn and 
Keen experimented with a number of non-water soluble solvents; including fat solvents 
(ether, benzene and glycerol), polysaccharides, serum, plasma and dextran but none of these 
solvents induced decidualisation. Decidualisation by oil injection (olive, sesame or paraffin) 
all led to a decidual response in primed rats, the authors hypothesise that it is the “oiliness” 
and persistence of these solvents that induces decidualisation by acting like an implanting 
blastocyst. 
Finn and Pope’s model uses an optimised schedule of oestradiol and progesterone injections 
(73) to mimic the oestradiol and progesterone dominant phases of the human menstrual cycle 
combined with induction of a decidualised cell reaction by oil injection (332).  Cessation of 
progesterone injections results in endometrial breakdown and a “menses like” event; which 
displays similar characteristics of menses in women including an inflammatory response, 
tissue necrosis, breakdown and luminal shedding.  
Despite the authors describing a “menses like” event this model was not widely used until 
2003, when Brasted et al., (233) reinvigorated interest and made further modifications to the 
Finn and Pope model. Notably, by using silastic progesterone-secreting pellets, rather than 
daily injections, to ensure a constant delivery of progesterone (333). Also they used the 
inbred C57BL/6 strain of mice to reduce intra-animal variation. The authors used this model 
to investigate cellular apoptosis and leukocyte infiltration during breakdown (233), but more 
importantly their studies were the first to define stages of breakdown in a rodent model. Also 
they show that “repair”, or re-epithelialisation, was complete within 48 hours of the initiation 
of breakdown (progesterone pellet removal) (233).  
This revised version of the mouse menses model has since been used to study a number of 
factors that might contribute to bleeding and subsequent repair (79, 188, 217, 230, 235, 239, 
318, 319, 334). As in primates, a critical window of progesterone withdrawal has been 
identified in the mouse model; with replacement of progesterone 8-12 hours after the 
removal of the progesterone pellet (withdrawal) being sufficient to stop bleeding (at 8 hours) 
or reduce bleeding (at 12 hours) (235). Replacement of progesterone at 8 hours was 
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sufficient to maintain the decidual cell response, with little cell death observed. Progesterone 
replacement after 12 hours was unable to prevent cellular apoptosis or bleeding. This study 
identified a critical window of breakdown in the mouse following artificial decidualisation, 
with the “first phase” of breakdown complete 12 hours after progesterone withdrawal (235). 
A number of studies have used mice to investigate a role for immune cells during 
endometrial breakdown and subsequent repair (217, 334). Menning et al., investigated the 
effects of inhibiting all granulocytes using an anti-mouse GR-1 antibody which binds to all 
cells that are GR-1
+
 (bone marrow derived monocytes, capable of differentiation into 
macrophages and dendritic cells). In GR-1
+ 
cell depleted mice concentrations of uterine 
MMPs 3, 9 and 10 were all significantly increased, suggesting that granulocytes may 
contribute to the regulation of the inflammatory response (334). A second study, which 
selectively inhibited neutrophils and eosinophils by use of the antibody RB6-8C5 observed 
delayed repair of the endometrium following breakdown. This antibody has been reported to 
have no effect on lymphocyte or macrophage numbers. The authors also noted that 
macrophages, as detected by immunolocalisation for F4/80,  were in low abundance and they 
suggest that they may not contribute to repair of the murine endometrium (217). 
Using this model it has been shown that the murine endometrium is capable of re-
epithelialisation in the absence of oestrogen (239). This was achieved by removal of all 
exogenous steroids by use of a soy-free diet, and all effects of any exogenous oestrogens 
were inhibited using letrozole, an inhibitor of aromatase (the enzyme required for synthesis 
of oestradiol from androstenedione). Follow up studies have also indicated a role for 
extracellular matrix and activin in epithelial cell repair (79, 319). 
A variation of this established model identified that pharmaceutical blocking of progesterone 
receptor, with mifepristone, was also adequate to induce a “menses like” event (335), and 
that breakdown was initiated at 16 hours after progesterone withdrawal. This is in line with 
the findings of Brasted et al., (233) indicating that the induction of breakdown was not 
affected by either method of progesterone withdrawal.   
1.9.4.3 Pseudopregnancy model of breakdown and repair 
The models described in 1.9.4.2 used ovariectomised mouse models, where all hormones 
were given exogenously by subcutaneous injection (oestradiol) or by secreting pellet 
(progesterone).  
Fan et al., have developed a mouse model without the need for ovariectomy, in which 
endogenous ovarian hormones contribute to the regulation of uterine tissue (188). Briefly, 
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intact mice, of the CD1 strain, were mated with vasectomised males and then on day 4 of 
pseudopregnancy females received an intrauterine injection of oil to induce decidualisation. 
Steroid withdrawal was then induced 2 days after oil injection by ovariectomy. Endometrial 
shedding is complete within 24 hours of ovariectomy  and re-epithelialisation was observed 
to occur at 48 hours (188) in the absence of oestradiol and progesterone.  
Endometrial repair has been investigated using this pseudopregnancy model. As in the non-
human primate model, VEGF was shown to be essential for re-epithelialisation, neo-
angiogenesis and vessel stability during the repair phase in the mouse (188). Mice that 
received an inhibitor of VEGF, the VEGF trap, at the time of steroid withdrawal failed to 
fully repair, and deficiencies in vasculature were observed. The pseudopregnancy model has 
also identified a role for the Wnt family signalling molecule Wnt7a in re-epithelialisation, as 
adenoviral knock downs of Wnt7a resulted in a failure of re-epithelialisation and degradation 
of basal glands (320).  
Using a variation of the pseudopregnancy model, Rudolph et al., developed a mouse model 
of breakdown in BALB/C mice that displayed overt menstruation, where blood is either 
visible at the opening to the vagina or following lavage with a small volume of water. In this 
model, females were given an injection of mifepristone, 2 days after oil injection to block the 
progesterone receptor and mimic progesterone withdrawal; bleeding was evaluated using 
vaginal lavage (336).  
The authors were the first to record overt menstruation in mice with blood flushed from the 
murine uterus, raising questions as to why previous mouse models of menses have not shown 
shedding and clearance of endometrial tissue.  
1.10  General conclusions and aims of this study 
The human endometrium is a multi-cellular tissue which under the influence of cyclical 
variations in concentrations of the ovarian steroid hormones oestrogen and progesterone 
undergoes cycles of growth, differentiation, shedding and repair. In a non-pregnant woman, 
menstruation, the shedding of the functional layer of the endometrium, is induced by the 
withdrawal of progesterone due to regression of the corpus luteum. This in turn initiates a 
cascade of events which cause tissue ischaemia, necrosis and subsequent clearance of the 
degraded tissue.  
Simultaneous shedding and repair of the endometrium occurs, suggesting that repair 
mechanisms are initiated whilst the tissue is in an oestrogen-depleted state. The mechanisms 
that drive re-epithelialisation and stromal cell compartment reorganisation are not fully 
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understood. It is widely accepted that re-epithelialisation occurs through basal gland 
epithelial cell proliferation; however there is evidence for a contribution from the underlying 
stroma.  It seems likely that the repair of the endometrium will occur through a combination 
of mechanisms with both the epithelial and stromal cell compartments of the residual basal 
layer contributing to the new luminal epithelium. A role for androgens has also not been 
previously explored. 
As the endometrium is a multi-cellular tissue, models using tissue explants (xenografts) have 
been developed to maintain tissue integrity and to complement studies using single cell 
cultures. Both non-human primates and mice have been used to study menstruation and 
endometrial repair. These studies have largely focussed on the identification of tissue 
remodelling factors, including the metalloproteinases, and immune cells, namely leukocytes 
and neutrophils. However, little attention has been paid to macrophages which are at their 
highest numbers during menstruation in women, and therefore may be contributing to repair 
as well as tissue breakdown.  
Models using ovariectomised mice, administration of exogenous steroids and oil-induced 
decidualisation have reported restoration of tissue integrity by 48 hours after progesterone 
withdrawal. However, studies using this model have not considered that the endometrium 
will shed and repair simultaneously. Nor have they shown overt menstruation, which has 
only been shown in a pseudopregnancy mouse model of breakdown. 
In the studies outlined in this thesis, the following questions have been addressed: 
1. Is it possible to establish a model of menses in the mouse, which mimics menses in 
women namely; simultaneous breakdown and repair, overt menstruation, immune 
cell influx, tissue necrosis and re-epithelialisation? 
2. Does the stromal cell compartment contribute to endometrial regeneration? 
3. Is there a role, if any, for androgens during endometrial repair? 
Therefore the hypotheses of this study were; as demonstrated in the human, the stromal cell 
compartment will contribute to endometrial repair in a murine model of menses and 
androgens will have an effect on breakdown and repair of the endometrium following 
progesterone withdrawal. 
In the present study, an established mouse model of endometrial breakdown was adapted and 
optimised to examine an early window of endometrial breakdown. Immunohistological 
examination of the endometrium was supported by mRNA expression data for candidate 
Chapter 1. Literature Review. 
36 
 
genes hypothesised to be involved in endometrial repair. The effect of androgens on repair 
was investigated using this mouse model.  
The results herein implicate androgens and stromal mesenchymal to epithelial transition in 
the restoration of endometrial tissue homeostasis during menstruation. These findings may 
inform development of new treatments for disorders associated with aberrant repair such as 
heavy menstrual bleeding and endometriosis. 
Chapter 2. Materials and Methods. 
37 
 
Chapter 2 Materials and Methods 
2.1 Animal work 
All animal procedures were carried out under the Home Office Animals (Scientific 
Procedures) Act 1986 under project licence number PPL 60/4208 and personal licence 
number PIL 60/12992.  
All animals were housed in standard conditions with food and water provided ab libitum 
with a constant light cycle of 12 hours.  
Wild type C57BL/6 mice were bred in house from available breeding stocks or purchased 
from Charles River (Charles River Laboratories International, Inc. 251 Ballardvale Street, 
Wilmington, Massachusetts, USA). 
2.1.1 Collection of control murine uterine tissue 
To monitor oestrous cycles, adult females of 4-8 weeks of age received daily cervical smears 
for 14 days. Each vaginal secretion was collected on glass slides, air dried, fixed in 
methanol, stained with haematoxylin and eosin and viewed under a microscope. Stages of 
oestrous were identified as diestrus, proestrus, estrus and metestrus seen in Figure 2-1.  
 
Figure 2-1: Haematoxylin staining of the oestrous cycle of the mouse.  Adapted from (337)). 
Mice were culled on an appropriate day, so that uterine tissue at each stage could be 
collected for analysis. One hour prior to culling, mice were injected intraperitoneally with 5-
bromo-2'-deoxyuridine (BrdU) (Sigma Aldrich, St Louis, Montana catalogue number) 
(2.5mg/ml in PBS) to enable identification of actively proliferating cell types at each stage of 
the cycle.  
2.1.2 Transgenic mice- the fms-EGFP mouse line- “The Mac green mouse” 
Macrophage colony stimulating factor (CSF-1) regulates differentiation, proliferation and 
survival of cells of the mononuclear phagocyte system (338). The gene is expressed 
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selectively in macrophage and trophoblast cell lineages and its activity is mediated by the 
CSF-1 receptor encoded by c-fms proto-oncogene (339, 340). 
The generation of these mice has been described previously (340–342). Founder stocks were 
obtained from Dr. Bernadette Dutia and Professor David Hume (Roslin Institute, University 
of Edinburgh). Two heterozygous EGFP positive males and two heterozygous EGFP 
positive females were cross bred with wild type C57BL/6 to form a breeding colony.  
2.1.3 Genotyping macrophage green fluorescent protein labelled mice 
2.1.3.1 Preparation of digestion buffer 
A 50ml stock solution of digestion buffer was prepared using the reagents listed in Table 2-1 
and kept at room temperature. 
Reagent Stock Final Concentration Volume for 50ml stock 
KCl 1M 50mM 2.5ml 
Tris-HCl pH8.3 1M 10mM 0.5ml 
Gelatine 0.2g/ml 0.1mg/ml 25μl 
Tween 20 20% 0.45% 1μl 
H2O  46.974ml 
Table 2-1: Digestion buffer reagents and volumes for stock solution. 
2.1.3.2 Preparation of stock proteinase K  
Proteinase K is a serine protease with broad peptide cleavage activity and therefore is used to 
digest proteins in biological samples.  
Stock Proteinase K (Promega, Wisconsin, USA) was re-suspended in 5ml of proteinase K 
reconstitution buffer (50mMTris-HCl (pH8) and 10mM CaCl2) (Promega) to a working 
concentration of 20mg/ml and aliquoted and stored at -20°C.  
2.1.3.3 DNA extraction from mouse ear biopsy 
For each reaction, 50μl of digestion buffer and 200μg/ml of proteinase K were added to each 
ear clip and then incubated at 55°C for 5 minutes and 95°C for 10 minutes. Suspensions 
were then stored at -20°C until PCR analysis could be completed. 
2.1.3.4 PCR for EGFP transgene in DNA sample from mouse ear biopsy 
PCR was carried out to amplify a region of the EGFP transgene using specific primers to 
EGFP. An internal control, fatty acid binding protein 2 (Fabpi), was used as a control for 
both DNA quality and the success of the PCR reaction. 
A final reaction volume of 10μl was prepared from 2x Biomix (Bioline, London, UK), 
100μM stocks of EGFP primers (Eurofins mwg operon, Ebersberg, Germany) and 100μM 
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Fabpi primer stocks (internal control) (Eurofins). Final concentrations, primer sequences and 
reaction volumes are shown in Table 2-2. Primer sequences for EGFP and Fabpi are shown 
in Table 2-3. A positive (known GFP animal), a negative control (known negative GFP 
animal) and a no template control (no DNA) were also prepared. 
PCR amplification was carried out under the following conditions; 35 cycles of 94°C for 30 
seconds; 65°C for 30 seconds; 72°C for 1 minute then 72°C for 7 minutes and finally 10°C 
for ten minutes. Samples were then kept at 4°C overnight OR at -20°C for later processing.  
Reagent Stock Final Concentration 
Volume per 10μl reaction 
(μl) 
2x Biomix 1x 5 
EGFP Forward Primer 100μM 100nM 0.1 
EGFP Reverse Primer 100μM 100nM 0.1 
Fabpi Forward Primer 100μM 100nM 0.1 
Fabpi Reverse Primer 100μM 100nM 0.1 
H20  3.6 
DNA  1 
Table 2-2: PCR mastermix reagents and volumes for 10µl reaction. 
Primer Primer Sequence 
EGFP Forward 5' GCA CGA CTT CTT CAA GTC CGC CAT GCC 3' 
EGFP Reverse 5' GCG GAT CTT GAA GTT CAC CTT GAT GCC 3' 
Fabpi Forward 5' CCT CCG GAG AGC AGC GAT TAA AAG TGT CAG 3' 
Fabpi Reverse 5' TAG AGC TTT GCC ACA TCA CAG GTC ATT CAG 3' 
Table 2-3: Primer sequences for EGFP and Fabpi. 
2.1.3.5 Automated analysis of DNA fragments using the QIAxcel system 
The QIAxcel system (QIAGEN) is an automated multi-capillary electrophoresis system for 
separation of DNA fragments with high detection sensitivity even at low concentrations of 
nucleic acids. The system uses high resolution cartridges capable of detecting fragments as 
small as 15 base pairs.  
2.1.3.6 DNA separation 
Samples were added to individual capillaries set in a pre-cast gel cartridge. Negatively 
charged nucleic acids migrate to the positively charged end of the capillary. As they migrate 
they pass a detector which measures fluorescence, this emission signal is converted into an 
electronic data by the photo multiplier (Figure 2-2). Results are displayed as an 
electropherogram (not shown) or as a gel image, (Figure 2-3). 




Figure 2-2: Sample separation of DNA fragments using the QIAxcel system adapted from the 
QIAxcel handbook. 
 
Figure 2-3: Gel image of typical DNA fragment analysis using QIAexcel.  Positive sample for EGFP 
shown in lane 2, negative sample shown in lanes 3 and 4. Internal Fabpi control shown at 500bp. 
2.1.4 Mouse model of menstruation and regeneration 
2.1.4.1 Preparation of steroids for injection 
A 1mg/ml stock solution and a 50μg/ml stock solution of β-oestradiol were prepared using 
crystallised β-oestradiol (E8875, Sigma) and 100% ethanol (VWR Prolabo, France).  
Final working concentrations of 1μg/ml and 50ng/ml were prepared using a 1/1000 dilution 
of stock solutions in sesame seed oil (S3547, Sigma).  
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2.1.4.2  Preparation of progesterone secreting pellets 
Lengths of rubber tubing (Dow corning silastic tubing Cat #508-008, 1.57mm I.D x 3.18mm 
OD) were washed in 70% ethanol and rinsed in distilled water before air drying. From this 
tubing, 14mm lengths were cut and one end sealed using adhesive sealant (Dow Corning 
multipurpose sealant 732). The pellets were then filled with crystalline progesterone (P1030, 
Sigma) and sealed.  
2.1.4.3 Enzyme-Linked Immunosorbent Assay (ELISA) for quantitative determination of 
progesterone secretion from pellets 
Prior to sub-cutaneous insertion, each progesterone pellet was incubated in 1ml of 1% 
charcoal stripped foetal calf serum (CSFCS) in phosphate buffered saline (PBS) 
(1%CSFCS:PBS) for a minimum of 48 hours at 37°C. The 1%CSFCS:PBS solution was 
collected and analysed on the same day. Determination of pellet progesterone secretion was 
carried out using a progesterone enzyme-linked immunosorbent assay (ELISA) kit 
(DEMEDITEC diagnostics, Germany). This ELISA is based on the principle of competitive 
binding where progesterone in the sample of interest competes with a progesterone 
horseradish peroxidase (HRP) conjugate for binding to a polyclonal anti-progesterone 
antibody which has been pre-coated to the microtiter wells of the ELISA plate. The amount 
of bound peroxidase is inversely proportional to the amount of progesterone in the sample. 
2.1.4.3.1 Assay procedure 
Aspirated 1%CSFCS:PBS solution, along with 6 known standards and 3 control samples 
(CSFCS media spiked to be “low”, “medium” and “high” for progesterone) (Table 2-4) were 
dispensed in duplicate in 25μl volumes into microtiter wells pre-coated with a polyclonal 
anti-progesterone antibody and left to incubate at room temperature for 5 minutes. 
Progesterone conjugated to HRP, was added to each well in 200μl volumes. The plate was 
then incubated for 1 hour on a shaking plate to ensure thorough mixing of sample and 
enzyme conjugate. Wells were rinsed thoroughly 5 times with wash buffer and struck against 
absorbent paper to remove any residual liquid. A substrate solution containing 
tetramethylbenzidine was added to each well in 200μl volumes and left to incubate in the 
dark at room temperature for 15 minutes. The reaction was then stopped by the addition of 
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Standard/ Known Control Concentration (ng/ml) 
Std 0 0 
Std 1 0.3 
Std 2 1.25 
Std 3 2.5 
Std 4 5 
Std 5 15 
Std 6 40 
Low Progesterone 5 
Medium Progesterone 15 
High Progesterone 30 
Table 2-4: Progesterone concentrations of known standards and controls (ng/ml). 
2.1.4.3.2 Assay characteristics 
The range of the assay was between 0-40ng/ml. Cross reactivity of the antibodies with other 
steroid hormones were previously tested by the manufacturer and are depicted in Table 2-5.  
Steroid Cross Reaction (%) 
Progesterone 100 
17α OH Progesterone 0.3 
Estriol <0.1 









Table 2-5: Specificity of antibodies. 
Intra assay variation and inter assay variation indicate the precision and repeatability of the 
assay. Intra assay variation, describes the variation within a data set from on experiment, an 
intra assay variation of <10 is acceptable. Inter assay variation describes the variation from 
one assay plate to another, an inter-assay variation <15 is generally acceptable. Intra and 
inter assay variations shown below in Table 2-6 and Table 2-7 respectively. 
Sample n Mean (ng/ml) CV (%) 
1 20 0.62 5.4 
2 20 4.67 6.99 
3 20 10.8 6.86 
Table 2-6: Intra assay variation. 
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Sample n Mean (ng/ml) CV (%) 
1 12 0.56 9.96 
2 12 4.55 4.34 
3 12 10.65 5.59 
Table 2-7: Inter assay variation. 
2.1.4.3.3 Assay data analysis 
The optical density of each well was read at 460nm. Standard curve and average absorbance 
values were calculated using Masterplex Readerfit (MiraiBio Group, Hitachi Solutions, 
California, USA). 
Pellets that were identified to be secreting ≥10mg/ml of progesterone were chosen for 
subsequent animal studies.  
2.1.4.4 Mouse model of menstruation protocol 
A mouse model of menstruation was established in house using a protocol adapted from 
(233). An overview of the adapted protocol is shown in Figure 2-4.  
 
Figure 2-4: Mouse model of menstruation and regeneration.  Ovex; ovariectomy, E; β-oestradiol, P; 
progesterone. β-oestradiol concentrations in brackets.  
Female C57BL/6 mice of 8-10 weeks of age were ovariectomised under iso-fluorane induced 
anaesthesia (Merial), whilst also receiving a post-operative injection of the analgesic, 
buprenorphine (Vetergesic, 0.1mg/kg, Alstoe animal health). Animals were allowed to 
recover for seven days following surgery, to allow for depletion of endogenous steroid 
production. On days 7-9, mice received sub-cutaneous injections (0.1ml) of β-oestradiol in 
sesame seed oil (1μg/ml), resulting in a final dose of 100ng/100μl. On day 13 after 
ovariectomy, mice were anaesthetised under iso-fluorane and progesterone secreting pellets 
were place sub-cutaneously. On days 13-15 mice received daily sub-cutaneous injections 
(0.1ml) of β-oestradiol in sesame seed oil (50ng/ml), resulting in a final dose of 5ng/100μl. 
To induce endometrial decidualisation, stimulation of one uterine horn was performed under 
iso-fluorane induced anaesthesia using a single embryo transfer device (Datesand, 
Manchester, UK). Twenty microlitres of sesame seed oil was delivered trans-vaginally into 
the uterine lumen of one horn. The contra-lateral horn was untreated and served as a control.  
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Progesterone withdrawal was induced when pellets were removed 90 hours after oil 
injection, designated as time 0. Animals were culled by asphyxiation by carbon dioxide gas 
at 0, 4, 8, 12, 24 and 48 hours after steroid withdrawal. 
Each animal received intra-peritoneal injections of BrdU (2.5mg/ml in PBS) and 
Hypoxyprobe® (15mg/ml in PBS) 90 minutes prior to culling to measure cellular 
proliferation and cellular oxygen tension respectively.  Hypoxyprobe® is a reagent which 
forms protein adducts within cells that are at a pO2 pressure of less than 10mmHg, <1% 
oxygen and is visualised by as a brown stain following immunohistochemistry. The intensity 
of immunostaining is directly proportional to oxygen tension. Strong immunostaining is 
indicative of very low oxygen tensions, cells are exposed to very hypoxic conditions, 
whereas, the absence of immunostaining indicates cells that are under normoxic conditions 
(>1% oxygen).   
 Blood from each animal was collected by venepuncture, centrifuged for 5 minutes at 13,000 
rpm and the supernatant serum collected and stored at -20°C for future analysis. 
Uteri were dissected, cleaned of fat and weighed. Tissue was cut into pieces and stored in 
either RNAlater (QIAGEN) at -80°C for subsequent RNA extraction or in 10% neutral 
buffered formalin (NBF) overnight for histological analysis. 
Decidualisation was considered successful where a 400% increase in uterine horn weight as 
compared to the non-decidualised contra lateral control horn was observed. Any mouse in 
which the oil treated horn did not meet this criteria was excluded from the study. 
2.1.4.4.1 Enzyme immunoassay for quantitative determination of progesterone in 
sera 
Progesterone concentrations in sera were measured to ensure steroid withdrawal had 
occurred. Determination of progesterone in sera was carried out as described in 2.1.4.3, 
using 25μl volumes for each sample. 
2.2 RNA extraction 
Extraction of RNA from either mouse uterine tissue or human cell monolayer extracts was 
performed using the RNeasy mini kit according to manufacturer’s instructions (QIAGEN).  
Pieces of mouse uterine tissue previously stored in RNAlater (RNA stabilisation reagent) at -
80°C were thawed to room temperature. Each sample was weighed and a 30mg piece cut 
from the original sample. Any remaining tissue was restored in RNAlater at -80°C.  
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2.2.1 RNA extraction performed using the RNA easy mini kit 
All mouse uterine horn samples were placed in RNeasy Lysis Buffer (RLT) with 1% β-
mercaptoethanol and homogenized using metal beads and a tissue lyser (QIAGEN) 
according to manufacturer’s instructions. All cell extracts were placed in RLT+1% (v/v) β-
mercaptoethanol and homogenised using QIAshredder spin columns. Seventy percent 
ethanol was added to all lysates to aid binding conditions and each sample was added to an 
RNeasy mini spin column. Following a series of wash steps (as detailed in the RNeasy mini 
kit handbook) total RNA bound to the column whilst all contaminants were washed away. 
The purified total RNA was then eluted in 30μl of RNase free water.  
2.2.2 RNA quantification using Nanodrop 
The total concentration of RNA in each sample was determined using a Nanodrop ND-100 
Spectrophotometer (Thermoscientific, Delaware, USA), which measured the absorbance of 
eluted RNA. Each sample was then standardised to a concentration of 100ng/μl using RNase 
free water and stored at -80°C. 
2.3 Synthesis of complementary DNA  
Reverse transcription of RNA to a single complimentary strand of DNA (cDNA) was 
performed using the Superscript VILO cDNA synthesis kit (InVitrogen) according to 
manufacturer’s instructions, using the volumes outlined below in Table 2-9.  
Reagent Stock Volume per 40µl reaction (µl) 
5x Vilo 8 
10x Enzyme 0.5 
RNA (100ng/µl) 2 
Water 29.5 
Table 2-8: Reagent volumes used for synthesis of complementary cDNA. 
Each reaction contained a final concentration of 1x VILO reaction mix, 0.125x Superscript 
enzyme and 100ng/μl of RNA in a final volume of 40μl. Samples were then incubated under 
the following conditions: 25°C for 10 minutes, 42°C for 60 minutes and 52°C for 5 minutes 
in a thermal cycler (MJ Research PTC-200 Thermo Cycler, BC-MJPC200). 
2.4 Quantitative Real Time PCR- TaqMan method 
Quantitative real time polymerase chain reaction (qRTPCR) is used to amplify and quantify 
specific PCR products whilst significantly reducing any background or false positives.  
The TaqMan® method relies on fluorescent probes; in the current study these were supplied 
from the Universal Probe Library (Roche), to enable detection of specific PCR products after 
each PCR cycle. The fluorogenic probes have two fluorescent dyes; a 5’-end reporter dye 6-
Chapter 2. Materials and Methods. 
46 
 
carboxy-fluorescein (FAM) and a 3’-end quencher dye 6-carboxy-tetramethyl-rhodamine 
(TAMRA) (Figure 2-5, A) that binds to an amplicon defined by the specific primer pair 
(Figure 2-5, B). The quencher molecule inhibits the fluorescence emitted by reporter dye via 
fluorescence resonance energy transfer (FRET). The 5’-3’ exonuclease activity of the Taq 
polymerase cleaves the dual-labelled probe resulting in the release of the reporter dye 
(Figure 2-5, C). Fluorescence is measured proportionally to the release of the FAM 
fluorophore.  
 
Figure 2-5: Quantitative RTPCR TaqMan Method.  A. Fluorogenic probes have two fluorescent dyes; 
a 5’ reporter (FAM) and a 3’ quencher (TAMRA). Specific primer pairs for the gene of interest were 
designed using the Universal Probe Library Assay Design Center (Roche Applied Science). B. Primers 
and probe bind to the amplicon defined by the specific primer pair. The 3’ quencher inhibits 
fluorescent emissions by the reporter dye. C. The exonuclease activity of Taq polymerase cleaves the 
dual labelled probe which results in the release of the reporter dye. Fluorescence is measured. 
(Adapted from (343)). 
2.4.1 Quantitative Real Time PCR (qRTPCR) 
A final reaction volume of 15µl (Table 2-9) was prepared for each sample that contained 
qPCR SuperMix with ROX premixed (InVitrogen, California, USA), an internal control 
gene 18s (VIC- conjugated); forward and reverse primers for the gene of interest (FAM-
conjugated). Primers for each gene of interest were designed using the Universal Probe 
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Library Assay Design Center (Roche Applied Science, Penzberg, Germany) and purchased 
from Eurofins (mwg operon, Germany). Primer sequences are shown in . 
Each reaction was prepared in duplicate and plated onto a 96 well MicroAmp Fast Optical 
reaction plate (Applied Biosystems, California, USA) and PCR amplification was carried out 
under the following conditions: 95°c for 10 minutes then 40 cycles of 95°c for 15 seconds 
then 60°c for 1 minute on a fast real-time PCR System (Applied Biosystems, 7900HT). 
Reagent Stock Final Concentration 
Volume per 15μl 
reaction (μl) 
2x Express Supermix 1x 7.5 
Forward Primer 20μm 200nM 0.15 
Reverse Primer 20μm 200nM 0.15 
Probe 10μm 100nM 0.15 
Housekeeping gene 18s primer 10nM, probe 40nM 0.112 
DEPC H2O  4.375 
cDNA  1.5 
Table 2-9: Reaction volumes for TaqMan qRTPCR 
2.4.2 Quantification of gene expression 
Quantification of gene expression relies on plotting the detection of fluorescence against the 
number of cycles on a logarithmic scale. The threshold cycle (Ct) is defined as the number of 








Figure 2-6: Quantification of gene expression. Detection of fluorescence is plotted against the 
number of cycles (x axis) on a logarithmic scale. 
The Ct value is indirectly proportional to the amount of PCR product formed. Analysis was 
performed using the ΔΔCt method where the fold change is relative to a reference sample as 
well as an internal control. Sample Cts were normalised to the internal control 18s ribosomal 
RNA, where ΔCt= Gene of Interest Ct- 18s Ct. The fold change, ΔΔCt, was then calculated 
as the sample ΔCt – control sample ΔCt. 
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Gene name Accession Number Forward Primer Sequence Reverse Primer Sequence 
UPL Probe 
Number 
Mus musculus prolactin family 8, subfamily 
a, member 2 (Prl8a2) 
NM_010088.1 tcagctggacaatttgaaaca tgtgacattagagtggcagtga 21 
Mus musculus estrogen receptor 1 (alpha) 
(Esr1) 
NM_007956.4 gctcctaacttgctcctggac cagcaacatgtcaaagatctcc 97 
Mus musculus androgen receptor (Ar) Nm_013476 ccagtcccaattgtgtcaaa tccctggtactgtccaaacg 58 
Mus musculus wingless-related MMTV 
integration site 4 (Wnt4) 
NM_009523 ctggactccctccctgtctt atgcccttgtcactgcaaa 62 
Mus musculus wingless-related MMTV 
integration site 7a (Wnt7a) 
NM_009527.3 cgctcatgaacttacacaataacg acaggagcctgacacaccat 78 
Mus musculus cadherin 1 (Cdh1) NM_009864.2 atcctcgccctgctgatt accaccgttctcctccgta 18 
Mus musculus cadherin 2 (Cdh2) NM_007664.4 cctccatgtgccggatag caccagaagcctccacagac 74 
Mus musculus Vimentin (Vim) NM_011701.4 tgcgccagcagtatgaaa gcctcagagaggtcagcaaa 79 
Mus musculus keratin 18 (Krt18) NM_010664.2 agatgacaccaacatcacaagg tccagaccttggacttcctc 78 
Mus musculus vascular endothelial growth 
factor A (Vegfa, isoform 1) 
NM_001025250.3 aaaaacgaaagcgcaagaaa tttctccgctctgaacaagg 1 
Mus musculus chemokine (C-X-C motif) 
ligand 12 (Cxcl12), transcript variant 3 
NM_001012477.1 ctgtgcccttcagattgttg taatttcgggtcaatgcaca 41 
Mus musculus angiopoietin 1 (Angpt1) NM_009640.3 cggatttctcttcccagaaac tccgacttcatattttccacaa 50 
Mus musculus angiopoietin 2 (Angpt2) NM_007426.3 cacactgaccttccccaact cccacgtccatgtcacagta 82 
Mus musculus platelet/endothelial cell 
adhesion molecule 1 (Pecam1), transcript 
variant 2, mRNA 
NM_001032378.1 cggtgttcagcgagatcc actcgacaggatggaaatcac 45 
Mus musculus snail homolog 1 (Drosophila) 
(Snai1) 
NM_011427.2 gtctgcacgacctgtggaa caggagaatggcttctcacc 71 
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Gene name Accession Number Forward Primer Sequence Reverse Primer Sequence 
UPL Probe 
Number 
Mus musculus snail homolog 2 (Drosophila) 
(Snai2) 
NM_011415.2 tgcaagatctgtggcaagg cagtgagggcaagagaaagg 71 
Mus musculus Wilm's tumor 1 homolog 
(Wt1) 
NM_144783.2 cagatgaacctaggagctaccttaaa tgcccttctgtccatttca 3 
Mus musculus platelet derived growth 
factor receptor, beta polypeptide (Pdgfrb), 
transcript variant 1 
NM_001146268.1 tcaagctgcaggtcaatgtc ccattggcagggtgactc 67 
Mus musculus connective tissue growth 
factor (Ctgf) 
NM_010217.2 tgacctggaggaaaacattaaga agccctgtatgtcttcacactg 71 
Mus musculus MAD homolog 3 
(Drosophila) (Smad3) 
NM_016769.4 tccgtatgagcttcgtcaaa ggtgctggtcactgtctgtc 32 
Mus musculus chemokine (C-C) motif 
ligand 2 (Ccl2) 
NM_011333.3 catccacgtgttggctca gatcatcttgctggtgaatgagt 62 
Mus musculus colony stimulating factor 1 
(macrophage) (Csf1) 
NM_001113529.1 caggtggaactgccagtataga gagggtagtggtggatgttcc 12 
Mus musculus matrix metallopeptidase 3 
(Mmp3) 
NM_010809.1 ttgttctttgatgcagtcagc gatttgcgccaaaagtgc 7 
Table 2-10: Primer sequences, accession numbers and UPL probe numbers used for genes of interest. 
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2.5 RT2 Profiler PCR array- SYBR® green method 
RT
2
 profiler arrays (SABiosciences, Frederick, MD, USA) combine the real time 
performance of PCR and the ability of a microarray to detect expression of many genes 
simultaneously. The arrays are designed to contain a panel of 96 primer sets containing 
housekeeping genes, quality controls and 84 genes that are related to a specific biological 
pathway. RNA samples used in RT
2
 profiler PCR array were subject to quality assessment 
based on an RNA integrity number (RIN). Samples where RIN<6.0 were excluded. 
The RT
2
 profiler array uses SYBR® green based detection which differs to the Taqman 
method. Unlike Taqman, where a specific probe is used for a target sequence, SYBR® green 
can be added to any sample where it binds to all double stranded DNA present in the sample. 
During the PCR sequence, DNA polymerase amplifies the target sequence identified by the 
primers and creates PCR products to which the SYBR® green dye binds. As the PCR 
progresses, more product is created and an increase in fluorescent intensity is detected 
proportional to the amount of PCR product produced.  
The SYBR® green method can result in false positives as the SYBR® green dye may bind to 
non-specific double stranded DNA sequences, therefore validation of the array was carried 
out using the Taqman method, which has a higher specificity.  
2.5.1 RNA quantitation using Agilent Technologies 
Agilent RNA kits (Agilent Technologies, Waldbronn, Germany) are designed to analyse 
RNA, using the RNA Integrity Number (RIN) as a measurement of overall RNA quality.  
2.5.1.1 Preparing the gel 
RNA samples were analysed using the Agilent RNA 6000 Nano Kit (Agilent Technologies, 
5067-1511). Briefly, 550µl of the RNA gel matrix was pipetted onto a spin filter and 
centrifuged at 1500g for 10 minutes. The gel was then aliquoted into 65µl volumes and 
stored for future use at 4°C.  
One microlitre of RNA dye concentrate was then added to one aliquot, mixed well and 
centrifuged at 13000g for 10 minutes.  
2.5.1.2 Loading the Gel dye mix and marker 
The gel dye mix was loaded onto the RNA chip as per manufacturer’s instructions as 
detailed in the quick start guide. Five microlitres of the RNA marker were then added to all 
sample wells.  
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2.5.1.3 Loading the ladder and samples for analysis 
Prior to loading onto the RNA chip, 1.2µl of each RNA sample, extracted as described 
previously, were denatured at 70°C for two minutes. The ladder was loaded onto the RNA 
chip as per manufacturer’s instructions as detailed in the quick start guide. One microlitre of 
each RNA samples was added to an individual sample well on the RNA chip. The chip was 
then vortexed using an IKA vortexer for 1 minute at 2400rpm. The chip was then run on a 
2100 Agilent Bioanalyser to measure eukaryote total RNA. RNA quality is displayed as an 
electropherogram (Figure 2-7) and a gel-like image (Figure 2-8), and as a RIN. A RIN 
greater than 6.0 was accepted for further analysis by PCR array. 
 
Figure 2-7: Electropherogram shows sharp peaks for the 18s and 28s ribosomal RNA. Time in 
seconds is displayed along the x axis, where fluorescence is displayed on the y axis. 
 
Figure 2-8: Digital gel-like image depicting sharp bands for 18s (~2000) and 28s (~4000) ribosomal 
RNA.  Any sample which had failed the RNA quality control would be highlighted in red.  
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2.5.2 RNA quantification using Nanodrop 
The total concentration of RNA in each sample was determined using a Nanodrop ND-100 
Spectrophotometer, which measured the absorbance of eluted RNA. Each sample was then 
standardised to a concentration of 400ng/μl using RNase free water to be used in the profiler 
array. 
2.5.3 cDNA synthesis using the RT2 first strand kit 
Reagents from the RT
2
 First Strand Kit were thawed prior to use, centrifuged and set on ice. 
A genomic elimination (GE) mix was prepared for each sample as outlined in Table 2-11. 
RT Component Volume per 10µl sample 
RNA 400ng/µl 
Buffer GE 2µl 
RNase free water Variable 
Table 2-11: Genomic elimination mix. 
Each GE mix was incubated at 42°C for 5 minutes then immediately set on ice for a 
minimum of 1 minute. The reverse transcription (RT) mix was prepared as outlined in Table 
2-12, 10µl of the RT mix was added to each tube containing the GE mix and mixed 
thoroughly by pipetting. Samples were then incubated at 42°C for 15 minutes then the 
reaction immediately stopped by incubating at 95°C for 5 minutes, 91μl of RNase free water 
was then added to each sample and all reactions were then placed on ice.  
RT Component Volume x24 samples 
5x Buffer BC3 96µl 
Control P2 24µl 
RE3 Reverse Transcriptase Mix 48µl 
RNase free water 72µl 
Table 2-12: Reverse transcription mix. 
2.5.4 Real-Time PCR for RT2 profiler PCR arrays 
A PCR components mix was prepared for each sample as shown in Table 2-13: . Using a 384 
well plate (4x96 well format), 10µl of each sample was added to the appropriate wells. The 
plate was then sealed using optical adhesive film, and centrifuged for 1 minute at 1000g at 
room temperature.  
Reagent Volume per sample 
2x RT
2
 SYBR Green Mastermix 650µl 
cDNA synthesis reaction 102µl 
RNase free water 548µl 
Table 2-13: PCR components mix. 
Real time PCR amplification was performed using the Applied Biosystems 7900HT Fast 
Real-Time PCR system, following the two step cycling programme as detailed in Table 2-14.  
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Cycles Duration Temperature 
1 10 minutes 95°C 
40 15 seconds 95°C 
 
1 minute 60°C 
Table 2-14: Thermal cycling programme for PCR amplification. 
The RT
2
 SYBR green mastermix uses hot-start Taq DNA polymerase, which prevents any 
polymerase activity prior to heat activation which reduces amplification of any non-specific 
PCR products. SYBR green fluorescence was detected during the annealing step in each 
cycle and the threshold Ct for each well was calculated. 
2.6 Tissue processing 
All samples were fixed in NBF overnight at room temperature, rinsed in 70% ethanol and 
then stored in 70% ethanol before tissue processing in a core facility according to standard 
protocols (www.crh.ed.ac.uk/surf).  
Uterine samples were orientated in the wax blocks so that transverse sections of the uterine 
horn could be cut. 
Serial 5μm sections were cut using a Leica RM2125RT microtome onto X-tra adhesive pre-
cleaned micro slides (Surgipath, Leica Biosystems, Peterborough, UK) and incubated 
overnight at 57°C. Slides were stored at room temperature until future use. 
2.7  Histological examination of murine uterine sections 
2.7.1 Haematoxylin and eosin staining 
Haematoxylin and Eosin staining (H&E) is a commonly used histological staining method. 
Haematoxylin colours the nucleus of a cell blue, whilst eosin colours cytoplasmic structures 
in varying shades of pink to red.  
On serial sections mounted on slides, H&E staining was carried out on sections 300µm apart 
to determine a working area of uterus for further immunohistological analysis. 
Tissues sections were dewaxed in xylene (VWR Prolabo) for 10 minutes (two 5 minute 
washes) before being rehydrated at 20 second intervals through descending concentrations of 
alcohol. Sections were washed in distilled water before submersion in Mayer’s haematoxylin 
for 3 minutes. Following a further wash in water slides were dipped in 1% acid alcohol then 
followed by another wash in water. Slides were then passed through Scott’s tap water for 10 
seconds, washed in water then passed through eosin for 10 seconds before a final wash in 
water. Slides were then dehydrated through ascending concentrations of alcohols before a 
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final immersion in xylene to remove any alcohol on the slides. Slides were then mounted 
using Pertex (CellPath) and coverslips (VWR Prolabo). 
2.7.2  Immunohistological examination of proteins 
Immunohistochemistry (IHC) is a multistep method by which proteins are detected in tissues 
by exploiting the use of antibodies which bind to specific antigenic regions on proteins 
against which they are raised (primary antibodies). 
Antigens can either be detected by enzyme mediated chromogenic detection (IHC method) 
or by fluorochrome detection (immunofluorescence (IF) method) using a secondary antibody 
raised against the IgG of the species in which the primary antibody was prepared (Figure 
2-9).  
 
Figure 2-9: Immunohistological examination of proteins. 
Unless otherwise stated, the detection method of each antigen was performed using a 
standard protocol. Unless otherwise stated, all wash steps were carried out twice for 5 
minutes at room temperature. 
2.7.2.1 Dewaxing and rehydrating of tissue sections 
Tissue sections were dewaxed in xylene and rehydrated in descending concentrations of 
alcohol as previously described. 
2.7.2.2  Antigen retrieval  
Antigen retrieval is a technique employed to tackle the loss of immunoreactivity to some 
proteins which occurs during tissue fixation. Formalin fixation remains the fixative of 
choice, despite formalin fixation resulting in protein cross-linking (344), which “masks” or 
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“cloaks” the protein limiting the ability of protein epitopes to bind to their complementary 
antibodies. Antigen retrieval allows for the breaking of these cross-linkages, precipitation of 
protein and rehydration of tissue sections (345). 
Key to the method of antigen retrieval is the exposure to heat (346) in an acidic or alkaline 
retrieval buffer (347, 348). Conditions are selected to denature but not destroy proteins 
within the tissue and are particularly recommended for proteins within the nucleus, e.g. 
steroid receptors. Unless otherwise stated all antigens were retrieved in citrate buffer (pH6). 
Briefly, fixed sections mounted on slides were immersed in 0.01M citrate buffer, (pH6) and 
were exposed to heat using a decloaking chamber (Biocare Medical, CA, USA) on a set 
programme where the temperature of the citrate buffer was slowly risen to 124°C then 
decreased to 90°C over a 10 minute period. Slides were slowly brought back to room 
temperature by the addition of tepid water.  
2.7.2.3 Endogenous peroxidase blocking 
An endogenous peroxidase blocking step is included to reduce non-specific background 
staining that may be caused by the HRP-conjugate binding to endogenous peroxidases in the 
tissue of interest. 
Sections were blocked in 3% hydrogen peroxide (H2O2) (VWR Prolabo) in methanol (Fisher 
Chemical) for 30 minutes then washed twice in TBS (IHC method) or PBS (IF method) for 5 
minutes.  
2.7.2.4 Serum blocking  
Normal serum from the species that the secondary antibody was raised in was used to 
prevent non-specific binding of the secondary antibody.  
Sections were blocked in 20% normal animal serum (NAS; 20% animal serum +TBS 
+0.05% bovine serum albumin (BSA)) for 30 minutes at room temperature then washed in 
the appropriate wash buffer. 
2.7.2.5 Primary antibody application 
Primary antibodies were added at an optimised dilution in NAS and left to incubate 
overnight at 4°C. Controls included a positive tissue control, a tissue negative control as well 
as an antibody negative control where the primary antibody was replaced with 20% normal 
serum. A complete list of primary antibodies and their working dilutions are shown below in 
Table 2-15. 
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Polyclonal sheep anti-BrdU Fitzgerald 20-BS17 1/4000 1/5000 Rabbit 
Rabbit polyclonal anti-CD31 Abcam 28364   1/1500 Goat 
Mouse monoclonal anti-
Hypoxyprobe® 
hpi clone 4.3.11.3 1/100   Goat 
Mouse monoclonal anti-Pan 
cytokeratin 
Sigma C2562 1/2000 1/4000 Goat 
Rabbit monoclonal anti-
Vimentin 
Cell Sigalling Tech 
#5741 
  1/600 Goat 
Rabbit polyclonal anti-
Snail/Slug* 
Abcam 63371 1/750   Horse 





1/400   Goat 
Rabbit monoclonal anti-Green 
fluorescent protein† 
Invitrogen A11122 1/250     
Table 2-15 Primary antibodies and their suppliers and concentrations. 
2.7.2.6 Secondary antibody application 
Following overnight incubation of primary antibodies, sections were washed and then  
incubated at room temperature with either biotinylated secondary antibodies (IHC method) 
or with peroxidase-conjugated secondary antibodies (IF method) diluted 1/500 in NAS  for 
30 minutes. A complete list of secondary antibodies are shown below in Table 2-16. 
Antibody Name Supplier & Cat. No. 
Rabbit anti sheep biotinylated Vector BA 6000 
Rabbit anti sheep peroxidase AutogenBioclear ABN001HRP 
Rabbit anti goat biotinylated DAKO E0466 
Rabbit anti mouse biotinylated DAKO E0464 
Rabbit anti mouse peroxidase DAKO P0260 
Goat anti rabbit biotinylated Vector BA1000 
Goat anti rabbit peroxidase Vector PI1000 
Goat anti mouse biotinylated Vector BA9200 
Goat anti mouse peroxidase Abcam 6823 
 Table 2-16: Secondary antibodies and their suppliers. 
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2.7.2.7 Antigen detection 
2.7.2.7.1 Enzyme mediated chromogenic detection- immunohistochemistry method 
Enzyme mediated chromogenic detection involves the addition of enzyme which binds to the 
secondary antibody and then a substrate of that enzyme is introduced to form a visible 
reaction product in the form of a precipitate. The most commonly used enzymes for 
chromogenic detection are streptavidin-horseradish peroxidase (HRP) or streptavidin 
alkaline phosphatase (AP). For single antigen detection, unless otherwise stated, 
streptavidin-HRP was used.  
Sections were incubated with streptavidin horseradish peroxidase (Vector, SA-5004), diluted 
in TBS, for 30 minutes at room temperature. Positive signals were visualised using the 
chromogen 3, 3-diaminobezidine (DAB) (Vector, Peterborough, UK) which formed a brown 
precipitate (Figure 2-10). Reactions were stopped by immersing the sections in water. 
 
Figure 2-10: Enzyme Mediated Chromogenic Detection- Immunohistochemistry Method. After 
incubation with primary and secondary antibodies, sections are incubated in streptavidin horse 
radish peroxidase (Strep-HRP) and positive signals visualised by DAB. 
2.7.2.7.2 Fluorochrome detection- Immunofluorescence method 
Fluorochrome detection is commonly used to identify multiple antigens in the same tissue 
and also to determine if any co-localisation of target antigens has occurred. The Tyramide 
Signal Amplification (TSA
TM
) system (PerkinElmer, Massachusetts, USA) allows for signal 
amplification and enables sub-cellular localisation of low abundance antigens. This results in 
increased sensitivity without an increase in background staining. Signal amplification by 
tyramide is activated by the catalytic activity of HRP, which converts tyramide into a 
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reactive intermediate that covalently bind to electron rich moieties to generate high-density 
labelling of the target protein. 
Following incubation with secondary antibodies, sections were washed and incubated for 10 
minutes in the dark with the Tyramide kit (Figure 2-11), diluted 1/50 in the kit diluent. In the 
case of a double stain, the red cyanine-3 fluorophore were used first as the green cyanine-5 
fluorophore is more sensitive to photobleaching. All following steps were carried out with 
minimal light exposure. To prevent photobleaching, slides were covered with foil during all 
wash steps and incubated in the dark. 
 
Figure 2-11: Enzyme Mediated Chromogenic Detection- Immunofluorescence Method. 1. After 
incubation with primary and secondary antibodies, sections are incubated with the tyramide signal 
amplification kit for 10 minutes. 2. Tyramide enables sub-cellular, high density labelling.  
2.7.2.8 Nuclear counterstaining 
2.7.2.8.1 Nuclear counterstaining- Immunohistochemistry method 
Sections were counterstained in haematoxylin for 3 minutes and dipped in 1% acid alcohol 
(1% hydrochloric acid in 70% ethanol) before a thorough wash in water. Sections were then 
passed through ascending concentrations of alcohol; 70%, 80%, 95%; before immersion in 
xylene. Slides were then mounted with coverslips (VWR Prolabo) using Pertex (Cell Path). 
2.7.2.8.2 Nuclear counterstaining- Immunofluorescence method 
DAPI (4', 6-diamidino-2-phenylindole) is a fluorescent stain that passes through the cell 
membrane to bind to the A-T rich regions in DNA. Its emission wavelength is 461nm, 
therefore staining nuclei blue.  
Following washes in PBS, sections were counterstained with DAPI (Sigma, D9542), diluted 
1/1000 in PBS, for 10 minutes at room temperature. Sections were washed thoroughly in 
PBS, and then mounted with coverslips using the aqueous mounting medium permafluor 
(Immunotech, Marseille, France). 
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2.7.2.9 Modifications to the standard immunohistochemistry method 
*The Snail/Slug antibody cross-reacts with both proteins; antigen retrieval was carried out at 
pH9, slides were blocked in 3% hydrogen peroxide for 30 minutes and then blocked in 2.5% 
horse serum for 30 minutes. The primary antibody was diluted in 2.5% horse serum and 
incubated overnight at 4°C.  The ImmPRESS™ polymerised reporter enzyme detection 
system was used, where one drop of the anti-rabbit IgG was applied to each slide for 30 
minutes. This detection system was used to increase sensitivity and reduce the background 
that had been previously observed using the standard protocol. Sections were washed and 
positive signals were visualised by DAB. Sections were counterstained, dehydrated and 
mounted as previously described. 
† For green fluorescent protein (GFP), automated immunohistochemistry was performed 
using the Bond-max immunostaining machine (Leica Microsystems, UK). This automated 
system carries out a standard protocol as per manufacturer’s instructions including; antigen 
retrieval, wash steps and peroxidase blocking before incubating with the primary antibody. A 
polymer refine detection kit is utilised to increase sensitivity. Positive signals were visualised 
by DAB.  
2.7.2.10 Image analysis 
DAB positive sections were imaged using AxioVision 4.8 Software (Carl Zeiss,  Cambridge, 
UK) and a PROVIS microscope (Olympus Optical, London, UK) with an attached Canon 
DS126131 camera.  
Fluorescent sections were imaged using Zen 2009 software (Carl Zeiss, Cambridge, UK) and 
a Zeiss LSM 510 Meta Confocal microscope (Carl Zeiss, Cambridge, UK). 
2.8 Statistical Analysis 
Serum progesterone concentrations were analysed by One Way ANOVA using the standard 
error of the mean, using Bonferroni post hoc testing to compare each time-point to the 0 hour 
time-point and then each other time-point. 
mRNA concentrations for candidate genes were investigated across all time-points by One 
Way or Two Way Analysis of Variance (ANOVA) using the standard error of the mean. In 
Chapters 3 and 4 in each One Way ANOVA, Bonferroni post hoc testing was used to first 
compare all time-points to the 0 hour time-point before column to column analysis, which is 
indicated on each graph. In Chapter 5 where treatment with DHT was investigated, each 
Two Way ANOVA compared no treatment v treatment for each time-point by Bonferroni 
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post hoc testing as indicated. Data was analysed using Graphpad Prism 5, where significance 
was accepted where p<0.05. 
For the SABioscience PCR arrays, analysis was performed using SABiosciences web portal, 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php); data analysis was 
performed using the ΔΔCt as described previously. Each time-point (8 and 24 hours) was 
compared to the 0 hour time-point by Student t test. Array validation by Taqman qRTPCR 
was performed by One Way or Two Way ANOVA as described in the figure legends. 
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Chapter 3 Establishment of a mouse model of 
menses for use as a functional model of endometrial 
breakdown and repair 
3.1 Introduction 
The human endometrium displays a remarkable ability of cyclical regeneration and 
remodelling, a process which can occur up to 400 times during a women’s reproductive 
lifespan (82). Endometrial proliferation, differentiation and shedding occur under tightly 
controlled conditions, governed by the ovarian steroid hormones; oestrogen and progesterone 
(72). The cellular and molecular mechanisms that occur during the normal cycle have been 
widely studied (72, 87, 148–150); however mechanisms governing the repair and re-
establishment of tissue homeostasis following menses have yet to be fully elucidated. 
Understanding these mechanisms is essential if we are to devise new therapies for 
endometrial pathologies, such as heavy menstrual bleeding, endometrial cancer or 
endometriosis. 
The cascade of events that culminates in tissue destruction, loss of cell integrity and 
subsequent shedding of the upper functional layer of the endometrium at the time of menses 
(186) is generally accepted to be precipitated by the withdrawal of progesterone following 
the regression of the corpus luteum (62, 72, 349).  Notably, some recent microscopy studies 
have revealed that shedding of the endometrium is a locally occurring, progressive process, 
with areas of partially shed, shed and regenerating endometrium observed in close proximity 
within the tissue (148). This observation would suggest that progesterone withdrawal not 
only initiates the onset of tissue breakdown but may also contribute to a molecular cascade 
stimulating endometrial repair. In the endometrium, restoration of tissue integrity is very 
rapid, with complete re-epithelialisation of the denuded basal layer of the endometrium 
occurring within 48 hours (201), thereby limiting the amount of blood loss from the exposed 
basal vasculature. Aberrations in the efficient regulation of this initial repair process may be 
a cause of the gynaecological complaint of heavy menstrual bleeding (HMB) (350). 
It is well established that proliferation and differentiation of the functional layer of 
endometrium during the menstrual cycle is sex steroid-dependent being entrained by 
fluctuations in concentrations of ovarian steroid hormones in the general circulation (44). 
However, the rapid phase of endometrial regeneration, during which the tissue undergoes re-
epithelialisation, neo-angiogenesis and vessel remodelling occurs whilst circulating 
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oestrogen and progesterone concentrations are low (44). This suggests that initial repair is 
not governed directly by ovarian derived steroid hormones. Notably, in an ovariectomised 
mouse model (239), restoration of endometrial integrity was observed to occur after 
shedding of the tissue, even in the absence of  ovarian derived oestrogen action. However in 
contrast to mice, women are known to have significant circulating adrenal steroids (44). If, 
consistent with data from mice, the human endometrium is capable of restoration of tissue 
integrity in the absence of oestrogens, then other mechanisms must be pivotal in regulating 
the early repair of the epithelium and the remodelling of the stromal cell compartment after 
shedding of the functional layer.  
Studies of the processes involved in the regulation of menses and repair face major 
challenges because only a few Old World Primates (315) and bat species (316) undergo 
physiological menstrual cycles. Other mammals, such as mice, who also display cyclical 
changes in both steroid hormone production and in their endometrial cell morphology, do not 
experience endometrial shedding following progesterone withdrawal, rather a process of re-
absorption and stromal cell re-organisation (317). Therefore, in order to study the human 
endometrium, models must either be in vivo animal models that aim to mimic menstruation 
and subsequent repair (231, 233, 234) (described in section 1.9) or in vitro studies using 
human tissue explants (219, 221, 225, 351, 352), as studies using isolated human cells are 
less relevant because of the loss of intercellular signalling and architecture.  
Due to their close relationship and existence of menstrual cycles a few non-human primate 
animal models have been used to study endometrial cycling. The macaque is the main non-
human primate used to study endometrial function; the cynomolgus monkey (Macaca 
fascicularis) and the rhesus macaque (Macaca mulatta) are used to study endometrial cancer 
(353, 354) and menstruation (235, 329, 355, 356) respectively. The baboon (Papio anubis) 
(357–359) and the rhesus macaque (360–362) have been used to study endometriosis. 
However, there are drawbacks in using non-human primate models, including handling and 
housing costs, as well as low reproduction rates (363). A mouse model has the advantage of 
shorter generation times, larger litter sizes, increased genetic similarity in inbred strains to 
reduce animal variation and the option to use genetically modified transgenic animals; over-
expression, knockout or cell specific targeting (364). The mouse uterus, like the human, has 
both basal and apical compartments within the uterine lining as well as developed uterine 
glands, stroma and a vascular compartment. The mouse endometrium also displays cyclical 
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changes in steroid receptor expression (98) and cellular morphology (97) during the oestrous 
cycle that parallel those reported in human endometrium during the normal menstrual cycle. 
In 1984, Finn and Pope (234) were the first to describe a protocol for the artificial induction 
of endometrial decidualisation and endometrial breakdown in the mouse, using a timed 
schedule of hormonal injections. In their model, stromal cell decidualisation had to be 
induced by oil injection as in rodents, unlike in women, decidualisation only occurs naturally 
in response to blastocyst implantation (365, 366). Progesterone support was then withdrawn 
from these animals to mimic luteal regression. The success of this model was evident when 
features of menstruation normally seen in women were observed in the murine uterus, these 
included immune cell infiltration and tissue degeneration (234). The model was later 
improved by Brasted et al., (233) who used an inbred strain of mice to reduce intra-animal 
variation, and altered the modes of delivery of the steroid hormones to include the use of a 
progesterone-secreting pellet.  In their study, uteri were harvested at 0, 16, 20, 24, 36 and 48 
hours after the withdrawal of progesterone. Based on haematoxylin and eosin sections they 
showed endometrial breakdown at 16 hours and complete restoration of endometrial 
architecture by 48 hours. This revised model has been used to study leukocyte infiltration 
(233), extracellular matrix dynamics (79), re-epithelialisation (318), and matrix 
metalloproteinases (230). Notably, all these studies focussed on a window of 12-48 hours 
after the withdrawal of progesterone during which 16 hours was classed as the time-point 
where menstruation begins, 24 hours as the time-point where re-epithelialisation was 
occurring and 48 hours classed as the time-point where complete repair and regeneration has 
occurred.  
Pseudopregnancy models of endometrial breakdown have been developed, in which 
endogenous ovarian hormones contribute to endometrial regulation (188, 334, 336). Briefly, 
intact mice are mated with vasectomised males, on day 4 of pseudopregnancy the 
endometrium is artificially decidualised by oil injection, then 48 hours later ovariectomy 
induces steroid withdrawal and initiates endometrial shedding. Endometrial shedding is 
reported to be complete by 24 hours after steroid withdrawal, with complete restoration of 
tissue integrity by 48 hours (188, 336). Rudolph et al., also reported overt menstruation 
using the pseudopregnancy model (336), which had not been previously reported in the Finn 
and Pope or Brasted models using exogenous steroid hormones.  
Menses in women is characterised by overt bleeding, simultaneous breakdown and repair, 
immune cell influx, tissue necrosis and re-epithelialisation. Recent SEM studies into 
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endometrial breakdown and repair in women have revealed that tissue breakdown and repair 
occur concurrently (148) and so repair mechanisms must be initiated early and prior to full 
breakdown and clearance of the tissue. Therefore, in previous mouse models of endometrial 
breakdown and repair, the time-points chosen to investigate repair (24 hours in the 
ovariectomy model, 36 hours in the pseudopregnancy model) may be too late to study early 
repair mechanisms. Overt menstruation has only been reported in the pseudopregnancy 
model of breakdown, highlighting a limitation to the ovariectomy model.  
With these observations in mind, the purpose of the studies described in this chapter was to 
develop a mouse model of breakdown and repair capable of identifying specific time-points 
for tissue breakdown, early repair and tissue remodelling. 
3.1.1 Aims of the chapter 
1. To establish a model of menses in the mouse which mimics menstruation in women; 
namely a model which exhibits overt menstruation and simultaneous breakdown and 
repair. 
2. To study an “early” window of endometrial repair using this mouse model of 
menstruation. 
3. To identify specific time-points where tissue destruction, re-epithelialisation and 
endometrial cell proliferation occur.  
4. To investigate the dynamics of re-epithelisation of the endometrium during the early 
repair window. 
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3.2 Materials and methods 
3.2.1 Mouse model of menstruation  
A mouse model of menstruation was established in house using a protocol adapted from 
Brasted et al., (233). Table 3-1 outlines the adaptations made to the Brasted protocol.  The 
full protocol is described in section 2.1.4 and outlined in Figure 2-4.  
3.2.2 Tissue processing and immunohistochemistry   
All samples were fixed in NBF overnight at room temperature, rinsed in 70% ethanol and 
then stored in 70% ethanol before tissue processing as described in section 2.6. 
Immunohistochemistry was carried out using the standard protocol outlined in section 2.7.2 
using the antibodies outlined in Table 2-15 and Table 2-16.  
Images were analysed as detailed in section 2.7.2.10. 
3.2.3 Enzyme immunoassay for quantitative determination of progesterone 
secretion in sera 
Determination of progesterone secretion in blood sera was carried out using a progesterone 
enzyme-linked immunosorbent assay (ELISA) kit (DEMEDITECH diagnostics, Germany) 
as described in section 2.1.4.4.1. 
3.2.4 RNA extraction 
RNA extraction was carried out as detailed in section 2.2.  
3.2.5 Synthesis of complementary DNA using VILO cDNA synthesis kit 
Reverse transcription of RNA to cDNA was performed using the Superscript VILO cDNA 
synthesis kit (InVitrogen) according to manufacturer’s instructions, using the volumes 
outlined below in Table 2-8. Samples were then incubated under the conditions detailed in 
section 2.3 
3.2.6 Quantitative Real Time PCR 
Quantitative real time PCR was carried out as detailed in section 2.4.  
Statistical analysis was performed as detailed in section 2.8. 
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Protocol Exogenous Hormone Schedule 
Time Between 












E2, s.c. delivery, 0.1ml, 100ng. 









table to show 
adaptations 
made by 
Brasted et al.  
P4, s.c. delivery, 0.1ml 500µg, 
Vehicle: Arachis oil, Days 12,13,14 
E2, s.c. delivery, 0.1ml, 10ng. 







   
Brasted et 
al., 2003 
E2, s.c. delivery, 0.1ml, 100ng. 














Crystalline P4 pellet, incubated 
for 16h in 1% CSFCS in PBS at 
37°C prior to sub cutaneous 
implantation. Days 13-17. 
E2, s.c. delivery, 0.1ml, 5ng. 
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Protocol Exogenous Hormone Schedule 
Time Between 













E2, s.c. delivery, 0.1ml, 100ng. 


















Crystalline P4 pellet, incubated 
for 16h in 1% CSFCS in PBS at 
37°C prior to sub cutaneous 
implantation. Days 13-17. 
E2, s.c. delivery, 0.1ml, 5ng. 










   
Adaptation 
2- Dec Time 
E2, s.c. delivery, 0.1ml, 100ng. 
















   
 
Crystalline P4 pellet, incubated 
for 16h in 1% CSFCS in PBS at 
37°C prior to sub cutaneous 
implantation. Days 13-19. 
E2, s.c. delivery, 0.1ml, 5ng. 
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Protocol Exogenous Hormone Schedule 
Time Between 














E2, s.c. delivery, 0.1ml, 100ng. 





90 hours 60 








Crystalline P4 pellet, incubated 
for 48 hours in 1% CSFCS in PBS at 
37°C prior to sub cutaneous 
implantation. Days 13-19. 
E2, s.c. delivery, 0.1ml, 5ng. 









lumen at 4 
hours. 
Table 3-1: Establishment of a mouse model of menstruation that mimics human menstruation.  Adaptations made to the Brasted model are shown in red as 
outlined in Adaptations 1, 2 and 3. Key; s.c. sub-cutaneous injection, dec; decidualisation, E2; oestradiol, P4; progesterone, TP: time-point, CSFCS; charcoal stripped 
foetal calf serum. Success rate: the number of mice fully decidualised at 0 hours or evidence of decidualisation then breakdown at the later time-points.  
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3.3.1 Establishment of a mouse model that mimics menstruation in women 
In order to establish a functional model of breakdown and repair, a number of adaptations 
were made to the model described by Brasted et al., as outlined in Table 3-1. The first minor 
adjustment (Table 3-1, adaptation 1) was to change the type of oil used to deliver the 
exogenous oestradiol, as first observations were that the arachis (peanut) oil did not stay in 
solution and therefore may have had an adverse effect on oestrogen priming and 
decidualisation, as no mice had undergone decidualisation. Following this change 
observation of the uterine horns after 49 hours suggested that decidualisation had begun but 
was not complete (one mouse was observed to have undergone partial decidualisation).  
In keeping with the length of decidualisation described by Finn and Pope (234), (70 hours), 
the length of time allowed for decidualisation was extended to 90 hours (Table 3-1, 
adaptation 2). Partial decidualisation of the uterine horn was observed in 50% of the mice, 
where small sections of the horn had decidualised but other areas of the horn were 
comparable to the non-decidualised horn. Artificial decidualisation of one uterine horn had 
been performed via a flank incision, then injection of oil through the myometrium into the 
lumen. A number of limitations were observed whilst carrying out this procedure; it was 
difficult to orientate the syringe exactly into the lumen itself, without piercing straight 
through the opposite uterine wall, furthermore, whilst injecting the oil a proportion of the oil 
would reflux back out of the point of syringe entry.  
These observations led us to adopt vaginal delivery of oil (Table 3-1, adaptation 3) using a 
non-surgical embryo transfer device, which allowed direct delivery of oil into one horn and 
also eliminated an invasive surgical technique. Progesterone pellet incubation was also 
lengthened from 16 hours to 48 hours to ensure that progesterone secretion had been 
stimulated prior to pellet implantation. Upon dissection, after 90 hours of decidualisation, 
one uterine horn was decidualised and was significantly larger and heavier than the contra-
lateral non-decidualised horn (evidence of which is shown in section 3.3.4).  
A set of time-points were selected specifically to focus on investigation into early breakdown 
and repair; 0 hours (classed as the time of pellet removal and the initiation of steroid 
withdrawal), 4 hours, 8 hours, 12 hours and 24 hours. A small number of mice were 
collected at 48 hours after the withdrawal of the progesterone pellet (n=6). 
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3.3.2 Evidence of endometrial shedding  
Evidence of endometrial breakdown was initially investigated by observing the vagina for 
blood and by carrying out a vaginal smear of each animal, as described in section 3.2.1. The 
percentage of mice bleeding at each time-point was calculated and is displayed in Figure 3-1. 
 
Figure 3-1: Percentage of mice bleeding following progesterone withdrawal.  The percentage was 
calculated as those that were identified to be bleeding at each time-point from the total number of 
mice investigated for each time-point. 
No mice were found to have blood cells in their vaginal smear at 0 hours (time of pellet 
removal and induction of progesterone withdrawal). As early as 4 hours after the withdrawal 
of progesterone, blood cells were detected in the vaginal smear of 46% of the mice. Blood 
was also observed at 8 hours (71%) and 12 hours after progesterone withdrawal, with 87.5% 
of mice having a blood positive smear at 12 hours (Figure 3-3, A). By 24 hours the 
consistency of the blood had changed with no blood present in the vaginal smears, but blood-
containing material still present in the uterine horn when they were dissected. These mice 
were classed to have ceased bleeding by 24 hours.  
3.3.3 Evidence that hormonal withdrawal initiates endometrial shedding 
To confirm that the uterus was undergoing endometrial breakdown due to the withdrawal of 
progesterone, serum progesterone levels were measured by ELISA, and are depicted in 
Figure 3-2. Progesterone concentrations were significantly (p<0.001) decreased from 0 hours 
(12±3ng/ml) to 4 hours (2.6±4ng/ml) after withdrawal. Serum concentrations at the later 
time-points were also significantly decreased (p<0.001) in comparison to the 0 hour time-
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point. The lowest concentration was observed at 8 hours (p<0.001, 1.5±1.0ng/ml) after the 
removal of the progesterone secreting pellet, no significant differences were found between 
the latter time-points. These results are consistent with progesterone withdrawal observed in 
women at the time of menses. 
 
Figure 3-2: Serum progesterone concentrations following withdrawal of progesterone. 
Progesterone concentrations (ng/ml) were detected to decrease following withdrawal of the 
progesterone pellet at 0hrs. Statistical analysis was carried out by One Way ANOVA followed by 
Bonferroni post hoc testing, where stars indicate comparison between each time-point and the 0 
hour time-point.  
3.3.4 Gross morphology of the uterus upon dissection following progesterone 
withdrawal 
Consistent with the adaptations described in section 3.3.1 the use of a non-surgical trans-
vaginal stimulus versus surgical insertion for initiation of decidualisation resulted in full 
decidualisation of one uterine horn (Figure 3-3, B), observed alongside its contra-lateral 
control horn (non-decidualised). Notably, blood cells were visually detectable in the vagina 
(Figure 3-3, A) and lumen (Figure 3-3, C) of the non-decidualised horn following vaginal 
lavage but 24 hours after progesterone withdrawal, breakdown of tissue within the 
decidualised horn was obvious (Figure 3-3, D). Endometrial tissue that had shed from the 
uterine horn and leaked out through the cervix during dissection is also shown in Figure 3-3, 
D.  
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Mean uterine horn weights for non-decidualised and decidualised horns at each time-point 
are shown in Figure 3-4. Consistent with successful induction of decidualisation, at the time 
of progesterone withdrawal, the weight of the decidualised horn (black bars) was 
significantly greater (p<0.001) than that of the non-decidualised horn (white bars). 
Progesterone withdrawal did not have any effect on the mean weight of the non-decidualised 
horn (white bars) and the weight of the decidualised horn was significantly greater than that 
of the non-decidualised horn (p<0.001) at 0, 4, 8 and 12 hours after progesterone withdrawal. 
No significant difference was observed at 24 hours.  
To confirm that the uterine horns, classed as “decidualised horns”, had undergone a decidual 
response, mRNA concentrations for prolactin (Prl8), a marker of decidualisation (367), were 
examined by qRTPCR. Relative mRNA concentrations at each time-point are displayed in 
Figure 3-5. At the 0 hour time-point the mRNA concentration for prolactin in the 
decidualised horn was shown to be 2000 fold higher than that of the non-decidualised 
control; mRNA concentrations for Prl8 were detected to significantly decrease following 
progesterone withdrawal (p<0.05, 4 hours; p<0.001, 8-24 hours). The lowest Prl8 mRNA 
concentration was detected 24 hours after progesterone withdrawal (p<0.001). The rapid and 
significant reduction in Prl8 mRNA (p<0.001) at 12 hours was in marked contrast to the 
maintenance of uterine wet weight at this time.  
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Figure 3-3: Morphology of the uterus following decidualisation and progesterone withdrawal. A; 
Blood detected in the vaginal smear, 12 hours after withdrawal. B; The non decidualised control 
(left) and the decidualised horn (right) upon dissection (12 hours after withdrawal). C; Blood cells 
were detectable in lumen of the non decidualised horn following vaginal lavage (24 hours after 
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Figure 3-4: Mean uterine horn weights following progesterone withdrawal. Non-decidualised horns 
(white bars) showed no significant differences in uterine weight (g). Decidualised horns were 
significantly heavier than their non-decidualised controls at 0, 4, 8, 12 and 24 hours (p<0.001). No 
significant difference was observed between non-decidualised and decidualised horns at 24 hours. 
Statistical analysis was performed by Two Way ANOVA and Bonferroni post hoc testing. 
 
Figure 3-5: qRTPCR for prolactin8 (Prl8), a marker of decidualisation, following withdrawal of 
progesterone. mRNA expression for the decidualised horn (black bars) normalised against the 0hr 
non-decidualised control horn. Statistical analysis was performed by One Way ANOVA and 
Bonferroni post hoc testing, where each time-point was first compared to the 0 hour time-point and 
then to each other time-point.  
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3.3.5 Histological examination of endometrial breakdown and repair following 
progesterone withdrawal  
Uterine morphology in the control (non-decidualised) horn at 0 hours is shown in Figure 3-6 
as an illustration of tissue morphology in the absence of decidualisation. In the non-
decidualised uterine horn (Figure 3-6, A), an intact epithelium lines the lumen, which can be 
clearly seen in the centre of the tissue. The functional and basal layers of the tissue are 
clearly detected due to the greater stromal density of the basal compartment (outlined by the 
dashed lines). The outer myometrial muscular layers can be seen surrounding the uterine 
horn. At a higher magnification, (Figure 3-6, B) glandular structures (G) lined by epithelial 
cells can be seen within the loosely packed stromal cell compartment of the functional layer 
(FS).  
The decidualised horn at the time of progesterone withdrawal (0 hours) was observed to have 
undergone extensive stromal cell remodelling during the 90 hour decidualisation period, as 
shown in Figure 3-6, C and D. Large nuclei were observed within the decidualised cell mass 
(Figure 3-6, F) which filled in the centre of the uterine horn (DS), with a compacted stromal 
compartment in the outer basal layer (BL) (Figure 3-6, E). Flattened epithelial cells (as 
detected by immunohistochemistry for pan-cytokeratin) were observed lining the lumen 
(Figure 3-6, E) which was much reduced in volume in comparison to the 0 hour control horn 
(Figure 3-6, B). 
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Figure 3-6: Morphology of the non-decidualised (A-B) and decidualised (C-F) uterine horns at the 
time of progesterone withdrawal.  Dashed lines depict the different cellular compartments that 
comprise the endometrium, transverse section. A; Non-decidualised horn at 0 hours. B; An intact 
epithelium lines the lumen, a loosely packed stromal compartment (FS) is observed in the functional 
layer, compared to the basal layer (BL). C+D; Given animal variability, two representative uteri are 
shown in images C and D. C-D; Stromal remodelling was observed in decidualised horn, identified by 
densely packed stromal compartment (DS). E; A flattened, intact epithelium, as indicated by brown 
staining for epithelial marker pan-cytokeratin, lines the condensed lumen. Inset, negative control. F; 
Decidualised stromal cells display large rounded nuclei. M; myometrium, BL; Basal layer, LE; luminal 
epithelium, DS; decidualised stroma, FS; functional stroma, G; glands. Scale bars as indicated. Images 
are representative of 3 animals. 
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As in humans, variation was found to occur in the morphology of the murine uterine tissues 
following pellet removal. However, this is the first report of striking morphological changes 
occurring in the decidualised horn within 4 hours of progesterone withdrawal (Figure 3-7, A 
and B) with the decidualised cell mass observed to have started to shed into the lumen 
(Figure 3-7, D) by 4 hours. Immunohistochemistry for epithelial marker pan cytokeratin 
allows identification of luminal and glandular epithelial cells (Figure 3-7, C and D). The 
leading edge of the decidualised cell mass is lined by luminal epithelial cells (arrowheads).    
Initial breakdown of the decidualised stroma into the lumen was also detected (Figure 3-7, 
D).  
 
Figure 3-7: Morphology of decidualised uterus 4 hours after progesterone withdrawal.  Given 
animal variability, two representative uteri are shown in images A and B. A+B; Morphology of uterus 
4 hours after progesterone withdrawal. C; Immunohistochemistry for pan cytokeratin (epithelial 
marker) demonstrates that the leading edge of the decidual cells is lines by luminal epithelial cells 
(arrowheads)  D; Decidualised cells begin to shed into the lumen. Leading edge of the decidualised 
cells are stained for cytokeratin (arrowheads). M; myometrium, BL; Basal layer, LE; luminal 
epithelium, DS; decidualised stroma. Scale bars as indicated. Images are representative of 3 animals. 
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By 8 hours after withdrawal of progesterone support (Figure 3-8, A, B), a mass of 
decidualised cells that had become detached from the underlying uterine tissue were clearly 
visible in the centre of the uterine lumen (Figure 3-8, A and B). An area of exposed basal 
stroma was observed in Figure 3-8, C, (ES) where the decidualised functional layer had 
detached. Notably, in this region the absence of an epithelial cell layer was noted. In Figure 
3-8, D, an epithelial cell layer, positive for epithelial marker pan cytokeratin, can be seen 
lining the lumen, and glands (G) were observed in the basal layer in sites close to the luminal 
epithelium.  
By 12 hours, the time-point which was identified to have the highest percentage of mice with 
vaginal blood, sections of basal tissue adjacent to the shed decidualised cell mass appeared to 
be denuded of epithelium, as demonstrated by a lack of cells positive for pan cytokeratin 
(Figure 3-9, B, arrowheads). In contrast, other areas of the tissue in the same section had 
round epithelial cells lining the lumen (Figure 3-9, A, arrows) and glands were detected in 
the basal layer (G). Blood vessels were also detected in sites close to the luminal epithelium 
(Figure 3-9, A, arrowheads). 
In uterine horns retrieved at 24 hours after the removal of the progesterone secreting pellet, 
some variation was observed with some uteri having a few regions of recently shed decidua 
and incomplete epithelialisation of the luminal surface (Figure 3-10, A). Round epithelial 
cells can be observed lining the luminal surface (pan cytokeratin staining, Figure 3-10, C, 
arrowheads). In other uterine samples (Figure 3-10, B) an intact, invaginated luminal 
epithelium was present (Figure 3-10, D) consistent with re-epithelialisation of the 
endometrium being completed. 
Histological examination of uterine horns collected at 0, 4, 8, 12 and 24 hours demonstrated 
that endometrial breakdown begins within 4 hours of progesterone withdrawal, as evidenced 
by blood in the vaginal lavage. Breakdown and shedding of the functional stromal layer 
occurred within 8-12 hours and re-epithelialisation was observed to occur, or had occurred, 
by 24 hours. Evidence of round epithelial cells at 24 hours suggests that repair mechanisms 
have already been initiated. Therefore the set of time-points chosen are adequate for further 
investigation into the mechanisms that contribute to repair and re-establishment of tissue 
integrity.  
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Figure 3-8: Morphology of decidualised uterus 8 hours after progesterone withdrawal.  Given 
animal variability, two representative uteri are shown in images A and B. A+B; Decidualised cells that 
have detached from the basal layer are observed in the lumen. C; Area of denuded endometrium 
following detachment of the decidualised cells from the basal layer. The exposed stroma apparently 
lacks an epithelial cell layer. D; Pan cytokeratin staining identifies flattened epithelial cells observed 
lining lumen. Glands appear in basal layer, close to luminal epithelium. M; myometrium, BL; Basal 
layer, LE; luminal epithelium, G; glandular epithelium, ES; exposed stroma. Scale bars as indicated, 
scale bar in D, 20um. Images are representative of 4 animals. 
 
Figure 3-9: Morphology of decidualised uterus 12 hours after progesterone withdrawal.  A; Round 
epithelial cells observed lining the lumen (LE), near basal glands (G) and blood vessels (arrowheads). 
B; The decidualised cell mass detaches from basal layer exposing the basal layer (BL) to the lumen, 
immunohistochemistry for pan cytokeratin highlights that there are no epithelial cells lining the 
lumen at this time (arrowheads). BL; Basal layer, LE; luminal epithelium, G; glandular epithelium. 
Scale bars as indicated. Images are representative of 2 animals. 
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Figure 3-10: Morphology of decidualised uterus 24 hours after progesterone withdrawal.  Given 
animal variability, two representative uteri are shown in images A and B. A+B; Shed cells from the 
decidualised functional layer are present in the uterine lumen of both animals. C; 
Immunohistochemistry for pan cytokeratin highlights an area of recently exposed basal stromal 
compartment with round epithelial cells present on the luminal surface (as indicated by 
arrowheads). D; An intact luminal epithelium containing columnar epithelial cells are observed. LE; 
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3.3.6 Re-epithelialisation of the endometrium  
3.3.6.1 Evidence for re-epithelialisation by epithelial cell proliferation  
To investigate epithelial cell proliferation and its contribution to re-epithelialisation and 
restoration of an intact endometrium, mice were injected with bromodeoxyuridine (BrdU) 90 
minutes prior to culling (see section 2.1.4.4). BrdU is a synthetic nucleoside that incorporates 
into replicating DNA during the S phase of the cell cycle. Administration of BrdU at this 
time was used to label cells that were actively proliferating at the time of culling.  
Incorporation of BrdU was detectable in uterine tissues at all time-points. BrdU positive cells 
were detected in both the functional and basal layers of the endometrium in tissues collected 
at the time of progesterone withdrawal (Figure 3-11, A). BrdU positive cells were detected in 
the decidualised stroma (Figure 3-11, B), however decidualised cells in the centre of the 
decidualised cell mass were largely BrdU negative (Figure 3-11, A). Stromal cells in the 
basal layer were also BrdU positive (Figure 3-11, C), as were a number of luminal epithelial 
cells (Figure 3-11, D).  
BrdU positive cells were detected in the endometrium 4 hours after withdrawal of 
progesterone (Figure 3-12, A). A number of BrdU positive cells in the luminal epithelium 
were detected (Figure 3-12, B and F), BrdU positive cells were also detected in the 
decidualised stroma (Figure 3-12, C-E). BrdU positive cells were largely localised to the 
non-decidualised cells in the basal layer adjacent to the decidualised stroma (Figure 3-12, C-
F).  
Microscopic observations suggested that the highest numbers of BrdU positive epithelial cell 
nuclei were identified 12-24 hours after the withdrawal of progesterone, however 
quantification is required. At 12 hours after withdrawal, the luminal epithelium contained a 
number of cells positive for BrdU (Figure 3-13, A and B). Notably, stromal cells in the basal 
layer adjacent to a region of exposed endometrium lacking a proliferative epithelial cell layer 
were also identified to be BrdU positive (Figure 3-13, C, arrowheads).  Flat epithelial cells 
positive for BrdU are observed lining sections of the lumen (Figure 3-13, C, arrows). 
Stromal cells in the basal layer close to glandular structures were BrdU positive (Figure 
3-13, D), whilst the glandular epithelium of glands in the basal layer was BrdU negative 
(Figure 3-13, D-F). In Figure 3-13, E, sections of the endometrium appeared ‘ragged’, 
following shedding of the functional layer; however a few BrdU positive, flat epithelial cells 
are present.  In another area of the tissue in the same cross-section (Figure 3-13,F), round 
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epithelial cells positive for BrdU were identified in what appeared to be a more ‘intact’ 
epithelium compared to that in Figure 3-13, E.  
Luminal epithelial cell proliferation was still evident at the 24 hour time-point (Figure 3-14, 
A). However, due to animal variation in the length of time taken to repair, BrdU positive 
luminal epithelial cells were not detected in every sample (Figure 3-14, D). BrdU positive 
cells appeared to be lining vascular structures (Figure 3-14, B, arrowheads) as well as an 
possible increase in the number of BrdU positive epithelial cells (Figure 3-14, B and C). In 
some samples, cells in the basal glandular epithelium were also found to be positive for 
BrdU (Figure 3-14, D), a finding which was not detected at the earlier time-points.  
 
Figure 3-11: Endometrial cell proliferation at the time of progesterone withdrawal (0 hours).  A; 
BrdU positive cells (brown staining) were identified at 0 hours, in the basal layer, decidualised 
stroma and in the luminal epithelium,  inset negative control. B; BrdU positive cells are observed in 
the decidualised stroma adjacent to the basal layer. C; Decidualised cells towards the centre of the 
lumen are largely BrdU negative, a large number of cells in the basal stroma are BrdU positive. D; 
Luminal epithelial cells are BrdU positive. M; myometrium, BL; Basal layer, LE; luminal epithelium, 
DS; decidualised stromal cells. Scale bars as indicated. Images are representative of 4 animals. 
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Figure 3-12: Endometrial cell proliferation 4 hours after progesterone withdrawal.  Two 
representative uteri are shown in A-D and E-F. A; BrdU positive cells (brown staining) were localised 
to the basal stroma, the decidualised functional stroma and in the luminal epithelium. B; BrdU 
positive cells in the luminal epithelium. C; BrdU positive cells in the basal layer adjacent to the 
decidualised cells appeared to be more densely populated. D; BrdU positive cells were associated 
with the vasculature of the basal layer and outer myometrial layer (arrowheads). E; In another 
sample, BrdU positive cells were localised to the basal layer (arrows). F; BrdU positive cells were 
localised to the basal stroma (arrows), luminal epithelium and the vasculature (arrowheads). BL; 
Basal layer, LE; luminal epithelium, DS; decidualised stromal cells, M; myometrium. Scale bars as 
indicated. Images are representative of 3 animals. 
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Figure 3-13: Endometrial cell proliferation 12 hours after progesterone withdrawal. Two 
representative uteri are shown A-D and E-F. A; BrdU positive cells (brown staining) were observed in 
the luminal epithelium. B; BrdU positive cells were localised to sites in the basal stroma. C; Stromal 
cell in close proximity to an area of denuded endometrium are positive for BrdU (arrowheads). Flat 
epithelial cells were identified lining the lumen (arrows). D; Stromal cells in the basal layer were 
positive for BrdU, however the glandular epithelium was negative (G). E; In another sample, BrdU 
positive flat epithelial cells are observed lining the lumen, the glandular epithelium is negative for 
BrdU. F; The glandular epithelium is negative (G), round luminal epithelial cells are BrdU positive. BL; 
Basal layer, LE; luminal epithelium, SC; shed cells, G; glandular epithelium.  Scale bars as indicated. 
Images are representative of 4 animals. 
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Figure 3-14: Endometrial cell proliferation 24 hours after progesterone withdrawal. Two 
representative uteri are shown A-C and D. A; Large proportions of the luminal epithelial cells are 
positive for BrdU. B; Cells associated with the vasculature are BrdU positive (arrowheads). C; Luminal 
epithelial cells are stacked on top of each other, and are also BrdU positive. D; In another sample, 
BrdU positive stromal cells are observed to be “scattered” through the stromal cell compartment. 
Notably, the glandular epithelium contains BrdU positive cells (arrows). BL; Basal layer, LE; luminal 
epithelium, SC; shed cells. Scale bars as indicated. Images are representative of 2 animals. 
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3.3.6.2 Evidence for re-epithelialisation by epithelial cell migration  
To complement and extend preliminary observations based on histological evaluation 
(section 3.3.5) immunohistochemistry for pan-cytokeratin was used to monitor the location 
of epithelial cells in the endometrium 8-24 hours after removal of the progesterone pellet.  
At the 8 hour time-point in this model, the endometrium has begun to detach from the 
underlying basal stromal compartment (Figure 3-15, A). The protruding edge of the 
decidualised cell mass was lined with epithelial cells (Figure 3-15, B, arrowheads). At this 
time-point areas of denuded endometrium were observed in the remaining basal layer of the 
tissue (Figure 3-15, A and C, arrowheads), as evidenced by the absence of pan-cytokeratin 
positive cells. Note that in Figure 3-15, D, positive immunostaining for pan-cytokeratin was 
detected in the luminal epithelium adjacent to an area of denuded endometrium highlighted 
by the arrowheads.  
By 24 hours after the withdrawal of progesterone, the decidualised functional stroma has 
detached from the underlying basal layer (Figure 3-16, A). An area of denuded endometrium 
was observed (Figure 3-16, B and C, arrowheads).  Adjacent to this region were a layer of 
pan-cytokeratin positive epithelial cells (Figure 3-16, C), of which the ‘leading edge’ of 
these cells appeared to be made up of round epithelial cells (Figure 3-16, D). These cells 
appeared to be “rolling” towards an area of denuded endometrium. 
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Figure 3-15: Staining for pan-cytokeratin revealed partial re-epithelialisation of the endometrium, 
8 hours after progesterone withdrawal.  A; The decidualised cell mass is observed to be detaching 
from the underlying stromal cell compartment, inset negative control. B; The epithelium of the 
protruding edge of the decidualised stroma remains positive for pan-cytokeratin (arrowheads). C; 
The decidualised stroma has detached from underlying basal stroma, resulting in an area of denuded 
endometrium (arrowheads) as evidenced by the lack of positive staining for pan-cytokeratin. D; An 
area of remaining luminal epithelium is positive for pan-cytokeratin, adjacent to an area of denuded 
endometrium (arrowheads). Cytokeratin positive glandular epithelial cells are also observed in the 
basal layer. BL; Basal layer, LE; luminal epithelium, G: glandular epithelium, SC; shed cells. Scale bars 
as indicated. Images are representative of 2 animals. 
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Figure 3-16: Staining for pan-cytokeratin revealed epithelial cell dynamics, 24 hours after 
progesterone withdrawal. Epithelial cells (pan-cytokeratin positive) were detected in the luminal 
and glandular epithelial cell compartments. A; The shed decidualised cell mass is observed to be 
detaching from the underlying stromal cell compartment. B; The denuded, underlying stroma is 
observed as indicated by the arrowheads next to a region of luminal epithelial cells. C; The luminal 
epithelium is observed next to an area of denuded basal stroma (arrowheads). D; Round epithelial 
cells were observed to be “rolling” along an area of the denuded basal stroma. LE; luminal 
epithelium, G: glandular epithelium, SC; shed cells. Scale bars are as indicated. Images are 
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3.3.6.3 Evidence of stromal and epithelial cell dynamics during breakdown and repair 
To complement these observations, qRTPCR was performed for genes that had been 
previously described to encode proteins for mesenchymal (stromal cell) markers; Cdh2 (N 
cadherin), Wnt4 and vimentin (Vim), and epithelial cell markers; Cdh1 (E cadherin), Wnt7a 
and cytokeratin 8 (Krt8). Concentrations of mRNAs for these genes across the breakdown 
and repair window are depicted in Figure 3-17.  
Concentrations of mRNAs for Cdh2 were significantly up-regulated 4 hours (p<0.001) after 
progesterone withdrawal when compared to the 0 hour time-point, mRNA concentrations 
then  significantly decreased from 4 hours (p<0.01, p<0.001) so that by 12 and 24 hours, 
concentrations were similar to that of 0 hours. Wnt4 mRNA concentrations in the 
decidualised horn were increased by 10 fold when compared to the control horn and were 
maintained until 12 hours where mRNA concentrations were significantly decreased 
(p<0.05) from the time of progesterone withdrawal. Concentrations further decreased at 24 
hours (p<0.001). Concentrations of mRNAs for vimentin were significantly up-regulated at 4 
and 8 hours after the withdrawal of progesterone (4 hours; p<0.001, 8 hours; p<0.01), and 
displayed a similar trend to that of Cdh2, with the greatest concentration detected at 4 hours, 
then a steady decrease towards the 24 hour time-point. 
Concentrations of mRNAs for Cdh1 were significantly up-regulated at 24 hours (p<0.001) in 
comparison to the 0 hour time-point. No significant difference in mRNA concentrations were 
observed between 0-12 hours. Concentrations of Wnt7a mRNA displayed similar dynamic 
changes to Cdh1, where a trend of an increase was detected at 4 hours and 12 hours before a 
significant increase was detected at 24 hours (p<0.001).  Concentrations for keratin 18 
(Krt18) mRNA steadily increased from the 0 hour time-point, with significant increases 
observed at 24 hours (p<0.01).  




Figure 3-17: Evidence of stromal and epithelial cell dynamics during the window of breakdown and repair.  mRNA concentrations for genes that encode proteins 
for known stromal (Cdh2, Wnt4, vimentin) and epithelial cell markers (Cdh1, Wnt7a and Krt18). mRNA concentrations for the decidualised horn (black bars) were 
normalised against the 0 hour control horn. Statistical analysis was performed by One Way ANOVA and Bonferroni post hoc testing, comparing each time-point to 
the 0hr decidualised time-point and then to each time-point. 
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3.3.7 Evidence for re-epithelialisation of the endometrium by stromal cell 
differentiation 
Immunohistochemistry for pan-cytokeratin was initially carried out to locate epithelial cells 
at the luminal surface and in the basal glands. Surprisingly, pan cytokeratin positive cells 
were also documented in the stromal cell compartment (Figure 3-18, A-F).  
Notably, pan-cytokeratin positive stromal cells (arrowheads) were localised to areas adjacent 
to the denuded, luminal surface of the endometrium (depicted by arrows), where the 
decidualised functional stroma (SC) had detached from the underlying basal layer.  
In Figure 3-18, A, two separate areas of the endometrium contained subsets of pan-
cytokeratin positive stromal cells. In Figure 3-18, C and F a small number of stromal cells 
were positive for pan-cytokeratin, in comparison to Figure 3-18, D, which shows a cluster of 
pan-cytokeratin positive stromal cells adjacent to the lumen.  
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Figure 3-18: Evidence of pan cytokeratin positive stromal cells. Pan-cytokeratin, used as a marker 
for epithelial cells, was observed in a subset of cells in the underlying stromal cell compartment at 24 
hours after progesterone withdrawal. Two representative uteri are shown A-D and E-F. A; Shed 
decidualised cells are observed in the lumen, next to areas of denuded basal stroma. B; Pan-
cytokeratin positive glandular epithelial cells (G) are detected in close proximity to the denuded 
luminal surface (illustrated by the arrows). C; Positive immunostaining for pan-cytokeratin is 
detected in glandular epithelial cells and in stroma cells adjacent to the lumen (arrowheads). D; A 
subset of stromal cells adjacent to the luminal surface are pan-cytokeratin positive (arrowheads). 
E+F; In another sample, positive pan-cytokeratin stromal cells (arrowheads) were detected adjacent 
to the luminal surface of a denuded area of endometrium (arrows). BL; basal layer, G: glandular 
epithelium, SC; shed cells. Scale bars as indicated. Images are representative of 3 animals. 
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3.4 Discussion  
The current study used a new mouse model to investigate cellular and molecular events that 
occur during endometrial breakdown and repair. Studies using human tissue samples have 
highlighted evidence for synchronous breakdown and repair of the endometrium during 
menses (148). Previously described mouse models have been used to study a number of 
factors that may be involved in endometrial repair, however we believe that these do not 
allow for investigation of early repair mechanisms. For ease in descriptive purposes, 
previously described models and our own are outlined in Table 3-2.  
A previously described mouse model of menses (Brasted model) failed to focus on time-
points relevant to this time period choosing instead to examine breakdown at 16 hours after 
progesterone withdrawal, and epithelial repair at 24 hours, with complete restoration 
observed by 48 hours (233). An alternative model that relied on induction of 
pseudopregnancy and subsequent anti-progestin treatment (mifepristone) (Rudolph model) 
resulted in protracted breakdown occurring between 0-48 hours after the actions of 
progesterone were blocked (336). An extended repair phase was also recorded, with repair 
initiated at 48 hours and complete by 120 hours after administration of mifepristone 
treatment (336).  
 
Chapter 3. Establishment of a mouse model of menses for use as a functional model of endometrial breakdown and repair.  
95 
 
Hormone Administration Decidualisation Method Method of Progesterone Withdrawal Publications 
Ovariectomy then exogenous 
hormones by sub-cutaneous injection 
Oil injection via flank Cessation of hormone injections Finn and Pope, 1984 (234) 
Ovariectomy then exogenous 
hormones by sub-cutaneous injection 
and progesterone pellet 
Oil injection via flank Pellet removal 
Brasted et al., 2003 (233); Kaitu'u-Lino et 
al., 2005, 2007, 2009, 2010 (230, 239, 
318, 319, 368); Evans et al., 2011 (79); 
Menning et al., 2012 (334); Wang et al., 
2013 (235) 
Ovariectomy then exogenous 
hormones by sub-cutaneous injection 
and progesterone pellet 
Oil injection via flank Mifepristone Xu et al., 2007 (218) 
Ovariectomy then exogenous 
hormones by sub-cutaneous injection 
and progesterone pellet 
Oil injection via vagina Pellet removal Cousins, 2014 (369) 
Pseudopregnancy to harness 
endogenous ovarian-derived steroids 
Oil injection via flank Ovariectomy Fan et al., 2008, 2012 (188, 320) 
Pseudopregnancy to harness 
endogenous ovarian-derived steroids 
Oil injection via flank Mifepristone Rudolph et al., 2012 (336) 
Table 3-2: Previously described mouse models of menses. Our newly refined model is in italics. 
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3.4.1 Model adaptation and selection of dissection time-points for a window of 
early breakdown and repair 
Unlike humans, mice do not undergo spontaneous decidualisation and therefore do not 
naturally menstruate (317, 365, 366). The first description of the artificial induction of 
endometrial decidualisation and breakdown in the mouse was by Finn and Pope in 1984 
(234). This method was subsequently refined by Brasted et al., (233) and has been used to 
study re-epithelialisation (318), leukocyte infiltration at the onset of breakdown (233), 
extracellular matrix dynamics during repair (79) and a role for metalloproteinases during 
repair (230). Other models which relied on endogenous steroid hormone production induced 
by pseudopregnancy (described in section 1.9.4.3) have been used to study hypoxia at the 
onset of endometrial breakdown and immune cell dynamics in a prolonged breakdown and 
repair window (188, 320). 
The protocol described in this study, was adapted in-house from a previously described 
protocol (233). Notably, we extended the period of decidualisation from 49 to 90 hours. This 
adaptation was made following a pilot study where we observed only partial decidualisation 
of the stimulated horn (where the wet weight of decidualised horn was not significantly 
greater than the control horn) at 49 hours. In their pioneering study, Finn and Pope describe 
decidualisation as a progressive response to artificial stimuli (234) and in their original 
method, stimulation was carried out 4-6 hours after the last progesterone injection, and 
decidualisation was recorded up until 70 hours later (234).   
Another notable change, from the Brasted model, included induction of artificial 
decidualisation using oil stimulus delivered via the vagina rather than by puncturing the wall 
of the uterus. This method is more physiologically relevant to the natural process of 
decidualisation which occurs in the presence of a blastocyst in the mouse. It also eliminates 
the possibility of any other inflammatory responses that may occur during flank incision and 
injection of oil through the myometrium as adopted by other groups. 
After a decidualisation period of 90 hours, mean decidualised horn wet weights were greater 
at 0 hours than those previously published by Brasted et al., (233) (~0.15g v~ 0.07g), 
however by 24 hours had decreased to a weight similar to the 24 hour time-point reported in 
the original publication (~0.07g) (233). Consistent with the findings recorded by Brasted et 
al., we noted an increase in the mean wet weight of the decidualised horn during breakdown 
(8-12 hours) which then decreased by 24 hours consistent with shedding and subsequent 
restoration of normal uterine architecture.  
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In the current study tissues recovered at 4, 8 and 12 hours after the withdrawal of the 
progesterone pellet were examined in detail and as complete restoration of endometrial 
integrity was observed in the majority of mice at 24 hours, this was used as the last time-
point for our investigation of early repair mechanisms. 
3.4.2 Evidence for endometrial breakdown and shedding during an early 
window of breakdown and repair 
In the current study, evidence of endometrial breakdown occurred by 4 hours after 
progesterone withdrawal, as evidenced by blood cells in the vaginal smear (Figure 3-1). This 
finding is in contrast to previously described mouse models, where 8 hours was identified as 
the earliest time-point where blood cells were observed in the vaginal smear (334), with 
authors reporting maximal bleeding 24 hours after withdrawal. A study by Xu et al., (218), 
who used the ovariectomy model and mifepristone administration, reported no vaginal 
bleeding before 16 hours. In a more recent paper Rudolph et al., (336) used the 
pseudopregnancy model and mifepristone administration and reported bleeding at 24 hours.  
In the current study, vaginal bleeding was detected at the 4 hour time-point  and was also 
detected 8 hours later at the 12 hour time-point, suggesting that bleeding persists for at least 
8 hours after the onset of bleeding, a finding consistent with previous studies (218). Mean 
uterine horn weights for the non-decidualised and decidualised horns were significantly 
different at 0, 4, 8, and 12hours (Figure 3-4). However, the mean uterine wet weight of the 
decidualised horn at 24 hours after the withdrawal of progesterone was not significantly 
different than the non-decidualised horn, suggesting that a degree of regression of the uterine 
horn had occurred due to shedding and repair of the endometrium.  
Consistent with a previous report using a mouse model of menstruation (233), in our study 
removal of the progesterone pellet led to a rapid fall in serum levels of progesterone from a 
mean value of 12.4332ng/ml at 0 hours to 2.62ng/ml by 4 hours, continuing to decrease to 
2.1ng/ml by 24 hours. To confirm decidualisation of the functional stroma in response to oil 
injection, prolactin mRNA concentrations were measured and were detected to be down-
regulated from maximal concentrations at 0 hours to the lowest concentration at 24 hours. To 
our knowledge this is the first study to report molecular and histological evidence of 
decidualisation of the functional layer in a mouse model of menses. Degradation of the 
decidualised cell mass was observed microscopically and confirmed by decreasing 
concentrations of prolactin mRNA.  
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The striking difference in uterine phenotype observed in the non-decidualised control horn 
and the oil treated decidualised horn at 0 hours (Figure 3-6) was consistent with previous 
reports (79, 218, 230, 233). Evidence for early breakdown of the endometrium, as observed 
by red blood cells in the lumen, was consistent with histological evaluation which revealed 
shedding of the decidual cell mass into the lumen as early as the 4 hour time-point (Figure 
3-7).  
Previous studies that used the ovariectomy and pseudopregnancy mouse models to examine 
breakdown and repair within the uterus selected time-points at 24 hours intervals (79, 188, 
218, 230, 318, 336), and have not considered that a number of molecular and morphological 
changes may occur within one 24 hour period. In our study, tissue collection at 4 hour 
intervals revealed changes within the uterus which have not been previously reported.  
For example, we observed that after the withdrawal of the progesterone pellet, breakdown of 
the decidualised cell mass occurs within 4 hours. By 8 hours the decidual cell mass was 
observed to “bud” out into the lumen, whilst progressively detaching from the underlying 
basal stroma to reveal a partially denuded endometrium, whilst still being attached to another 
area of the basal layer. By 12 hours the functional layer was observed to have has fully 
detached, and 12 hours later (24 hours after progesterone withdrawal) re-epithelialisation 
was nearly or totally complete.  
Complete re-epithelialisation was observed in most animals by 24 hours, but due to some 
animal variation some animals were still undergoing repair of their epithelium at this time 
(Figure 3-10). This is consistent with reports in other mouse models (233, 318, 336) and 
similar to the variance in duration of menstruation recorded in women.  
It is important to note that in this model, as in women, endometrial repair is occurring in 
steroid-depleted conditions, as demonstrated by the clearance of progesterone (Figure 3-2). 
These findings would be consistent with data reported in a mouse model by Kaitu’u-Lino et 
al., (239) who administered a dose of letrozole (an aromatase inhibitor) at the time of 
progesterone withdrawal, to suppress any effects of exogenous oestrogens, and observed 
complete restoration of endometrial integrity within 48 hours of progesterone withdrawal 
and letrozole administration.  
3.4.3 Endometrial re-epithelialisation occurs during an early window of 
breakdown and repair via two possible mechanisms 
In women, histological evaluation suggests that menstruation and loss of the functional layer 
of the tissue results in exposed regions of the basal compartment with naked stroma and 
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glands. The current dogma is that regeneration of the functional layer of the endometrium 
requires rapid re-epithelialisation, and was first described in human endometrial samples 
taken during the menstrual phase by Novak and Te Linde in 1924 (241). They stated that the 
new epithelium arose from stumps of the glands located in the basal layer of the 
endometrium (Figure 3-19, A). Based on results in subsequent studies, conducted using 
samples from women and mouse models, notably by Gargett and colleagues, it has been 
postulated that these basal glands contain endometrial stem cells residing in a tightly 
controlled stem cell niche (91) and that this population plays a key role in formation of the 
new epithelium following menses. Studies by Cervello et al., (259, 260) identified side 
population cells within the human endometrium as putative stem cells capable of generating 
endometrial-like tissues when transplanted into immuno-deficient mice. However, recent 
evidence by Garry et al., (169) revealed that Ki67 expression (a marker of cellular 
proliferation) was minimal in the stromal cell compartment of samples taken from women 
during the menstrual phase and virtually undetectable in the glandular epithelium during 
days 1-3 of menstruation even though re-epithelialisation was documented. The authors 
postulated that another mechanism must contribute to the new epithelial cell layer (Figure 
3-19, B) and suggested that a subset of cells close to the denuded luminal surface 
differentiate to give rise to the new epithelium. This differentiation process of mesenchymal-
epithelial transition (MET) and its reverse process of epithelial-mesenchymal transition 
(EMT) have been extensively studied in embryonic development (370, 371) and in the 
formation of tumours (372–374). However, whether it plays a key role in endometrial repair 
is yet to be tested in model systems. 
 
Figure 3-19: Potential mechanisms for re-epithelialisation. A. The current theory of re-
epithelialisation; mitotic division of epithelial cells in the basal glands followed by progressive 
migration of these new cells across the denuded stromal surface. B. New cells arise from small, 
undifferentiated cells near the luminal surface. Stromal-derived cells may also contribute to the 
glandular epithelium. Adapted from (169). 
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In the current study, we used the mouse model to investigate the potential for each of these 
two mechanisms in re-epithelialisation of the uterine compartment.  
3.4.4 Re-epithelialisation by mitotic division of epithelial cells  
In our mouse model of menses epithelial proliferation was quantified by staining for BrdU, 
incorporated into cells immediately prior to tissue recovery. Cells positive for BrdU were 
observed in both the stromal cell compartment of the basal layer and in the luminal 
epithelium at 4, 8, 12 and 24 hours after the withdrawal of progesterone. Peak proliferative 
activity within the epithelium was documented subjectively at 12 and 24 hours. Notably, 
epithelial cells within the glands were not immunopositive at 0, 4, 8 or 12 hours (consistent 
with the proliferation studies in women described by Garry et al., (169) described in section 
3.4.3).  
The first observation of basal glandular epithelial cell proliferation was not detected until 24 
hours after progesterone withdrawal at a time when the luminal epithelium was intact in 
most animals (Figure 3-14, F). This may suggest that luminal re-epithelialisation is initiated 
by proliferation of unshed luminal epithelial cells, whilst basal glandular epithelial cell 
proliferation contributes to re-establishment of the glandular compartment alone.  Subsets of 
stromal cells close to the luminal surface, and perivascular cells were also observed to be 
BrdU positive at 12 and 24 hours highlighting the complex nature of the tissue.  
An absence of glandular epithelial proliferation documented in our new model is in contrast 
to a recent study by Kaitu’u-Lino et al., who, using their own mouse model of menses, 
observed that glandular epithelial cell proliferation was maximal at 48 hours after the 
withdrawal of progesterone (318). The percentage of proliferating glandular epithelial cells 
(~20.8%) was also greater than the percentage of proliferating luminal epithelial cells 
(~18%).  However, direct comparisons to our own data are difficult as in their study, mice 
were injected with BrdU on 4 consecutive days during their putative proliferative phase 
(oestrogen stimulation alone) and therefore their analysis was based on cells that had 
retained their BrdU label over a 9 day period. This injection regime was used to identify a 
population of slow cycling cells, which the authors believe to be epithelial progenitors 
present in the glands (318). This is in contrast to our own study where BrdU incorporation 
was documented in cells that hadn’t undergone multiple divisions and were proliferating at 
the time of dissection, rather than those that had been proliferating for many days. In 
addition our observation of epithelial cells “rolling” across the denuded stroma at the leading 
edge of the luminal epithelium (Figure 3-16, D) implicates a combination of luminal 
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epithelial cell proliferation and migration as key processes involved in the early repair of the 
tissue.  
Consistent with the observation of an apparent increase in luminal epithelial cell 
proliferation at 12 and 24 hours, additional investigation into the transcription of genes 
encoding proteins for epithelial cell markers revealed that these were also significantly 
increased during this time. Concentrations for mRNAs for Cdh1, Wnt7a and Krt18 were all 
up-regulated at 12 hours, and further increased at 24 hours when compared to the 0 hour 
time-point.  
3.4.5 Re-epithelialisation by stromal cell differentiation  
In the current study, the possible contribution of cells within the stromal cell compartment to 
the new luminal epithelium was first investigated by immunohistochemistry, using pan-
cytokeratin to identify any cells expressing this classic epithelial cell marker.  
Subsets of stromal cells close to the luminal surface were observed to be cytokeratin positive 
(Figure 3-18). This new finding supports a hypothesis by Garry et al., who postulate that 
stromal cells may contribute to the new epithelial layer, and that these cells will reside close 
to the luminal surface and not deep in the basal layer (148). The discovery of pan-cytokeratin 
positive stromal cells at the 24 hour time-point, but not at 12 hours, may suggest that stromal 
cell differentiation, if occurring, is activated at the end of the repair window.  
The observation of these clusters of pan-cytokeratin positive cells may suggest that these 
cells are in a transition state from a mesenchymal to epithelial phenotype. Our findings are 
consistent with previous studies that have utilised mouse models of post-partum repair (375) 
and pseudopregnancy models of decidualisation and breakdown (376), where cytokeratin 
positive stromal cells were identified in the endometrium at time-points associated with 
repair after progesterone withdrawal.  
The studies presented in this chapter revealed that dynamic changes in mRNA 
concentrations for mesenchymal and epithelial markers were detected during the window of 
breakdown and repair (Figure 3-17). One striking observation is that the trends for each set 
of genes (stromal v epithelial) are mirror images of each other, as stromal cell markers 
decrease epithelial cell markers increase. Specifically, the total mRNA concentrations of 
stromal cell specific proteins are increased during breakdown of the tissue (4-8 hours) 
consistent with an increase in stromal cell proliferation detected in the basal layer of the 
tissue at this time (Figure 3-12). However, consistent with the observation of breakdown and 
Chapter 3. Establishment of a mouse model of menses for use as a functional model of 
endometrial breakdown and repair.  
102 
 
shedding of the decidualised stromal mass and initiation of re-epithelialisation, an increase in 
concentrations of mRNAs encoding epithelial markers (in parallel with a decrease in stromal 
markers) was detected in parallel with an increase epithelial cell proliferation in uterine 
tissue recovered at 12 and 24 hours (Figure 3-13 and Figure 3-14). This switch of stromal to 
epithelial proliferation, changes at the molecular level and the observation of pan-cytokeratin 
positive stromal cells adjacent to sites of denuded endometrium all suggest that our 
hypothesis of the stromal cell compartment contributing to the repair of the luminal 
epithelium may be occurring. MET is regulated by a number of key genes and downstream 
transcription factors (377–379), and in the next chapter we conducted a more detailed 
examination of the activity of these genes during our window of breakdown and repair.   
3.4.6 Summary 
In the current study a newly refined mouse model of menstruation was optimised and 
adapted from previously published protocols. Using this model we established novel time-
points for the investigation of endometrial breakdown and re-epithelialisation of the tissue 
and shed new light on the processes operating during this critical time window. 
In our model we report that the onset of breakdown of the tissue is rapid, occurring within 4 
hours after progesterone withdrawal.  Endometrial shedding was complete within 12 hours, 
whilst re-epithelialisation was occurring or was complete by the 24 hour time-point. We 
believe that this set of time-points is more indicative of those observed in women, where 
repair of the tissue is a rapid process, and occurs simultaneously with tissue breakdown 
(148). 
Having established a window of breakdown and repair, this model was used to investigate 
re-epithelialisation as a mechanism of repair. In our model, proliferation of the residual 
luminal epithelium was present during the repair phase, whilst basal glandular epithelium 
proliferation was minimal. This finding, along with evidence of luminal epithelial cell 
motility, suggests that residual luminal epithelial cells, not shed during breakdown contribute 
to the new luminal layer of cells. Furthermore, the presence of pan-cytokeratin positive 
stromal cells adjacent to denuded areas of recently shed endometrium is suggestive of MET 
as a potential mechanism of re-epithelialisation. From the evidence in this study, it is 
possible that both mechanisms; mitotic division of epithelial cells and mesenchymal-
epithelial transition contribute to the re-establishment of endometrial integrity.  
The results herein provide a novel description of the breakdown and re-epithelialisation in a 
mouse model of menstruation. In Chapter 1 (section 1.6.3) the cascade of events observed 
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during menstruation in women was described, including; induction of local hypoxia via 
arteriole vasoconstriction and immune cell influx. Using our new model of breakdown and 
repair, the following chapter will investigate a role for hypoxia in initiation of repair 
mechanisms and angiogenesis, a role for the endometrial macrophage in tissue remodelling 
and further investigation into MET as a potential repair mechanism. A role for androgens 
during menses will be discussed in Chapter 5. 




Chapter 4 Mechanisms that contribute to the 
restoration of endometrial integrity following menses 
4.1 Introduction 
In women extensive endometrial remodelling occurs during menses and the subsequent 
repair phase of every reproductive cycle. Due to its multi-cellular composition, in order to 
restore tissue homeostasis, the endometrium must undergo; re-epithelialisation, stromal cell 
remodelling and endothelial cell proliferation and stabilisation during this repair phase in 
preparation for steroid-derived proliferation and differentiation.  
4.1.1 Re-epithelialisation of the exposed stroma 
Re-epithelialisation is a crucial process in endometrial repair. Any delay can lead to 
prolonged bleeding which can cause anaemia in women. A widely accepted model  of 
endometrial regeneration, based on observations made by Novak and Te Linde, in 1924, 
suggests that a new population of glandular and luminal epithelial cells arise from the 
epithelium of glands that are retained in the basal layer after shedding of the functional layer 
(241).  
Recent data suggest that this model of endometrial repair needs to be revisited with recent 
advances in stem cell research having highlighted them as a potential resource involved in 
tissue regeneration. For example, recent work on human endometrial stem cells (262, 380) 
circulating progenitor cells (mouse and human) (266, 267, 381, 382) and human endometrial 
side population cells (259, 260, 268, 383, 384) implicate all of them as playing a role in 
repair of the tissue following menses. Notably, label retaining cells (LRCs) have been 
identified in both the stromal and epithelial cell compartments of the mouse endometrium 
(385, 386) during post natal development and these are postulated to be stem-like cells that 
contribute to the growth of the tissue. A mouse model used in studies prior to those described 
in Chapter 3 documented stem-like label-retaining cells in the endometrium in the basal 
glands. Clonogenic (stem-like) cells have also been identified in both the stromal and 
epithelial cell compartments of the human endometrium (251, 257, 387). 
Another possible mechanism involved in endometrial re-epithelialisation is cellular 
transdifferentiation. Recent scanning electron microscopy (SEM) studies have implicated 
stromal cell differentiation to epithelial cells as a possible mechanism for repair (148, 169). 
In Chapter 3, using a newly refined mouse model of breakdown and repair, stromal cells 
adjacent to areas of shed endometrium were found to be immunopositive for the epithelial 




marker cytokeratin. These novel findings led us to speculate that these cells were undergoing 
a morphological change and may be contributing to the new epithelial layer, and therefore 
prompted further studies as described in this chapter. Our preliminary findings would be 
consistent with data from Garry et al., who observed new epithelial cells on the luminal 
surface of the endometrium that were not connected to, or extensions of, the glandular 
epithelium (148). 
4.1.2 Mesenchymal to epithelial cell transition 
Mesenchymal to epithelial transition (MET) is a biological process by which mesenchymal 
cells lose their migratory and invasive phenotype, transforming into polarised epithelial cells 
which are anchored by cell adhesion molecules to the basement membrane (388, 389). In 
tissues the occurrence of MET is generally reported to be less common than epithelial to 
mesenchymal transition (EMT). EMT has been widely studied in the context of prenatal 
development and organogenesis (389–391) and cancer metastasis (372, 377, 379, 392–397). 
EMT has also been implicated in maintenance of tissue homeostasis in tissues such as the 
heart (398, 399), intestine (400, 401) and the mammary gland (402). MET has been studied 
in the context of hepatic stem cell differentiation (403); a role for MET has not previously 
been investigated in the context of restoration of endometrial homeostasis.  
Studies on EMT and MET in a variety of tissues/conditions have reported data 
demonstrating involvement of multiple molecular processes including activation of 
transcription factors, reorganisation of cytoskeletal proteins and changes in cell-surface 
expression markers (372, 377–379, 404). Recent reviews have summarised the cell surface 
expression markers that are used as markers for mesenchymal versus epithelial cell 
phenotypes in vivo (Figure 4-1). It is generally accepted that cells expressing both 
mesenchymal and epithelial markers are in an “intermediate” or “transition” state.  





Figure 4-1: Mesenchymal to epithelial transition (MET) and its reverse process epithelial to 
mesenchymal transition (EMT).  MET is driven by an up-regulation of adhesion molecules between 
mesenchymal cells, followed by cytoskeletal reorganisation and desmosome association. The 
polarity of cells is altered and tight junctions form, cells begin to express epithelial markers including 
cytokeratins (Adapted from (405–407)).  
A number of key genes and downstream transcription factors involved in the regulation of 
both processes have been identified. Wilms’ tumour 1 (WT1) is located on chromosome 11 
and encodes 36 protein isoforms (408). WT1 acts as a transcription factor for Snail (SNAI1) 
and Slug (SNAI2) (404). WT1 is essential during gastrulation and organogenesis; in a knock-
out mouse model with targeted ablation of WT1, the kidneys, gonads, spleen and adrenal 
glands fail to form and homozygous embryos die at mid-gestation (409, 410). WT1 has also 
been shown to be activated upon tissue injury (407).  
The transcription factors Snail and Slug have been shown to be repressors of expression of 
the epithelial cell protein E cadherin in tumour models, driving EMT over MET to support 
tumour formation (411–413).  
MET has been studied in a number of tissues, including the kidney (414–416), and skin 
(417). In vitro studies have demonstrated that renal fibroblasts can be driven towards an 
epithelial phenotype (415, 416). In vitro studies in different tissues have documented that 
during MET Snail is down-regulated in mesenchymal cells releasing its inhibition on E-
cadherin. An increase in E-cadherin expression drives an increase in cell-cell adhesion 
molecules (417). Mesenchymal cells begin to express epithelial cell markers during this 
intermediate step; becoming less motile and anchored to the basement membrane and 
desmosome formation follows. Increased E cadherin drives tight junction formation (414, 




417), finally cells undergo polarisation from a front-rear axis of polarity of mesenchymal 
cells to the apical-basal polarity seen in all epithelial cells  (reviewed by (418)). 
A role for MET during postpartum repair of the endometrium has been investigated in two 
mouse models. In the first study, uterine tissues were collected from an Amhr2-Cre knock in 
mouse line, whose myometrium was labelled for β-galactosidase. Uterine tissues were 
collected prior to pregnancy, at which time β-galactosidase was localised exclusively within 
the myometrium and stromal cells. Tissues were then collected 2 hours post-partum (day 0), 
one day post-partum (day 1) and three days post-partum (day 3). Dual staining for β-
galactosidase and cytokeratin was detected in the luminal epithelium 1 day post-partum and 
the glandular epithelium 3 days post-partum, raising the possibility that cells from the 
stromal cell compartment had contributed to the repair of the luminal epithelium and to the 
formation of the new glands (375).  
A second study utilised a pseudopregnancy model (as described in section 1.9.4.3), in which 
females were mated with vasectomised males and artificially decidualised before 
endometrial breakdown was induced by removal of the ovaries. In uterine samples removed 
during the breakdown and repair window, the authors detected cells dual stained for pan-
cytokeratin and vimentin in the stromal cell compartment adjacent to the myometrial-stromal 
border at 24 hours; and also adjacent to the shed cells/exposed stromal cell compartment at 
48 hours after ovariectomy (376).  Another fate mapping study conducted during postnatal 
development was carried out using an Amhr2-Cre; Rosa26-EYFP mouse model in which 
EYGP was expressed in all cells derived from the mesoderm (mesenchymal cells). At 
postnatal day 25, in virgin females, EYFP was not expressed in the glandular or luminal 
epithelium. However, after 3 pregnancies, EYFP was expressed in both the glandular and 
luminal epithelium, suggesting that stromal-derived cells do contribute to endometrial 
remodelling in the post-partum period in a non-menstruating species (376).  
4.1.3 A role for hypoxia during endometrial repair 
In vitro studies using human endometrial explants (419, 420) and in vivo studies in non-
human primates (188, 328) have reported that active angiogenesis occurs during the 
proliferative phase of the menstrual cycle, at a time when expansion of the functional layer 
of the endometrium is driven by rising concentrations of circulating oestrogens. Endothelial 
cell proliferation is suppressed during the secretory phase and vessel maturation and coiling 
occur (232) to prepare the endometrium for implantation and pregnancy. Despite oestrogen 




and progesterone being the key regulators of endometrial growth and differentiation, it is 
thought that they may not directly regulate VEGF-dependent angiogenesis (421).  
Progesterone withdrawal precipitates a cascade of molecular changes including increased 
expression of the enzyme COX-2, a key regulator of prostaglandin biosynthesis (422) 
resulting in the biosynthesis of prostaglandins which induce myometrial contractions and 
vasoconstriction of the spiral arterioles (reviewed  by 48). The net result of these changes is 
the generation of a hypoxic environment in the upper, decidualised, functional layer of the 
tissue which is typical of that associated with tissue necrosis and ischaemic injury (186). 
Hypoxia is associated with stabilisation of HIF, a key regulator of hypoxic response genes 
which are expressed in endometrial tissues during menses (190, 192, 193). 
Hypoxia has been shown to promote stromal and epithelial cell secretion of VEGF in human 
endometrial stromal cells in vitro (193), suggesting that hypoxia may be a key regulator of 
endothelial cell proliferation and stability during endometrial repair. Regulation of 
endothelial cell stability and remodelling is essential to the successful repair of the tissue. 
Neo-angiogenesis is likely to occur during menses and will involve a variety of pro-
angiogenic and anti-angiogenic factors the full details of which require further study. 
4.1.4 Immune cell influx and contribution to repair 
A diverse population of immune cells is present in the human endometrium, including 
neutrophils, macrophages and mast cells with their numbers fluctuating dependent upon 
cycle stage. Notably, leukocytes are reported to comprise up to 40% of endometrial tissue 
during endometrial breakdown (185, 214), consistent with the acceptance that menstruation 
is an inflammatory event.  
Tissue resident endometrial macrophages have been postulated to have many roles in the 
endometrium including; initiation of menses (71), tissue breakdown and clearance (148) and 
remodelling of the functional layer during early repair phases of the endometrium (423).  
Immune cell influx during endometrial breakdown and repair has been investigated using 
mouse models that include induced endometrial breakdown (217, 334). These studies 
reported that uterine natural killer cells (uNKs), macrophages, neutrophils and T cells are all 
present in the decidualised mouse endometrium prior to breakdown of the tissue. After 
progesterone withdrawal, one study reported that neutrophil numbers appear to increase 
whilst other immune cells types decrease (217). Inhibition of neutrophils by a monoclonal 
antibody, RB6-8C5, delayed repair of the murine endometrium suggesting a role for this cell 




type in breakdown and remodelling (217). Macrophage numbers were reported to increase 
during the repair phase, at a time when neutrophil numbers decreased (334), implicating a 
role for macrophages during remodelling of the mouse endometrium, at least in this model. 
These data are consistent with immunolocalisation studies in human endometrial samples 
from the menstrual phase, where an increase in neutrophils, eosinophils, T cells, B cells, 
macrophages and uNK cells was recorded upon progesterone withdrawal (185, 209, 214, 
424). Immunolocalisation studies in human tissues and in vitro cultures indicate that 
neutrophils are the dominant leukocyte during breakdown (207, 424), whereas macrophages 
are postulated to be key to tissue remodelling during the repair phase (215). 
In summary, the human endometrium is a multi-cellular tissue that undergoes a tightly 
regulated cycle of proliferation, differentiation, breakdown and repair; however the 
mechanisms that contribute to tissue restoration following menses are poorly understood. It 
is likely that a combination of interchanging mechanisms contribute to restoration of tissue 
integrity. We believe that studies in our novel mouse model can provide insights into 
regulatory events during this critical time window. 
4.1.5 Aims of the chapter 
1. To investigate a role for mesenchymal to epithelial transition during re-
epithelialisation of the endometrium. 
2. To investigate immune cell influx, specifically macrophages during breakdown and 
repair. 
3. To determine a role for hypoxia during endometrial breakdown. 
  




4.2 Materials and methods 
4.2.1 Mouse model of menstruation  
The mouse model established in Chapter 3 and described in section 2.1.4.4 was utilised to 
investigate mechanisms contributing to endometrial repair. The protocol is outlined in Figure 
2-4. 
4.2.2 Transgenic fms-EGFP mouse line- “The Mac green mouse” 
Generation of the Mac green mouse is described in Chapter 2.1.2. Founder stocks were 
generously provided by Dr. Bernadette Dutia and Professor David Hume (University of 
Edinburgh). Genotyping for EGFP positive mice was carried out as described in section 
2.1.2. Mac green mice were included in the menses model and dissected at each of the 
designated time-points.  
4.2.3 Immunohistochemistry   
All samples were fixed in NBF overnight at room temperature, rinsed in 70% ethanol and 
then stored in 70% ethanol before tissue processing as described in section 2.6. 
Immunohistochemistry was carried out using the standard protocol outlined in section 2.7.2 
using the antibodies outlines in Table 2-15 and Table 2-16. Modifications to the standard 
protocol were required for Snail/Slug and green fluorescent protein (GFP). Deviations to the 
standard protocol are outlined in section 2.7.2.9.  
Images were analysed as detailed in section 2.7.2.10. 
4.2.4 RNA extraction 
RNA extraction was carried out as detailed in section 2.2. 
4.2.5 Synthesis of complementary DNA using VILO cDNA synthesis kit 
Reverse transcription of RNA to cDNA was performed using the Superscript VILO cDNA 
synthesis kit (InVitrogen) according to manufacturer’s instructions, using the volumes 
outlined below in Table 2-8. Samples were then incubated under the conditions detailed in 
section 2.3 
4.2.6 Quantitative Real Time PCR 
Quantitative real time PCR was carried out as detailed in section 2.4.  
Statistical analysis was performed as detailed in section 2.8. 




4.2.7 RT2 Profiler PCR array 
RT
2
 profiler arrays contain a panel of genes containing housekeeping genes, quality controls 
and 84 genes that are related to a specific biological pathway. RNA samples used in RT
2
 
profiler PCR array were subject to quality assessment based on RIN. Samples were RIN<6.0 
were excluded. Two gene arrays were utilised in this study; Mouse Epithelial to 
Mesenchymal Transition Array (SABiosciences, PAMM-090Z) and Mouse Angiogenesis 
Array (SABiosciences, PAMM-024Z). 
RNA quantitation was performed as detailed in section 2.5.1. A RIN greater than 6.0 was 
accepted for further analysis by PCR array. cDNA synthesis was performed following the 
protocol outlined in section 2.5.3. Real time PCR was performed as detailed in section 2.5.4.  
PCR data analysis was performed using the SABiosciences web portal as detailed in section 
2.8. 
4.2.7.1.1 Putative pathway analysis by MetaCore™ 
MetaCore™ is an integrated software that utilises a manually curated database of known 
species specific interactions between protein-protein, protein-DNA and protein-RNA. 
MetaCore™ was used to map potential signalling and metabolic pathways of candidate 
genes investigated by PCR array.  
  





4.3.1 Evidence from a mouse model that re-epithelialisation of the endometrium 
involves mesenchymal to epithelial transition. 
Following an initial observation of cytokeratin positive cells in the stromal cell compartment 
of repairing endometrium in Chapter 3, further evidence for MET during endometrial repair 
was investigated by immunofluorescence, using double staining for the mesenchymal marker 
vimentin and the epithelial marker cytokeratin. 
During breakdown of the tissue (0-8 hours after P withdrawal), no co-localisation of 
vimentin and cytokeratin was observed (Figure 4-2, A and B) with vimentin localised 
exclusively within the stromal compartment of the basal layer and cytokeratin is only 
detected in the glandular and luminal epithelium. At 12 hours, a few dual labelled cells 
(yellow) were detected in the basal layer close to the myometrium (Figure 4-2, D; 
arrowheads) and interestingly, stromal cells in the basal layer were also strongly stained for 
cytokeratin (Figure 4-2, E). At 24 hours, in tissue samples exhibiting repair (Figure 4-2, F), 
the area of exposed stroma is highlighted by the white arrows, and is found adjacent to the 
shed functional layer (SC) present in the lumen. A higher powered image of one area in 
Figure 4-2, G, shows co-localisation of vimentin and cytokeratin in stromal cells adjacent to 
the lumen (white arrowheads). These cells are expressing both epithelial and mesenchymal 
markers and therefore can be considered as an intermediate phenotype that occurs in the 
process of MET.  
 





Figure 4-2: Epithelial cells stained for cytokeratin (green) and mesenchymal cells stained for 
vimentin (red) in the mouse endometrium.  A and B; 8 hours after progesterone withdrawal, the 
decidualised cells begin to detach from the underlying stroma (white arrows). The stromal cells of 
the underlying basal stroma were positive for vimentin (red), the glandular epithelium (G) and the 
encroaching luminal epithelium were positive for cytokeratin (green). No co-localisation for 
cytokeratin and vimentin was observed. C; 12 hours after progesterone withdrawal, vimentin 
positive decidualised cells were observed, budding into the lumen. D; Vimentin and cytokeratin 
positive cells were observed in the basal layer, close to the myometrium (arrowheads). E; stromal 
cells in the basal layer were positive for cytokeratin. F and G; 24 hours after progesterone 
withdrawal. An area of shed endometrium (indicated by white arrows) was observed. Co-localisation 
of vimentin and cytokeratin (white arrowheads) was detected close to the surface of the underlying 
basal layer. DS; decidualised stroma, M; myometrium, BL; basal layer, G: glandular epithelium, SC; 
shed cells. Scale bars as indicated. Images representative of 3 animals. 




4.3.1.1 MET array analysis  
To complement the observation of dual-labelled cells close to the luminal surface, additional 
evaluation of MET was investigated using a PCR array that profiles 84 key genes that are 
known to be involved in the EMT pathway (and therefore its reverse process MET). The 
cDNAs detected by the array include cell surface receptors, cell adhesion markers, 
extracellular and cytoskeleton genes and genes involved in migration, motility and 
morphogenesis, as well as key transcription factors of this process. The full gene list can be 
found in the Supplementary Table 1. 
Samples from three time-points were chosen for analysis; 0 hours as the time-point prior to 
breakdown, 8 hours after progesterone withdrawal (blood in vagina), as this was a time when 
the tissue is observed to be breaking down, and 24 hours after progesterone withdrawal, as in 
our model the endometrium was undergoing or had completed re-epithelialisation. Those 
genes in which a significant change in fold regulation was documented are shown in Table 
4-1, Table 4-2 and Table 4-3.   
Notably, at both the 8 hour and 24 hour time-points a greater proportion of genes were up-
regulated than down-regulated when compared with the 0 hour time-point; n=20 v 4 and 
n=43 v 5 respectively. Of the 21 gene changes that occurred between 8 and 24 hours, 12 
were up-regulated whereas 9 were down-regulated.  
A number of the changes detected in the mouse mirrored those reported in human tissue at 
time of menses (224, 226, 425), including a striking up-regulation in expression of Mmp-3 (a 
3 fold increase at 8 hours, and a 61 fold increase at 24 hours) and evidence of dynamic 
differences occurring between 8 and 24 hours. Mmp-9 was also significantly up-regulated 
between 8 and 24 hours (11 fold increase).  
Other notable changes included expression of the epithelial markers Krt7 (4 fold increase at 
8 hours and 28 fold increase at 24 hours when compared to the 0 hour time-point) and 
Cdh1(E cadherin) (5 fold increase between 0 and 24 hours). Cell adhesion molecules Dsc2 
(desmocollin2) and Spp1 (osteopontin) were also significantly up-regulated. Spp1 increased 
4 fold at 8 hours and 23 fold at 24 hours when compared to the 0 hour time-point. Dsc2 
increased 4 fold between 0 and 24 hours. Intracellular junction protein desmoplakin (Dsp) 
increased 9 fold at 24 hours when compared to the 0 hour time-point. Snail homolog Snai3, 
increased 5 fold at 8 hours and 15 fold at 24 hours. Platelet derived growth factor receptor 
beta (PDGFRβ) increased 2 fold at 8 hours and 4 fold at 24 hours.  




Gene Name p value Fold Regulation 
Col5a2 0.014999 1.3733 
Fzd7 0.004084 2.112 
Gng11 0.027026 -2.0012 
Igfbp4 0.007334 1.8312 
Il1rn 0.000873 2.0872 
Ilk 0.027785 1.4167 
Itgb1 0.001503 1.4681 
Krt19 0.000383 1.9973 
Krt7 0.001239 4.8209 
Mmp2 0.008265 2.0402 
Mmp3 0.013284 3.0056 
Mtap1b 0.021019 1.7783 
Pdgfrb 0.030445 2.1571 
Plek2 0.001445 2.1191 
Rgs2 0.001027 -2.7773 
Snai2 0.018714 -2.1138 
Snai3 0.006822 5.6312 
Spp1 0.001467 4.3785 
Stat3 0.001286 1.5821 
Steap1 0.000673 2.3442 
Tfpi2 0.008769 -1.8252 
Timp1 0.015419 1.6154 
Tmeff1 0.000078 2.3973 
Wnt11 0.000277 3.4224 
Number of genes significantly up-regulated 20 
Number of genes significantly down-regulated 4 
Table 4-1: Significant changes in gene expression 8 hours after progesterone withdrawal, as 
displayed by up- or down- fold regulation when compared against the 0 hour group, n=6. 
  




Gene Name p value Fold Regulation 
Akt1 0.004507 1.6241 
Bmp1 0.001376 1.7233 
Bmp7 0.04878 1.8035 
Cald1 0.006957 2.2812 
Camk2n1 0.04425 4.8329 
Cav2 0.03615 1.7465 
Cdh1 0 5.1764 
Cdh2 0.046312 1.4957 
Dsc2 0.000383 4.734 
Dsp 0.000257 9.5533 
Esr1 0.032215 1.5223 
Fn1 0.007739 3.0108 
Fzd7 0.011578 2.2833 
Gng11 0.016563 -2.7033 
Gsc 0.039591 2.8029 
Gsk3b 0.046881 1.4052 
Ilk 0.004121 1.8766 
Itgb1 0.006007 1.6552 
Jag1 0.002575 3.4856 
Krt19 0.000053 7.5293 
Krt7 0.000018 28.178 
Mitf 0.001484 -2.1751 
Mmp2 0.00544 2.7303 
Mmp3 0.001871 61.2906 
Msn 0.000728 1.8437 
Mtap1b 0.000492 2.1494 
Notch1 0.031693 1.6165 
Ocln 0.005327 11.2243 
Pdgfrb 0.000015 4.5738 
Plek2 0.044301 1.6349 
Ptp4a1 0.002475 1.8968 
Rgs2 0.001014 -4.2015 
Smad2 0.005844 1.3823 
Snai3 0.011681 15.8243 
Spp1 0.000141 23.2021 
Stat3 0.00232 1.8157 
Steap1 0.000283 4.6399 
Tcf4 0.001468 1.4002 
Tfpi2 0.002632 -2.1709 
Tgfb1 0.004964 1.783 
Tgfb2 0.004658 -1.497 
Tmeff1 0.000001 4.1575 
Tmem132a 0.00069 2.8066 
Tspan13 0.00039 3.2687 




Gene Name p value Fold Regulation 
Twist1 0.00125 3.294 
Vim 0.001135 1.7446 
Vps13a 0.035245 1.5401 
Zeb1 0.000009 2.4496 
Number of genes significantly up-regulated 43 
Number of genes significantly down-regulated 5 
Table 4-2: Significant changes in gene expression 24 hours after progesterone withdrawal, as 
displayed by up- or down- fold regulation when compared against the 0 hour group, n=6. 
 
Gene Name p value Fold Regulation 
Ahnak 0.036678 0.5404 
Cdh1 0.004232 2.0487 
Dsc2 0.038234 2.2635 
Dsp 0.007373 3.0514 
Egfr 0.002567 0.5275 
Gng11 0.04006 0.4894 
Igfbp4 0.015997 0.5351 
Jag1 0.035072 1.9634 
Krt19 0.044665 2.492 
Krt7 0.014579 3.8638 
Mitf 0.043177 0.3895 
Mmp3 0.010098 13.4799 
Mmp9 0.024631 11.2996 
Mst1r 0.049177 0.6576 
Ocln 0.047848 3.1545 
Plek2 0.041571 0.51 
Pppde2 0.006287 0.6375 
Rgs2 0.038365 0.437 
Spp1 0.023751 3.5029 
Tgfb2 0.008919 0.3996 
Tgfb3 0.025285 0.5698 
Number of genes significantly up-regulated 12 
Number of genes significantly down-regulated 9 
Table 4-3: Significant changes in gene expression 24 hours after progesterone withdrawal, as 
displayed by up- or down- fold regulation when compared against the 8 hour group, n=6. 
4.3.1.2 Dynamics of gene expression during the breakdown and repair window 
To complement and extend these observations, additional experiments focussed on 
examining the dynamics of expression of genes, previously described to be critically 
involved in regulation of MET and its reverse process EMT, across all of the time-points 
investigated in our model. Gene expression was quantified by qRTPCR (Figure 4-3). 
Concentrations of Wt1 mRNA in total uterine tissue extracts displayed dynamic changes 




across the window of breakdown and repair (4-24 hours). For example, the total 
concentration of Wt1 mRNA showed a trend of an increase at the 4 hour time-point when 
compared to the 0 hour time-point occurring at a time when breakdown of the tissue was first 
observed; concentrations were observed to decrease at 8 hours before being significantly 
decreased at 12 hours (p<0.01) and 24 hours (p<0.01) when compared to the 4 hour time-
point.  
Concentrations of Snail mRNA exhibited a similar pattern to that of Wt1, with a trend of an 
increase at 4 hours before a decrease of expression towards 24 hours, however no significant 
changes in mRNA concentrations were observed. Concentrations of the second snail 
homolog, Slug, showed no significant changes between 0 and 24 hours, however a trend of a 
decrease was observed at 8 hours which is consistent with data obtained from the array. 
Concentrations of the third Snail homolog Smuc (Snai3) were observed to be inversely 
regulated compared to Snai1. mRNA concentrations did not significantly change between 
the 0 and 12 hour time-points, however a significant increase in mRNA concentrations was 
observed between 12 and 24 hours (p<0.001), coincident with re-epithelialisation of the 
tissue. A significant increase between 0 and 24 hours is consistent with the increase observed 
in the array. 
Protein expression of WT1 and Snail (Snai 1 and 2) were evaluated by 
immunohistochemistry, and the localisation of these proteins is shown in Figure 4-4. 
Consistent with the mRNA data, the most intense immunostaining of WT1 was detected 4 
hours after progesterone withdrawal localised to both the decidualised stromal cells in the 
functional layer and the stromal fibroblasts in basal layer (Figure 4-4, A). WT1 
immunoexpression appeared to be less intense in the shed cells (SC) 12 hours after 
withdrawal of progesterone (Figure 4-4, B). Notably, WT1 was not expressed in the luminal 
(LE) or glandular (G) epithelium, and weaker immunostaining for WT1 was observed in the 
basal stromal cell compartment at 12 hours when compared to the 4 hour time-point. 
Endothelial cells were also observed to be WT1 immunonegative (Figure 4-4, B, inset 
image, black arrowheads). 
The homologs of Snail (Snail and Slug) were immunolocalised, by an antibody that 
recognised both proteins, to stromal cells as well as the glandular epithelium during 
breakdown at 8 hours after progesterone withdrawal (Figure 4-4, C). More intense 
immunoexpression of Snail/Slug was observed in the luminal epithelium and the surrounding 




stroma during repair, (Figure 4-4, D), in tissues recovered 24 hours after progesterone 
withdrawal. 
 
Figure 4-3: mRNA concentrations for candidate genes involved in mesenchymal to epithelial 
transition; Wt1, Snail (Snai1), Slug (Snai2), Smuc (Snai3) following progesterone withdrawal. mRNA 
expression for the decidualised horn (black bars) was normalised against the control 0 hour horn. 
Statistical analysis was performed by One way ANOVA and Bonferroni post hoc testing, where each 
time-point was compared to the 0 hour time-point and then each other time-point, where * p<0.05, 
** p<0.01, ***p<0.001. 





Figure 4-4: WT1 (A and B) and Snail/Slug (C and D) localisation in the mouse endometrium during 
breakdown and repair.  A; WT1 is immunopositive in decidualised stromal cells and also expressed 
in the stroma of the functional and basal layers at 4 hours after progesterone withdrawal (inset 
image is the negative control). B; WT1 is absent from the luminal epithelium (LE) and the glandular 
epithelium (GE) at all time-points. WT1 appears to be down-regulated in the basal layer and is largely 
absent from the shed cells in the lumen, 12 hours after progesterone withdrawal. Inset; endothelial 
cells are WT1 negative. C; Snail/Slug is expressed in the stromal cells and epithelial cells at 8 hours 
after progesterone withdrawal. D; staining for Snail/Slug was observed in the luminal epithelium and 
the adjacent stromal cells at 24 hours after progesterone withdrawal. BL; basal layer, G: glandular 
epithelium, SC; shed cells, DS; decidualised stroma, LE; luminal epithelium, M; myometrium. Scale 











4.3.1.3 Network analysis of the MET pathway 
To understand the potential interactions between the genes detected as being changed in both 
the array and in the MET regulatory genes (Wt1, Snai1, Snai2, Snai3), a basic gene network 
was generated using MetaCore™ (Thomson Reuters) software. To filter data, the full gene 
array list was input into the software, any gene that was found to have no interaction to any 
of the other 83 genes was removed from the network. As WT1 has been previously 
demonstrated as a master regulator of the Snail homologs those genes that are downstream of 
WT1 were highlighted to identify candidates for further investigation. The results of this 
analysis are depicted in Figure 4-5. Direct interactions between genes, known to be involved 
in EMT in other tissues, are depicted using arrows; green arrows denote stimulatory actions, 
whereas red lines denote inhibitory actions, a key for the symbols used in the array can be 
found in Supplementary Figure 1. A full list of gene names highlighted in the network can be 
found in Supplementary Table 1. 
From the network analysis it is evident that multiple cell compartments are involved in 
regulation of MET and that multiple interactions occur between each compartment. 
According to this network analysis, changes in expression of WT1 may play a role in 
modulating expression of MMP-9; this is consistent with data reported in the array, where no 
significant changes were observed in expression of Mmp-9 during breakdown (0-8 hours) at 
a time when Wt1 is increased (Figure 4-3). However, as expression of Wt1 is decreased (12-
24 hours) and therefore its putative inhibitory impact reduced, an 11 fold increase in Mmp-9 
was reported in the array between the 8 hour and 24 hour time-point. During EMT, WT1 has 
been reported to have direct stimulatory effects on Snail, whilst inhibiting Slug, E cadherin 
and Tgfb (399, 404, 426). In the current data, Slug mRNA was decreased at 8 hours, 
consistent with data reported in Figure 4-3. Increased mRNA concentrations of Wt1 were 
also coincident with low mRNA concentrations of E cadherin (Cdh1) reported in Figure 
3-17, during breakdown. Although the relative contributions of Wt1, Snai1 and Snai2 in 
EMT may be complex, it was notable that as Wt1 mRNA concentrations decreased increases 
in Tgfb and E cadherin were detected in the array.  
Genes upstream of E cadherin and N cadherin, common epithelial and mesenchymal markers 
used for cellular phenotyping, are also depicted in Figure 4-5. Interestingly, Mmp-2 and 
Mmp-9 have been reported to exhibit inhibitory actions on E cadherin (427–430), which may 
account for the low fold changes observed in E cadherin in the array.  




In summary, dynamic gene changes associated with regulation of cell identity are observed 
during breakdown (0-8 hours) and repair (8-24 hours). Of note, striking increases in 
epithelial markers (Krt7 and Cdh1), tissue remodelling factors (MMPs), cell adhesion 
molecules (Spp1 and Dsc2) and intracellular junction proteins (Dsp) were observed 24 hours 
after withdrawal of progesterone during the window of endometrial repair. This suggests a 
net effect of MET over EMT. Network analysis, using known gene interactions, 
demonstrates that MET is a complex regulatory pathway involving multiple cellular 
compartments. Candidates for further investigation were identified from the network analysis 
and include; Mmp-2 and Mmp-9, PDGFRβ and Twist. 




Figure 4-5: Known interactions of genes downstream of WT1, Snail and Slug. Arrows indicate direct effects on other genes in the pathway. Green arrows indicate 
activation, whereas red arrows show inhibitory action. Pathway generated using MetaCore™ software. Gene symbols are outlined in Supplementary Figure 1. 
 




4.3.2 A role for macrophages during endometrial breakdown and repair 
4.3.2.1 Identification of monocytes in the Mac green mouse 
Mice with EGFP-labelled cells of the monocyte lineage, the “Mac green mouse” (341), were 
used in the model of menstruation with tissues recovered at multiple time-points. 
Immunohistochemistry for EGFP was used to identify tissue resident macrophages during 
breakdown and repair so as to assess the numbers and locations of cells during uterine tissue 
remodelling. 
At the time of full decidualisation (0 hours, Figure 4-6), EGFP positive cells (putative tissue 
macrophages) were localised in the decidualised stroma (Figure 4-6, A), in blood vessels 
(Figure 4-6, B) the stromal cell compartment of the basal layer (Figure 4-6, C) and in the 
luminal epithelium (Figure 4-6, D). By 12 hours after progesterone withdrawal, a time when 
the decidual cells were observed to be detaching from the underlying basal layer (Figure 
4-7), macrophages appeared to have infiltrated the basal layer and were localised to areas 
adjacent to regions of shedding (Figure 4-7, C). Additionally, a significant population of 
macrophages were detected adjacent to the luminal epithelium (Figure 4-7, B, arrowheads). 
Figure 4-7, D, shows a portion of tissue where detachment of the decidual cells from the 
basal layer is well advanced. Macrophages are evident in the remaining basal layer, but also 
in the tissue mass that had been shed into the lumen and was in the process of breaking down 
(Figure 4-7, D, arrowheads).  
By 24 hours, the diameter of the uterus had reduced (Figure 4-8, A), and the luminal 
epithelium was continuous consistent with full repair. However, EGFP positive macrophages 
were still detected in the tissue at this time. In contrast to the 0 hour and 12 hour time-points, 
it was notable that macrophages were largely absent from the basal layer of the tissue (Figure 
4-8, B and C) but appeared to be localised within the stromal cell compartment immediately 
adjacent to the luminal epithelium (C, arrows) with some floating in the lumen (Figure 4-8, 
D). 
Figure NUMBER. mRNA concentrations of hypoxia driven genes following 
progesterone withdrawal. 
Black bars indicate mRNA expression in the decidualised horn compared to 
the control horn (0 hour non-decidualised). Statistical analysis was 
performed by Student t test, comparing each time-point to the 0 hour 
decidualised horn accepting P<0.05 as statistically significant. 





Figure 4-6: Localisation of EGFP positive cells (putative tissue macrophages) in fully decidualised 
tissue at the time of progesterone withdrawal (0 hours) in the mac green mouse.  Macrophages 
were identified by immunohistochemistry for green fluorescent protein (GFP) as indicated by brown 
staining. A; Macrophages were observed in the decidualised stroma, the basal layer and the luminal 
epithelium. B; EGFP positive cells are localised in the blood vessels (arrows) and the decidualised 
stroma. C; Positive immunostaining for macrophages detected in the basal layer of the 
endometrium. D; Macrophages were identified in the luminal epithelium. Elongated EGFP positive 
cells were detected adjacent to the luminal epithelium (arrowheads). BL; basal layer, DS; 
decidualised stroma, LE; luminal epithelium, M; myometrium. Scale bars as indicated. Images 










Figure 4-7: Localisation of EGFP positive cells (putative tissue macrophages), 12 hours after 
progesterone withdrawal. Macrophages were identified by immunohistochemistry for green 
fluorescent protein (GFP) as indicated by brown staining. A; Macrophages were observed in the basal 
layer and surrounding the luminal epithelium. B; Macrophages were observed adjacent to luminal 
epithelial cells (arrowheads). C; Immunopositive staining for macrophages observed in the basal 
layer of the endometrium. D; Macrophages were localised to the basal layer, but also shed during 
detachment of the functional stroma. SC; shed cells. BL; basal layer. Scale bars as indicated. Images 
representative of 3 animals. 
 
 





Figure 4-8: Localisation of EGFP positive (putative tissue macrophages), 24 hours after 
progesterone withdrawal. Macrophages were identified by immunohistochemistry for green 
fluorescent protein (GFP) as indicated by brown staining. A; Macrophages were localised primarily to 
the stromal cell compartment surrounding the luminal epithelium. B; Macrophages were observed 
adjacent to luminal epithelial cells. C; Macrophages were localised to regions adjacent to the luminal 
epithelium (arrows). Macrophages were largely absent from the basal layer of the tissue. D; 
Macrophages were also detected in the shed cells in the lumen. SC; shed cells. BL; basal layer. Scale 













4.3.2.2 Expression of genes involved in macrophage recruitment 
To complement these observational studies, qRTPCR was performed for genes that had been 
previously described as encoding proteins involved in macrophage recruitment, 
differentiation or proliferation (208, 423, 431–435), gene expression is outlined in Figure 
4-9. Concentrations of the chemokine Ccl2 did not change significantly during the window 
of breakdown (0-8 hours), however a significant increase in concentrations of Ccl2 mRNA 
was detected at at 24 hours (p<0.001). Concentrations of connective tissue growth factor 
(Ctgf) followed a similar pattern, with no change observed at the 4-12 hour time-points. A 
significant increase in concentrations of Ctgf was detected at 24 hours after progesterone 
withdrawal (p<0.001). No significant changes in concentrations of Smad3 mRNA were 
detected across the window of breakdown and repair. Similarly, no significant changes were 
observed for macrophage colony stimulating factor (mCsf), however a trend of a decrease in 
concentrations was observed from 0 hours through to the 12 hour time-point.  
 
Figure 4-9: mRNA concentrations for candidate genes involved in macrophage influx or 
differentiation; Ccl2, Ctgf, Smad3 and mCsf following progesterone withdrawal. mRNA expression 
for the decidualised horn (black bars) was normalised against the control 0hr horn. Statistical 
analysis was performed by One way ANOVA and Bonferroni post hoc testing, comparing each time-
point to the decidualised 0hr time-point, and then each other time-point, where ** p<0.01 and *** 
p<0.001. 




4.3.3 A hypoxic gradient exists during endometrial breakdown that may drive 
neo-angiogenesis during endometrial repair 
Evidence of hypoxia was investigated using the Hypoxyprobe® labelling system, where 
pimonidazole was injected intra-peritoneally 90 minutes prior to culling. This reagent forms 
protein adducts within cells that are at a pO2 pressure of less than 10mmHg, <1% oxygen 
and is visualised by as a brown stain following immunohistochemistry. The intensity of 
immunostaining is directly proportional to oxygen tension. Strong immunostaining is 
indicative of very low oxygen tensions, cells are exposed to very hypoxic conditions, 
whereas, the absence of immunostaining indicates cells that are under normoxic conditions 
(>1% oxygen).   
Weak immunostaining, consistent with a low level of hypoxia, was detectable across the 
uterine horn at the time of progesterone withdrawal (Figure 4-10, A-D) regardless of whether 
a decidual mass was present (C and D) or not (A and B). For example, positive 
immunostaining was localised to the stromal cell compartment immediately adjacent to the 
luminal epithelium in the non-decidualised control horn (A and B). In contrast, when a 
decidual mass was present, positive immunostaining for hypoxia appeared more intense in 
the decidualised stromal cells and was also detected in cells adjacent to the basal layer 
(Figure 4-10, C and D).  
In tissue recovered 4 hours after progesterone withdrawal there was very intense 
immunostaining localised to the decidualised stromal cells within the central tissue mass. In 
the tissue section illustrated in Figure 4-10 the myometrium and the basal layer remained 
unstained suggesting that they remained normoxic (Figure 4-10, E and F). Weak 
immunostaining was also detected in perivascular regions (F, arrowheads).  
By 8 hours, in samples where the central decidual mass had fully detached from the 
underlying endometrium, shed cells in the lumen (Figure 4-11, A and B) appeared to have 
very low oxygen levels, indicated by intense immunostaining. Positive immunostaining, 
consistent with hypoxia, was also observed in the stromal cells adjacent to the lumen (Figure 
4-11, B). A similar pattern of staining was also observed at 12 hours following progesterone 
withdrawal (C and D) however the intensity of immunostaining was not as strong as at 8 
hours. By 24 hours (Figure 4-11, E and F), weaker staining was evident in the shed cells, 
however the luminal epithelium and the stromal cell layers immediately adjacent to the 
lumen was positively stained.  





Figure 4-10 A hypoxic gradient exists during endometrial breakdown and repair, 0-4 hours after 
progesterone withdrawal. Hypoxia was visualised using the Hypoxyprobe® labelling system. A; 
Weak immunostaining, indicative of low oxygen levels (brown staining) was localised to the stromal 
cells of the functional layer in the non-decidualised, contra-lateral control horn at the time of 
progesterone withdrawal, inset negative control. B; Positive immunostaining for hypoxia was 
localised to the stromal cells adjacent to the luminal epithelium at 0 hours in the non-decidualised 
horn. C; Weak immunostaining was detected in the decidualised cell mass at the time of 
progesterone withdrawal. D; Evidence of hypoxia in decidualised stroma cells. E; Strong 
immunostaining, indicative of very low oxygen levels was detected in the decidualised stromal cells 4 
hours after progesterone withdrawal. F; Positive immunostaining for hypoxia was observed in blood 
vessels close to lumen. DS; decidualised stroma, FS; functional stroma, L; lumen. Scale bars as 
indicated. Images representative of 3 animals per time-point. 





Figure 4-11: A hypoxic gradient exists during endometrial breakdown and repair, 8-24 hours after 
progesterone withdrawal.  Hypoxia was visualised using the Hypoxyprobe® labelling system. A; 
Strong immunostaining for hypoxia (brown staining), indicative of very low oxygen levels was 
detected in the shed cells in the uterine lumen 8 hours after progesterone withdrawal. B; Strong 
immunostaining was detected in the shed cells and in the adjacent luminal epithelium. C; Strong 
immunostaining is localised to the shed cells and in the luminal epithelium 12 hours after 
progesterone withdrawal. D; Strong immunostaining observed adjacent to luminal epithelium. E; 24 
hours after progesterone withdrawal hypoxia is restricted to the luminal epithelium and stromal cells 
adjacent to the luminal epithelium. Underlying basal layer cells are under more normoxic conditions, 
illustrated by the absence of positive immunostaining. F; The luminal epithelium and proximal 
stromal cells are still under hypoxic conditions. SC; shed cells, FS; functional stroma, BL; basal layer, 
M; myometrium, L; lumen. Scale bars as indicated. Images representative of 3 animals per time-
point. 




4.3.3.1 Key genes that are involved in angiogenesis and endothelial cell stability appear 
to be regulated by hypoxia 
To investigate whether induction of hypoxia had an impact on the expression of genes 
previously reported to be regulated by low oxygen tension in vitro, gene expression was 
quantified using qRTPCR of total tissue extracts (Figure 4-12). Vascular endothelial growth 
factor (Vegfa) mRNA was significantly up-regulated at 8 hours (p<0.001) and 12 hours 
(p<0.05). The increase in mRNA concentrations observed at 8 hours is consistent with the 
strong staining for hypoxia observed at this time-point. In contrast to this, the chemokine 
Cxcl12 (also known as stromal cell derived factor 1) was significantly up-regulated at 24 
hours (p<0.001). Pecam-1, also known as the endothelial cell marker CD31, mRNA 
concentrations were also found to be significantly increased at 4 hours (p<0.001) after 
progesterone withdrawal consistent with an increase in hypoxia. Pecam-1 mRNA 
concentrations were significantly down-regulated by 24 hours (p<0.05).   
Expression of angiopoietins 1 and 2 (which are factors involved in endothelial cell stability 
and endothelial cell remodelling and breakdown respectively) also showed dynamic changes 
during the window of breakdown and repair. Angiopoietin 1 (Angpt1) showed a trend of an 
increase at 4 hours after withdrawal; before mRNA concentrations were significantly down-
regulated from 4 hours to 12 (p<0.01) and 24 hours (p<0.01) after withdrawal of steroidal 
support. Angiopoietin 2 (Angpt2) mRNA concentrations were maintained until 8 hours after 
withdrawal, but were then significantly down-regulated at 12 hours (p<0.001) and 24 hours 
after withdrawal (p<0.001). 




Figure 4-12: mRNA concentrations for candidate genes, Vegfa, Cxcl12, Pecam-1, Angpt1 and Angpt2, that may be regulated by hypoxia during the window of 
breakdown and repair following withdrawal of progesterone.   mRNA expression for the decidualised horn (black bars) normalised against the 0hr non decidualised 
control horn. Statistical analysis was performed by One Way ANOVA and Bonferroni post hoc testing, comparing each time-point to the 0hr time-point and each 
other time-point, where * p<0.05 ** p<0.01 and *** p<0.001. 




4.3.4 Endothelial cell dynamics during breakdown and repair 
Further evaluation of the regulation of angiogenesis during breakdown and repair was 
investigated by immunofluorescence.  
Endothelial cell proliferation was investigated by immunofluorescence for BrdU (as a 
marker of cells undergoing proliferation) and CD31 (PECAM-1). At the 0 hour time-point, 
endothelial cells in the basal layer were positive for BrdU (Overleaf, Figure 4-13, A and B). 
At the 4 hour time-point a number of BrdU positive endothelial cells were identified in the 





 cells were observed at 8 hours, a time when blood vessels in the 
stromal cell compartment were exposed to the lumen (Overleaf, Figure 4-13, E, white 
arrowheads), or at 12 hours after progesterone withdrawal suggesting a switch from 
endothelial cell proliferation to endothelial cell stabilisation at this time (Overleaf, Figure 
4-13, F). At 24 hours, where re-epithelialisation has been shown to occur (Overleaf, Figure 




 cells were detected in the basal layer; however there appeared 
to be fewer BrdU positive endothelial cells at this time-point in comparison to the 0 or 4 hour 








Overleaf, Figure 4-13: Endothelial cell proliferation and stability during breakdown and repair. 
Endothelial cells (red) and proliferating BrdU positive cells (green). A and B; At 0hrs, BrdU positive 
endothelial cells are identified in the basal layer and in the decidualised stroma (arrows). C and D; 4 
hours after withdrawal, BrdU positive endothelial cells (white arrows) reside near the lumen and in 
the decidualised cell mass. E; 8 hours after withdrawal, exposed blood vessels in the stromal cell 
compartment are adjacent to the lumen (white arrowheads). F; 12 hours after withdrawal, 
endothelial cells close to the exposed stroma do not appear to be proliferating. G and H; 24 hours 
after withdrawal, endothelial cells of small vessels are BrdU positive, white arrows. BL; basal layer, 
DS; decidualised stroma, SC; shed cells. All scale bars as indicated. Images representative of 2 
animals per time-point. 









4.3.4.1 Angiogenesis array analysis 
Additional evaluation of angiogenesis was investigated using a PCR array that profiles 84 
key genes that are involved in angiogenesis, including growth factors, cell adhesion 
molecules, proteases, cytokines and transcription factors. The full gene list can be found in 
the Supplementary Table 2. 
Samples from the three key time-points (0, 8 and 24 hours) were utilised. The differences in 
fold regulation of gene expression were analysed using the ΔΔCT method, where the 8 hour 
and 24 hour time-points were compared to the 0 hour time-point. Additionally the fold 
regulation between the 8 hour and 24 hours groups was analysed. Those genes in which a 
significant change in fold regulation was observed are shown in Table 4-4, Table 4-5 and 
Table 4-6. 
In contrast to the MET array, at both the 8 hour and 24 hour time-points a greater proportion 
of genes were down-regulated than up-regulated when compared to the 0 hour time-point; 
n=29 v 11 and n=26 v 19 respectively. A number of striking gene changes were detected, 
including; up-regulation of the chemokines Cxcl1 (4 fold increase; 0 hours versus 8 hours, 56 
fold increase; 0 hours v 24 hours and 11 fold increase; 8 hours v 24 hours), Cxcl2 (4 fold 
increase; 0 v 8), Cxcl5 (10 fold increase; 0 v 24, 11 fold increase; 8 v 24), and Ccl2 (7 fold 
increase; 0 v 24, consistent with mRNA concentrations detected by qRTPCR shown in 
Figure 4-9).  
Down-regulation of leukocyte cell derived chemotaxin (Lect1) was detected at 8 hours (6 
fold decrease) and 24 hours (51 fold decrease) when compared to the 0 hour time-point, with 
evidence of dynamic regulation occurring between 8 and 24 hours (10 fold decrease). 
Interestingly, HIF2α (Epas1) was down-regulated at 8 hours (~4 fold decrease) and at 24 
hours (~9 fold decrease). Consistent with data presented in Figure 4-9, angiopoietin 2 
(Angpt2) was down-regulated at 8 hours (~5 fold decrease) and 24 hours (~23 fold decrease). 
Consistent with reports in human tissue at menses, endothelin (Edn1) was up-regulated at 24 
hours (6 fold increase). A number of changes were detected at 24 hours when compared to 
the 0 hour time-point including; granulocyte colony stimulating factor (Csf3) (~32 fold 
increase), transforming growth factor a (Tgfa) (6 fold decrease), signalling molecule Sphk1 
(11 fold decrease) and tumour necrosis factor (Tnf) (24 fold increase). 
 
 




Gene Name p value Fold Regulation 
Akt1 0.000137 -2.5842 
Angpt2 0.00299 -4.9175 
Bai1 0.048497 -2.5934 
Cdh5 0.012848 -4.0682 
Csf3 0.025896 2.5198 
Cxcl1 0.004732 4.1928 
Cxcl2 0.006045 4.4648 
Efnb2 0.001374 -2.8566 
Egf 0.005832 -3.4239 
Eng 0.001554 -2.2298 
Epas1 0.000331 -3.9733 
Ephb4 0.00026 -1.8575 
Erbb2 0.000141 -2.1867 
Fgfr3 0.00048 -2.539 
Flt1 0.009749 -1.804 
Ifng 0.031845 -2.258 
Igf1 0.000008 -3.1822 
Il1b 0.00072 4.8631 
Il6 0.041614 1.7567 
Itgav 0.015424 -1.6608 
Kdr 0.000342 -1.7111 
Lect1 0.000234 -6.116 
Mapk14 0.00171 -1.3964 
Mmp9 0.001015 2.1744 
Nos3 0.006183 -1.4661 
Pecam1 0.0097 -1.5109 
Plau 0.022668 2.7188 
Plg 0.000315 3.5833 
Ptgs1 0.000024 -1.6422 
Ptk2 0.016074 -1.269 
Sphk1 0.000006 -4.9733 
Tek 0.000448 -1.4716 
Tgfa 0.000068 -3.4111 
Thbs1 0.010501 2.4701 
Tie1 0.006365 -1.4041 
Timp2 0.028328 -1.1885 
Tnf 0.003052 2.3139 
Vegfa 0.003885 2.1533 
Vegfb 0.038244 -1.2515 
Vegfc 0.004284 -1.8048 
Number of genes significantly up-regulated 11 
Number of genes significantly down-regulated 29 
Table 4-4: Significant changes in gene expression 8 hours after progesterone withdrawal, as 
displayed by up- or down- fold regulation when compared against the 0 hour group, n=6. 




Gene Name p value Fold Regulation 
Angpt1 0.046288 -1.7594 
Angpt2 0.000001 -22.9351 
Ccl11 0.02758 2.2697 
Ccl2 0.032995 7.0443 
Cdh5 0.004155 -3.0425 
Csf3 0.01885 31.9636 
Ctgf 0.035697 1.9539 
Cxcl1 0.004845 56.8512 
Cxcl5 0.001852 10.6539 
Edn1 0.006193 6.0435 
Efna1 0.043344 1.5754 
Efnb2 0.003062 -2.6326 
Egf 0.018678 -1.9777 
Eng 0.026026 -1.8363 
Epas1 0.000012 -8.9365 
Ephb4 0.041566 -1.7025 
F3 0.001286 4.2343 
Fgfr3 0.000062 -3.4944 
Flt1 0.006391 -2.0237 
Hgf 0.006579 2.1842 
Igf1 0.000002 -3.1035 
Il6 0.01492 1.9559 
Jag1 0.00324 1.6671 
Kdr 0.00011 -2.471 
Lect1 0.000004 -51.9476 
Mapk14 0.011274 -1.4252 
Mmp14 0.038408 1.4948 
Mmp9 0.00972 28.7339 
Nos3 0.003536 -2.0241 
Pdgfa 0.000588 2.8488 
Pecam1 0.000247 -2.0313 
Plau 0.007907 3.6989 
Plg 0.00004 4.7103 
Ptgs1 0.000002 -2.6514 
Ptk2 0.013642 -1.5107 
S1pr1 0.000788 -1.6036 
Sphk1 0 -11.2585 
Tek 0.010909 -2.0434 
Tgfa 0.000001 -6.0818 
Tgfb2 0.000026 -2.7031 
Tgfb3 0.025882 -1.9838 
Thbs2 0.000037 4.5008 




Gene Name p value Fold Regulation 
Tie1 0.00304 -2.1991 
Timp1 0.040893 -1.9155 
Tnf 0.003514 24.461 
Number of genes significantly up-regulated 19 
Number of genes significantly down-regulated 26 
Table 4-5: Significant changes in gene expression 24 hours after progesterone withdrawal, as 
displayed by up- or down- fold regulation when compared against the 0 hour group, n=6. 
 
Gene Name p value Fold Regulation 
Cxcl1 0.011036 11.4046 
Cxcl5 0.018181 11.2299 
Epas1 0.035205 -2.6741 
F3 0.000182 3.3533 
Lect1 0.022018 -10.0984 
Mmp9 0.019236 11.1146 
Pdgfa 0.012495 1.9942 
Pecam1 0.012721 -1.5984 
Ptgs1 0.006979 -1.9196 
S1pr1 0.011802 -1.6882 
Sphk1 0.031526 -2.6915 
Tgfb2 0.002581 -2.6708 
Tgfb3 0.020302 -2.1296 
Thbs2 0.007458 4.175 
Tie1 0.049309 -1.8621 
Timp1 0.009032 -2.6922 
Tnf 0.009709 8.8916 
Vegfa 0.024635 -2.9003 
Number of genes significantly up-regulated 7 
Number of genes significantly down-regulated 11 
Table 4-6: Significant changes in gene expression 24 hours after progesterone withdrawal, as 
displayed by up- or down- fold regulation when compared against the 8 hour group, n=6. 
4.3.4.2 Network analysis of the angiogenesis pathway 
As in the MET array, a basic gene network was generated using MetaCore™ in order to 
identify targets for future investigation, the network is depicted in Figure 4-14 and the 
symbol key can be found in Supplementary Figure 1. From the network analysis, the first 
observation is that, like the MET array, multiple cell compartments are involved in the 
angiogenesis pathway. From the network, it is evident that HIF1α is a main regulator of this 
pathway; HIF1α is up-stream of 22 genes (Figure 4-15) and has been shown to regulate 
activation of key genes including VEGFa, angiopoietin 2, MMP-2, endothelin and TNFα. 




Another gene that may be a key regulator of endometrial vessel repair/stabilisation is MMP-
9. Network analysis shows that MMP-9 has known stimulatory actions on VEGF and 
endothelin, whilst inhibiting collagen IV, VEGFR-1 and fibronectin. From the network 
analysis TGFβ, fibronectin, MMP-9, MMP-2 were identified as candidates for future 
investigation. 
 




Figure 4-14: Interactions of key genes involved in angiogenesis.  Arrows indicate direct effects on other genes in the pathway. Green arrows indicate activation, 
whereas red arrows show inhibitory action. Pathway generated using MetaCore™ software. Gene symbols are outlined in Supplementary Figure 1. 




Figure 4-15: Downstream targets of HIF1α, a known regulator of angiogenesis. Green arrows indicate activation, whereas red arrows show inhibitory action. 
Pathway generated using MetaCore™ software. Gene symbols are outlined in Supplementary Figure 1. 





4.4.1 Contribution of the stromal cell compartment to endometrial repair 
It is likely that a number of mechanisms contribute to the repair of the endometrium, 
including; epithelial cell proliferation, stromal cell transformation, stem cell differentiation, 
vessel remodelling and remodelling by immune cells. The data reported in this chapter 
provides evidence of a role for the stromal cell compartment in endometrial repair.  
4.4.1.1 MET as a mechanism of re-epithelialisation 
It has been proposed that a primary mechanism responsible for endometrial repair is the 
proliferation of the glandular epithelium of the residual basal glands; however recent studies 
by scanning electron microscopy have questioned this hypothesis. The re-appraisal of tissue 
repair by Garry et al., (148, 169), has suggested that new epithelial cells might also arise 
from transformation of cells in the stromal cell compartment. 
Mesenchymal to epithelial transition in the endometrium has not been widely studied. 
However, two mouse models have proposed a role for MET during post-partum remodelling 
and after artificial decidualisation. Both studies suggest that during homeostasis of the mouse 
endometrium, stromal and epithelial compartments are maintained by cells within their own 
compartment. However, post-partum, where extensive remodelling of the endometrium takes 
place, stromal fibroblasts differentiate and incorporate into the new epithelium (375, 376).   
In our mouse model of endometrial breakdown and repair, we have identified a subset of 
cells in the basal layer of the repairing endometrium that express both epithelial and 
mesenchymal markers (cytokeratin and vimentin respectively) (Figure 4-2).  These dual 
labelled cells were localised to the stromal cell compartment of the residing basal layer of the 
endometrium, just 12 hours after the withdrawal of progesterone (Figure 4-2, C-E). By 24 
hours, dual labelled cells were identified in the stromal cell compartment adjacent to the 
luminal surface (Figure 4-2, F and G). These cells were localised to regions where the stroma 
is exposed to the lumen (following shedding) and were not close to areas of proliferating 
luminal epithelial cells. These findings implicate a role for early repair mechanisms that are 
initiated prior to the shedding and dissociation of the functional layer, as well as a role for a 
stromal cell contribution to the new epithelium in areas of denuded endometrium.  
In their pseudopregnancy model of breakdown, Patterson et al., describe dual labelled pan-
cytokeratin and vimentin positive cells close to the myometrial-stromal border 24 hours after 
steroid withdrawal, and also adjacent to the lumen 36 hours post ovariectomy (376). Their 




findings are consistent with our own; however we believe the current study provides a better 
insight into the mechanisms of breakdown and repair as it more clearly mimics the repair 
processes in women, including overt menstruation and rapid repair processes. 
In the current study, the dynamic changes in mRNA concentrations and protein expression 
for Wilms’ tumour 1, Snail and Slug reported during the window of breakdown and repair 
(Figure 4-3) are consistent with a novel role for MET during repair of the epithelium after 
endometrial shedding. A role for MET in endometrial epithelial repair may indeed be a new 
concept, but its role in repair mechanisms in other tissues has been widely investigated, in 
the kidney, liver and lung ((415, 436, 437) and Daris, unpublished). This study is the first to 
investigate the potential molecular mechanisms of MET in the endometrium using a mouse 
model of endometrial repair. 
Complementary to these findings, using a focussed PCR array, we discovered striking 
changes in the expression of a number of genes known to regulate MET by comparing tissue 
recovered at 8 hours during breakdown and at 24 hours at a time when repair was complete 
or nearly so. Despite small fold increases in Snail and vimentin at the 8 hour and 24 hour 
time-points, which may suggest that EMT is occurring, epithelial cell markers, cell adhesion 
markers and intracellular junction proteins were all greatly up-regulated at 24 hours 
consistent with maturation of epithelial cells. It is important to note that the array was carried 
out on whole tissue extracts and therefore increases in epithelial markers may be attributable 
to an increase in epithelial cell number as well as stromal cell differentiation. These 
preliminary studies have demonstrated that dynamic changes in cellular morphology occur 
during endometrial repair phases, and that molecular mechanisms may be driving repair of 
the epithelium through stromal cell differentiation. Lineage tracing studies using this mouse 
model would complement the data reported.   
4.4.1.2 Contribution of immune cells to endometrial repair and remodelling 
Menstruation is accepted to be an inflammatory event, with a diverse population of immune 
cells present in the endometrium during breakdown (207, 208, 214, 217, 438, 439). 
Macrophages are proposed to play multiple roles in the regulation of endometrial function 
including; breakdown, repair and remodelling (reviewed by (94)).  
The use of monocyte lineage labelled mice (the Mac green mouse) enabled investigation of 
macrophage number and localisation in the endometrium during the breakdown and repair 
window. In contrast to a previous study, where neutrophils were determined to be the 
predominant immune cell present during repair (217), large numbers of EGFP-positive cells 




(putative tissue macrophages) were detected in the endometrium at the 24 hour time-point, a 
time where the endometrium is undergoing or has undergone repair. EGFP positive cells 
were mainly localised to the basal layer adjacent to areas of degenerating endometrium 
during breakdown. However, during repair, large numbers were observed adjacent to the 
luminal epithelium. This would suggest that macrophages may be playing two roles; tissue 
breakdown during the early time-points and tissue remodelling during later time-points. This 
is consistent with repair mechanisms in other tissues, for example in the lung, where alveolar 
macrophages contribute to epithelial repair in the later stages of an inflammatory response 
(440), driving anti-inflammatory mechanisms.  
The techniques used for the generation of the Mac green mouse involved targeted insertion 
of the EGFP gene downstream of the c-fms gene promoter. The c-fms gene encodes the 
receptor for macrophage colony stimulating factor (m-CSF-1) and is selectively expressed in 
all macrophages. c-fms mRNA and protein is normally absent from mature granulocytes (i.e. 
neutrophils) however the targeting strategy means that expression of the EGFP reporter gene 
may be retained in progeny from the common bone marrow progenitor. Therefore, a very 
small number of the EGFP-positive cells detected in the mouse endometrium may not be 
macrophages, and could be granulocytes or lymphocytes. Further investigation with dual 
staining techniques is required to definitively confirm that tissue resident EGFP positive 
cells are macrophages. In this study, uterine tissues were fixed in neutral buffered formalin, 
which was not conducive to staining with F4/80, a marker used by previous groups (217, 
334, 341, 441). Dual staining of EGFP and a neutrophil marker such as Ly-6B.2 would 
determine whether some EGFP positive cells are neutrophils available to participate in both 
breakdown and repair.  
Using mouse models of breakdown and repair (217, 334) it has been reported that 
endometrial repair is merely delayed, not inhibited, by neutrophil neutralisation indicating 
that another immune cell must be able to contribute to, and complete, repair. Based on our 
new data we believe that immune cell is the macrophage.  
4.4.1.3 Secretion of factors from the stromal cell compartment contributing to 
endometrial repair 
CCL2 and connective tissue growth factor (CTGF) have been implicated in the process of 
endometrial repair (208, 423, 438) in women. CCL2, also known as monocyte chemotactic 
protein (MCP-1), is a chemoattractant for macrophages, NK cells, basophils and 




lymphocytes (442–446). The protein expression of CCL2 has been shown to vary across the 
human menstrual cycle, with peak expression observed during menses (205, 208, 447).  
In the current study, using our mouse model, we detected low concentrations for mRNAs for 
Ccl2 during breakdown however these were markedly increased during the repair phases 
(Figure 4-9, 12-24 hours) consistent with an apparent increase in numbers of macrophages in 
the endometrium at 24 hours (Figure 4-8). CCL2 is not a chemoattractant for neutrophils 
(448), therefore would have no direct action of neutrophil infiltration at this time. CCL2 has 
been reported to be secreted from human endometrial stromal fibroblasts (449–451) and 
macrophages (452) in vitro, hence the increase in macrophages observed during the repair 
phase may contribute to increase in total mRNA. We speculate that, during breakdown, 
fibroblasts and macrophages in the basal layer may secrete CCL2 in order to recruit 
macrophages from the blood stream in preparation for repair. During repair, resident 
macrophages may secrete increased levels of CCL2 to drive in situ proliferation.  
Connective tissue growth factor is an important growth factor involved in wound healing in 
the skin (453) and also displays cycle and cell-specific immunostaining in the endometrium 
(423, 454), where stromal cell expression of CTGF was greater during the secretory phase 
than in the proliferative phase (454), with the greatest expression reported during the 
menstrual phase (423). CTGF is reported to be expressed by macrophages and its expression 
is regulated by hypoxia (423). In an in vitro human epithelial cell culture model, exposure to 
hypoxia significantly up-regulated CTGF mRNA and protein in a time-dependent manner 
(423). This finding is consistent with those in our model, where Ctgf mRNA concentrations 
were detected to increase in the uterus at the 8 hour time-point, coincident with exposure to 
strong hypoxic conditions (as demonstrated by strong immunostaining for the 
Hypoxyprobe®) at 4-8 hours after steroid withdrawal (Figure 4-10). CTGF has been 
reported to promote stromal fibroblast proliferation in an in vitro model using rat kidney 
fibroblasts (455), as well as promoting differentiation of human mesenchymal stem cell into 
fibroblasts in vitro (456), and therefore may play a role in remodelling of the stromal cell 
compartment during repair.  
From the data reported herein it is unclear as to the cellular localisation of CCL2 and CTGF, 
for example whether macrophages or stromal cells are involved in the transcription of these 
genes. Further investigation, by immunohistochemistry, would identify the cell types that 
express both of these factors. 




Macrophages have been shown to secrete a number of factors that may contribute to the 
repair of the endometrium. For example, it has been reported that alveolar macrophages 
secrete TNFα, a potent epithelial mitogen (440). Increased concentrations of mRNA 
encoding Tnfa were detected in the angiogenesis array at the 24 hour time-point, a time 
where endometrial repair and epithelial cell proliferation can be detected, coincident with 
peak numbers of macrophages. Murine endometrial macrophages have been reported to 
secrete osteopontin (Spp1), a cell adhesion molecule that contributes to endometrial 
remodelling during the early phases of pregnancy (457). Consistent with this finding, a 23 
fold increase in Spp1 was detected in the MET array at the 24 hour time-point, whilst the 
endometrium was undergoing repair.  
It is possible that macrophages play a dual role in human endometrial breakdown and repair. 
For example, despite a low number of macrophages detected in the tissue during breakdown, 
human macrophages have been reported to secrete VEGF (452) which may contribute to 
endothelial cell stability during breakdown; in our mouse model, Vegfa mRNA 
concentrations are up-regulated during the breakdown phase. During repair however, those 
macrophages localised to the basal stroma and those adjacent to the luminal epithelium may 
be secreting factors that aid re-epithelialisation such as TNFα or osteopontin.  
4.4.1.4 Contribution of endometrial “stem” progenitor cells 
Activation and proliferation of endometrial stem cells has been proposed as another potential 
mechanism of endometrial repair following shedding. A number of different sites have been 
postulated as sources for endometrial stem cells including; a basal gland epithelial stem cell 
niche, perivascular stem cells and bone marrow progenitors. 
Bone marrow derived cells have been identified in the stromal cell and epithelial cell 
compartments of the human endometrium (268) suggesting a potential role for these cells in 
endometrial regeneration. In vitro studies using haematopoietic progenitor cells (HPC) 
highlight a role for CXCL12 in chemotaxis and mobilisation of HPCs from the bone marrow 
to peripheral tissues (458, 459). HPCs can differentiate into multiple cell types in vitro  
including hepatocytes and neurons (263, 264), suggesting that the increase in Cxcl12 
transcription detected during repair of the mouse endometrium (Figure 4-12)  may therefore 
be driving mobilisation of HPCs to the endometrium, to contribute to endometrial stromal or 
epithelial cells. Furthermore VEGF has been reported as a chemoattractant for endothelial 
progenitor cells from the bone marrow (460) whilst also promoting their differentiation. 
Vegfa mRNA concentrations were increased 4-24 hours after the withdrawal of progesterone 




(Figure 4-12) so endothelial cell progenitor migration may be another mechanism in repair of 
the tissue, which merits further investigation. 
Putative perivascular mesenchymal stem cells have been identified in the human 
endometrium using two markers; CD146 and PDGFRβ (261). Isolated CD146+ PDGFRβ+ 
cells were multipotent and able to differentiate into four mesenchymal lineages, and are 
postulated to be pericytes which are able to give rise to both stromal and endothelial cell 
compartments of the endometrium (261). An increase in transcription of Pdgfrb was detected 
in our mouse model of breakdown at 8 hours and 24 hours. In the human endometrium 
PDGFRβ is localised to the stromal fibroblasts and perivascular regions, whilst being absent 
from the epithelium (461). A pilot study, using PDGFRβ-GFP labelled lineage tracing mice, 
has identified PDGFRβ positive cells in the luminal epithelium of the mouse endometrium 
during the normal oestrous cycle (Simitsidellis, unpublished), suggesting that mesenchymal 
stem cells may contribute to overall tissue homeostasis.  
4.4.2 Degenerating functional layer contributes to repair of the underlying basal 
layer 
Another contributor to re-epithelialisation and remodelling of the basal layer may, in fact, be 
the degenerating functional layer shed during menses. Laser capture studies on human 
tissues, taken during menses, have revealed that the shed functional stroma expresses gene 
products associated with extracellular matrix synthesis, prostaglandin synthesis and high 
levels of IL-8, which may be involved in the recruitment of leukocytes to the endometrium 
during repair phases (462).  
A pilot study, using conditioned media from primary human decidualised stromal cells 
undergoing progesterone withdrawal (1,2 and 4 days after withdrawal), had no significant 
effect on human endometrial endothelial cell proliferation when compared to control media 
in a network formation assay (Cousins, unpublished). However, as little endothelial cell 
proliferation was observed during the repair phase in the mouse model, it is possible that 
secreted factors from the degenerating functional stroma do not promote proliferation of 
endothelial cells, but may promote stability. Furthermore, it would be of interest to 
investigate the effect, if any, of progesterone withdrawal conditioned media in a wound 
healing assay of primary epithelial cells to determine if secreted factors from the 
degenerating functional stroma contribute to epithelial cell repair.  




4.4.3 A role for hypoxia in the regulation of endometrial repair 
4.4.3.1 Hypoxia and angiogenesis 
It has been recognised that hypoxia is involved in tumour development, ischaemic injury and 
during endometrial breakdown (186, 189, 190, 192, 193, 393, 439, 463–470). Hypoxia-
inducible factor (HIF) is a dimeric protein complex which has been shown to be a key 
regulator of a cell’s response to low oxygen tensions. Under hypoxic conditions, the beta and 
alpha subunits dimerise to bind to hypoxia response elements which activate transcription of 
target genes (463). Candidate genes investigated in the angiogenesis PCR array were 
analysed for HIF-dependent regulation; those genes that are known to be regulated by HIF1α 
are shown in Figure 4-15.  
An apparent gradient consistent with transient hypoxia was observed during the window of 
breakdown and repair in the mouse model. To complement this novel finding, candidate 
genes, including Vegfa, Cxcl12 and the angiopoietins were regulated in parallel to staining 
for hypoxia during this window (Figure 4-10, Figure 4-11 and Figure 4-12). Of these 
candidate genes, endometrial expression of VEGF has been shown to be directly regulated 
by hypoxia (191, 193, 471) by a HIF1α dependent mechanism (193, 472).  Vegfa mRNA 
concentrations were up-regulated at 4 and 8 hours, consistent with strong staining for 
hypoxia in the endometrial stroma and epithelium (Figure 4-10 and Figure 4-12).  VEGF is a 
key regulator of angiogenesis (473); endothelial cell proliferation was observed at the 4 and 
8 hour time-points consistent with an increase in Vegfa expression (Overleaf, Figure 4-13, B 
and C). 
Angiopoietin 2 has been shown to play a dual role in endometrial repair; Angiopoietin 2 
drives tissue remodelling in the presence of high VEGF concentrations (474), whilst it 
contributes to vessel destabilisation in low VEGF concentrations (475). These data are 
consistent with our findings, where Angpt2 mRNA concentrations were maintained during 
initial breakdown of the endometrium (0-8 hours) (Figure 4-12) in the presence of increased 
Vegfa mRNA concentrations (Figure 4-12).  Endothelial cell proliferation was also detected 
(Overleaf, Figure 4-13, B and C) at these time-points suggesting that Angpt 2 may be 
contributing to endothelial cell remodelling at this time.  
In women, ANGPT1 and ANGPT2 mRNA concentrations are observed to be at their highest 
during the secretory phase of the human cycle (475), consistent with our findings in  mice 
where Angpt1 and Angpt2 were at their highest mRNA concentrations levels in the 
decidualised tissue prior to removal of progesterone and breakdown (0 hours). Endometrial 




expression of ANGPT 2 has been shown to be regulated by hypoxia, (476, 477) by both HIF-
dependent (478) and HIF-independent mechanisms (479). 
CXCL12, (also known as stromal-derived factor) is a chemokine that has been shown to 
regulate several functions, including angiogenesis (191, 469, 470), haematopoietic stem cell 
mobilisation (460) and monocyte chemotaxis (480, 481). CXCL12 was initially investigated 
in this study for its role in angiogenesis. mRNA concentrations of Cxcl12 were detected as 
being down-regulated during breakdown of the mouse endometrium (0-8 hours), but 
concentrations increased at 12 and 24 hours, consistent with a decrease in staining for 
hypoxia. Regulation of CXCL12 by hypoxia has been demonstrated in vitro, where 
endometrial primary stromal cell expression of CXCL12 was down-regulated when exposed 
to hypoxia (191). In contrast to this, hypoxia up-regulates the receptor for CXCL12, CXCR4, 
in endothelial cells, monocyte derived macrophages and in cancer cells (469, 482).  
Recently, the proliferative capacity of CXCL12 has been investigated in vitro, with CXCL12 
promoting endometrial epithelial and stromal cell proliferation in an oestrogen dependent 
manner (483). In our model, Cxcl12 was observed to increase, in the absence of both 
oestrogen and progesterone, 12 hours after the withdrawal of steroidal support. It is possible 
that in our model, VEGF drives initial angiogenesis and vessel stabilisation under hypoxic 
conditions, at a time where we detected endothelial cell proliferation. However as 
breakdown ensues, and oxygen tensions return to more normoxic levels, VEGF 
concentrations decrease coincident with an increase in CXCL12, which may support vessel 
stabilisation over vessel proliferation; which can be observed during foetal development 
(484–486). Macrophages have been reported to secrete CXCL12 in vitro (452), which may 
account for the increase in the concentrations of Cxcl12 mRNA during repair phases as this 
was at a time when an increased number of macrophages were detected.  
In the current study, very little endothelial cell proliferation was detected during the repair 
phase; this is consistent with findings from Kaitu’u-Lino et al., who, in their mouse model, 
detected a greater number of proliferating endothelial cells during decidualisation of the 
mouse endometrium in comparison to the repair phase (368). However, it is likely that 
during the repair phase, VEGF-dependent angiogenesis by endothelial cell proliferation is 
not the most critical event with endothelial cell sprouting or branching likely to be key to 
vessel stabilisation in preparation for the proliferative phase of the next cycle.  




4.4.3.2 Hypoxia and monocyte recruitment 
A role for hypoxia in monocyte recruitment has been identified in pathological conditions 
including tumours, wound healing and ischaemic inflammatory sites (441, 487–489). High 
numbers of macrophages are associated with endometrial cancers (490, 491), where hypoxia 
inhibits expression of CCR2, the receptor for CCL2, to limit macrophage migration (492) so 
that they remain as tumour-associated macrophages. Hypoxia has been reported to increase 
concentrations of CCL2 in a HIF-dependent manner in in vitro models of cancer (493, 494),  
airway inflammation (495) and ischaemic brain injury (489). HIF-dependent down-
regulation of CCL2 has been reported in a model of murine renal fibrosis (496). In mice with 
specific myeloid cell HIF activation, inflammation was suppressed due to inhibition of 
receptors for chemokine receptors including CCR2 (496).  These findings indicate that HIF 
regulation of inflammatory responses is context dependent. A role for hypoxia in 
macrophage migration during menses has not been reported and merits further investigation.  
In our mouse model of breakdown and repair, mRNA concentrations for Ccl2 maintained at 
a low level during endometrial breakdown, a time where the immunostaining for hypoxia 
was most intense. However an increase in mRNA concentrations for Ccl2 was detected at 12 
and 24 hours during the repair phase of the tissue, when immunostaining for hypoxia was at 
its weakest. This might suggest that in normal function, hypoxia may limit macrophage 
activation and migration from the bone marrow during endometrial breakdown, in favour of 
another immune cell, but when the tissue returns to more normoxic conditions, during repair, 
macrophages are able to infiltrate to aid scavenging and tissue remodelling. 
4.4.4 Summary 
In the current study, using our refined mouse model of endometrial breakdown and repair, a 
role for stromal cell differentiation, macrophage infiltration and hypoxia during endometrial 
repair was investigated.  
The identification of dual labelled cytokeratin and vimentin positive cells in the stromal cell 
compartment adjacent to the lumen supports our hypothesis that MET contributes to re-
epithelialisation during the repair window. Analysis of genes known to be involved in EMT 
and MET were investigated by a PCR array; dynamic changes were observed at both the 8 
hour (breakdown) and 24 hour (repair) time-points. Up-regulation of epithelial cell markers 
and adhesion molecules during the repair phase suggest a net effect of MET over EMT. 
Lineage tracing studies would complement these data.  




A hypoxic gradient was observed across the uterine horn during the window of breakdown 
and repair, which coincided with dynamic changes in mRNA concentrations of genes 
involved in angiogenesis, vessel stabilisation and remodelling and monocyte chemotaxis. 
Investigation of the uterine macrophage population revealed an influx of macrophages 
during the repair phase, which is likely to contribute to remodelling of the tissue after 
breakdown and shedding.  
From the results presented in this chapter, it is clear that a number of factors will contribute 
to the restoration of tissue integrity. These studies support the hypothesis that hypoxia plays 
a key role in the initiation of repair processes, either by driving angiogenic factors or 
regulating the influx of macrophages which cumulatively contribute to re-establishment of 
an intact endometrium following menses.  
 
Chapter 5. A role for androgens in endometrial function. 
153 
 
Chapter 5 A role for androgens in endometrial 
function 
5.1 Introduction 
The regulation of endometrial function by ovarian derived oestrogens and progestagens has 
been extensively studied, whilst the full impact of androgens on endometrial function is yet 
to be elucidated.  
5.1.1 Circulating androgens and receptor expression 
The main sources of androgens in women are the ovary and the adrenal, which together 
account for approximately 50% of total androgen synthesis. Peripheral sites like the skin or 
adipose tissue account for the other 50% of androgen synthesis (136, 137) .  
A study by Abraham, in 1974, determined relative circulating concentrations of androgens in 
women during their menstrual cycle. Two pro-androgens, (classed as those which have no 
androgenic effect unless they are metabolised to testosterone), androstenedione and 
dehydroepiandrosterone (DHEA) were found to peak during the late proliferative/early 
secretory phase, in parallel with peak oestradiol concentrations (44). A third pro-androgen, 
DHEA sulphate (DHEAS) was observed to be maintained across the menstrual cycle. The 
potent androgen testosterone exhibited fluctuations through-out the menstrual cycle with its 
lowest concentrations observed during the early proliferative phase, a mid-cycle peak, before 
decreasing during the secretory phase, to concentrations that were still higher than during the 
proliferative phase. The amount of non-aromatisable androgen dihydrotestosterone (DHT) 
was low in peripheral circulation, which is in line with reports that the majority of DHT is 
synthesised locally in target tissues by the conversion of testosterone to DHT  by 5α 
reductase (497, 498). Two isozymes of 5α reductase are present in the human endometrium 
(499) suggesting that DHT may play a role in endometrial function.  
The second part of Abraham’s study involved suppression of ovarian-derived androgen 
production using dexamethasone, to determine adrenal contributions of testosterone, DHEA, 
DHEAS and androstenedione. This confirmed that androgens from the adrenals do not 
fluctuate during the menstrual cycle and that ovarian-derived androgens are likely to be 
under endocrine regulatory feedback loops (44). A later study in 1986, demonstrated that 
elevated concentrations of testosterone (delivered intravenously to cycling women) altered 
LH pulsatility, in this study aromatisation of androgens to oestrogens was inhibited by 
testolactone (an aromatase inhibitor) (500).   
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Androgens exert their primary effects on gene expression via the androgen receptor (AR) 
(101, 104, 110, 501) (as discussed in section 1.5.4). Immunolocalisation studies have 
identified AR in the nuclei of stromal fibroblasts in both the functional and basal layers of 
the human endometrium, with most intense immunoexpression during the proliferative 
phase. Expression in the stroma of the functional layer gradually decreases during the 
secretory phase (98, 143). AR has also been immunolocalised to the glandular epithelial cell 
compartment of the basal layer during the proliferative phase (502), with a decrease in 
expression detected during the secretory phase until no immunostaining for AR is observed 
by the late secretory phase (143). In the functional layer, AR is immunolocalised to the 
glandular epithelium in the mid-late secretory phase (144). AR expression has been shown to 
be up-regulated in women who are treated with anti-progestins (503). 
5.1.2 A role for androgens during endometrial function 
A possible role for androgens in endometrial function has been demonstrated in vivo in a 
murine model of decidualisation. In this model 1mg of testosterone or DHT (in combination 
with oestradiol) on days 6-8 of the protocol was able to maintain the decidual mass, in the 
absence of progesterone, following artificial decidualisation by oil injection on day 5 (146). 
However, androgens alone could not initiate the decidual response (146), which requires 
exposure to progesterone, thereby highlighting the importance of progesterone during this 
process. These results suggest that androgens may play a supporting role during 
decidualisation. Two in vitro models using human endometrial stromal cells have 
demonstrated that both DHT and testosterone are able to stimulate biosynthesis of prolactin 
(a decidualisation marker) in the absence of progesterone (504, 505). Prolactin production 
was enhanced when testosterone and progesterone were administered in combination, 
supporting the suggestion that androgens may contribute to endometrial decidualisation in 
women and may therefore be involved in preparing the endometrium for pregnancy.   
An anti-proliferative effect of androgens has been documented in a number of studies, 
including those in female to male transsexuals, where long term use of androgens results in 
endometrial atrophy (506–508). Furthermore, in a study in post-menopausal women, 
treatment with testosterone alone had no effect on endometrial thickness or proliferation 
(509).  In comparison, treatment with oestrogen or oestrogen and testosterone resulted a 
significant increase in the number of proliferating cells and in endometrial thickness (509). 
An in vivo study in the macaque has highlighted the possible anti-oestrogenic potential of 
androgens (503) which might complement the role of progestins in limiting excessive 
endometrial proliferation.  
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In contrast to oestradiol and progesterone, whose serum concentrations fluctuate across the 
menstrual cycle, circulating concentrations of testosterone are maintained (Table 1-1). 
Despite circulating concentrations of testosterone being much greater than those of oestradiol 
at both the late secretory and early proliferative phases, a role for androgens in tissue 
breakdown at menses or in tissue remodelling during repair phases has not been investigated.  
An in vitro study using human endometrial stromal cells treated with DHT revealed a subset 
of genes that were androgen-regulated. These genes were related to two pathways; the 
regulation of apoptosis and stromal cell migration (144), which could implicate androgens in 
the regulation of endometrial repair. In recent studies, Kajihara and colleagues have 
suggested that androgens may promote resistance to oxidative stress (504) and increase 
formation of gap junctions (510) both of which are important for cellular transformation of 
decidualised stromal cells.  
5.1.3 Androgens, the androgen receptor and endometrial disorders 
Increased circulating androgens have been linked to a decline in endometrial function and 
fertility. For example, increased serum androgen concentrations have been detected in 
women with recurrent miscarriage (511), where both circulating concentrations of 
testosterone and androstenedione were significantly greater compared to control women. 
Observed increases in testosterone concentrations across the menstrual cycle in women with 
recurrent miscarriage were correlated with a decrease in placental protein 14 (a marker of 
decidualised endometrium) (511), suggesting that increased androgens have a detrimental 
effect on the receptivity of the endometrium. 
Polycystic ovarian syndrome (PCOS) is associated with hyperandrogenism (305), caused by 
overproduction of androstenedione from ovarian thecal cells. This overproduction results in 
an increased number of growing follicles which then become atretic (309, 310). Women with 
PCOS tend to display sub-fertility and amenorrhoea. A study measuring expression of AR in 
women with PCOS has revealed that endometrial AR expression is significantly greater in 
glandular and luminal epithelial cells, at both proliferative and secretory phases when 
compared to control women (no PCOS) (512). Furthermore, mRNA concentrations for AR 
are significantly up-regulated in PCOS women compared to control women (512). 
Additionally, endometrium from PCOS women had delayed or no protein expression of 
integrin αvβ3, a marker of endometrial receptivity (512). Women with PCOS exhibit 
unopposed oestrogens due to chronic anovulation, which may also lead to endometrial 
hyperplasia (513, 514). Women with PCOS are thought to be at a higher risk for endometrial 
cancer, though a definitive link is still to be established. 
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The post-menopausal ovary is hormonally active, contributing to circulating testosterone 
levels (515–517). The conversion of testosterone to oestrogens to create a hyperoestrogenic 
state is implicated in the development of endometrial cancers, where women with 
endometrial malignancies have increased expression of aromatase (518). Expression of 
androgen receptor has been described in endometrial cancer (499, 502, 519, 520) and 
Ishikawa cells, derived from a well differentiated endometrial adenocarcinoma, are also AR 
positive (521). 
The AR contains a CAG polymorphic repeat in exon 1 (522, 523), the length of this repeat is 
directly correlated to the transcriptional activity of AR, in that the longer the repeat the lower 
the transcriptional activity (524, 525). Receptors with longer repeats also have decreased 
binding to androgens (522, 525).  
Furthermore, PCOS and endometrial cancer have also been linked to the length of the CAG 
repeat. PCOS women have a shorter CAG in comparison to “normal” control women (526–
528) suggestive of a more active form of the protein, whereas an increase in CAG repeat 
length has been reported in women with endometrial cancer compared to healthy controls 
(529, 530). However, other studies have questioned the role of AR polymorphisms in 
endometrial cancer (531, 532). 
The anti-proliferative effects of androgens have highlighted them as one therapy choice in 
the treatment of endometriosis, an inflammatory condition where endometrial glands and 
stroma grow outside of the uterus (287). Endometriosis is often associated with infertility 
implicating endometrial dysfunction (286). Danazol (an androgenic compound), promotes 
atrophy of the endometrium and endometrial lesions as well as reducing pain associated with 
endometriosis (533, 534), however its use as a treatment for endometriosis has been 
discontinued in some countries due to its androgenic side effects, including weight gain and 
hirsutism.  
In summary, the human endometrium is exposed to fluctuations in both oestradiol and 
progesterone across the menstrual cycle, regulating cell proliferation and cellular 
differentiation. In contrast to oestradiol and progesterone, concentrations of androgens such 
as testosterone and androstenedione are maintained across the cycle. Aberrant androgen 
concentrations are associated with endometrial disorders; however a role for androgens in 
“normal” function has not been fully explored. From previous studies it is likely that the AR 
plays an anti-proliferative role which may regulate tissue dynamics through-out the cycle.   
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5.1.4 Aims of the chapter 
1. To investigate a role for androgens in restoring endometrial integrity after 
breakdown using a mouse model of menses 
2. More specifically, to investigate if androgens have an effect on re-epithelialisation 
and angiogenesis. 
5.2 Materials and methods 
5.2.1 Mouse model of menstruation  
The mouse model established in Chapter 3 and described in section 2.1.4.4 was utilised to 
investigate mechanisms contributing to endometrial repair. Mice underwent the protocol as 
detailed in section 2.1.4.4 with one minor deviation. On day 19 mice received a single, 
0.1ml, sub-cutaneous injection of 2mg/ml dihydrotestosterone-proprionate (A2570-000, 
Steraloids, Rhode Island, USA) in sterile PBS. At the same time the progesterone pellets 
were removed to induce progesterone withdrawal (pellet withdrawal was designated as 0 
hours). The protocol is outlined in Figure 5-1. 
 
Figure 5-1: Mouse model of menstruation and repair. Ovex; ovariectomy, E; β-oestradiol, P; 
progesterone, DHT; dihydrotestosterone-proprionate. β-oestradiol concentrations in brackets.  
5.2.2 Tissue processing and immunohistochemistry   
All samples were fixed in NBF overnight at room temperature, rinsed in 70% ethanol and 
then stored in 70% ethanol before tissue processing as described in section 2.6. 
Immunohistochemistry was carried out using the standard protocol outlined in section 2.7.2 
using the antibodies outlined in Table 2-15 and Table 2-16.   
5.2.3 RNA extraction 
RNA extraction was carried out as detailed in section 2.2.  
5.2.4 Synthesis of complementary DNA using VILO cDNA synthesis kit 
Reverse transcription of RNA to cDNA was performed using the Superscript VILO cDNA 
synthesis kit (InVitrogen) according to manufacturer’s instructions, using the volumes 
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outlined below in Table 2-8. Samples were then incubated under the conditions detailed in 
section 2.3 
5.2.5 Quantitative Real Time PCR 
Quantitative real time PCR was carried out as detailed in section 2.4.  
Statistical analysis was performed as detailed in section 2.8. 
5.2.6 RT2 Profiler PCR Array 
RT
2
 profiler arrays contain a panel of genes containing housekeeping genes, quality controls 
and 84 genes that are related to a specific biological pathway. RNA samples used in RT
2
 
profiler PCR array were subject to quality assessment based on RIN. Samples were RIN<6.0 
were excluded. Two gene arrays were utilised in this study; Mouse Epithelial to 
Mesenchymal Transition Array (SABiosciences, PAMM-090Z) and Mouse Angiogenesis 
Array (SABiosciences, PAMM-024Z). 
RNA quantitation was performed as detailed in section 2.5.1. A RIN greater than 6.0 was 
accepted for further analysis by PCR array. cDNA synthesis was performed following the 
protocol outlined in section 2.5.3. Real time PCR was performed as detailed in section 2.5.4.  
PCR data analysis was performed using the SABiosciences web portal as detailed in section 
2.8. 
5.2.6.1.1 Putative pathway analysis by MetaCore™ 
MetaCore™ utilises a manually curated database of known species specific interactions 
between protein-protein, protein-DNA and protein-RNA. MetaCore™ was used to map 
potential signalling and metabolic pathways of candidate genes investigated by PCR array.  
5.2.6.1.2 Multi-genome analysis of positions and patterns of elements of regulation 
(MAPPER) 
MAPPER is a large, computational database that allows identification of transcription factor 
binding sites (TFBS) within a known human, mouse or Drosophila gene/uploaded sequence. 
The search engine combines data from two online databases, TRANSFAC® AND JASPAR, 
along with Markov models that calculate the probability of TFBS within a gene.  
Candidate genes were investigated for putative androgen receptor/androgen response 
elements (ARE) along with tethering molecules Sp-1 and Ap-1 within 500 base pairs of their 
transcription start site.  
  




5.3.1 DHT delays the onset of menses 
A key observation made using vaginal lavage was that DHT treated animals began to bleed 
at a later time-point when compared to their matched untreated animals. Figure 5-2 shows 
the percentage of untreated (-DHT) (black line) and DHT treated (blue line) animals 
bleeding at each time-point. As previously shown in the untreated animals, bleeding began in 
46% of the animals at 4 hours with the highest percentage of bleeders observed at 12 hours 
(87.5%), with no blood detected in the vaginal lavage by 24 hours, suggesting re-
epithelialisation had occurred. In the DHT treated animals, blood cells were only detected in 
the lavage of one mouse at 4 hours (16%), whereas this number had increased by 8 hours to 
50%, a percentage similar to the untreated 4 hour time-point (46%). The number of mice 
with vaginal bleeding increased to 100% at 24 hours. These data suggest that administration 
of DHT was delaying the onset of menses, and was also likely to be delaying repair as all of 
the mice were still bleeding at 24 hours.  
 
Figure 5-2: DHT delays the onset of bleeding.  The percentage of mice bleeding at each time-point 
following the addition of DHT at 0 hours was plotted (blue line) against untreated animals (black line) 
(data previously shown in figure 3-2). N numbers for DHT treated animals are shown.   
  
Chapter 5. A role for androgens in endometrial function. 
160 
 
To complement these findings, the effect of DHT was further evaluated by investigating 
mRNA concentrations for prolactin 8 (Prl8), a marker of decidualisation (535), during the 
breakdown and repair window (Figure 5-3). 
Prl8 mRNA concentrations in DHT treated animals (blue bars) were significantly up-
regulated at 4 (p<0.001), when compared to the matched, untreated time-point (black bars). 
Concentrations of mRNA for Prl8 in the 4 hour DHT group were significantly greater than 
its equivalent untreated group, but were also greater than the 0 hour untreated group (not 
shown), which suggests that DHT may not only be maintaining decidualisation in the 
absence of progesterone but may also be enhancing the decidual response. A downward 
trend in Prl8 mRNA concentrations was observed towards the 24 hour time-point, and it was 
notable that Prl8 concentrations in the 24 hour DHT group were similar to that of the 
untreated 8 hour group.  
 
Figure 5-3: Prl8 mRNA expression in DHT treated animals (blue bars) compared to untreated 
animals (black bars). mRNA expression for the decidualised horns were normalised against the 0 
hour non decidualised horn. Statistical analysis was performed by Two Way ANOVA and Bonferroni 
post hoc testing, comparing each DHT time-point to their matched untreated time-point where *** 
p<0.001.  
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It was suspected that one potential impact of DHT might be to compensate for the decline in 
progesterone by maintaining the decidual tissue, delaying the onset of menses in our mouse 
model. To further investigate this, mRNA concentrations for ERα were measured. In the 
uterus, expression of ERα is normally down-regulated by progesterone, and therefore would 
be expected to increase once the inhibition by progesterone was removed following removal 
of the progesterone pellet. In the untreated group, mRNA concentrations for ERα were found 
to significantly increase 4 hours after the withdrawal of progesterone (p<0.001) and stayed 
significantly higher than the 0 hour time-point until the 24 hour time-point (p<0.05) (not 
shown). In the DHT treated animals (Figure 5-4), ERα mRNA concentrations were 
significantly decreased at 4 hours (p<0.001) when compared to the matched 4 hour untreated 
time-point. By 8 hours no significant difference was detected between untreated and DHT 
treated mice.   
 
Figure 5-4: ERα (Esr1) mRNA expression in untreated (black bars) and DHT treated (blue bars) 
animals. mRNA expression for the decidualised horns were normalised against the 0 hour non 
decidualised horn. Statistical analysis was performed by Two Way ANOVA and Bonferroni post hoc 
testing, comparing each DHT time-point to their matched untreated time-point where *** p<0.001.  
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5.3.2 DHT delays the onset of tissue breakdown 
Uterine morphology at each time-point is depicted in Figure 5-5and Figure 5-6. In the DHT 
treated animals, recovered 4 hours after the removal of the progesterone pellet (Figure 5-5, 
B), the gross morphology of the uterine horn resembles that of the untreated (-DHT) 4 hour 
time-point (Figure 5-5, A). An intact luminal epithelium was observed (Figure 5-5, C), along 
with decidualised stromal cells in the centre of the horn (Figure 5-5, D). In the DHT treated 
uterus recovered at 8 hours after progesterone withdrawal (Figure 5-5, F) the beginning of 
breakdown was observed (Figure 5-5, H) in the decidualised stroma. However, in 
comparison to the untreated tissue (Figure 5-5, E) shedding of the functional layer into the 
lumen had not occurred. Maintenance of the decidual response was observed in another area 
of the tissue (Figure 5-5, G).  
At 12 hours (Figure 5-6, A-D), decidualised cells in the centre of the uterine lumen, appeared 
to be apoptotic, adjacent to these cells was an area of stroma that appeared to be breaking 
down (Figure 5-6, C). Unlike in untreated tissues, breakdown of the functional layer into the 
lumen was not observed.  
By 24 hours (Figure 5-6, E-H), the entire functional stroma appeared apoptotic, due to the 
changes in cell morphology and loss of haematoxylin counterstain, but had not detached 
from the underlying basal layer (Figure 5-6 G and H), as demonstrated in the untreated 
uterus recovered at 12 hours after progesterone withdrawal (Figure 5-6, A). 
 
Overleaf, Figure 5-5: Morphology of the DHT treated uterine horn 4 hours (A-D) and 8 hours (E-H) 
after the withdrawal of progesterone.  A; Uterine morphology 4 hours after progesterone 
withdrawal in untreated mice. B; Uterine morphology of DHT treated mice at 4 hours. C; An intact 
epithelial layer is observed (LE). D; Decidualised stromal cells are observed in the centre of the horn. 
E; Morphology of the uterus 8 hours after progesterone withdrawal in untreated mice. F; 
Morphology of the uterus un DHT treated mice. G; The maintenance of the decidual response is 
observed in another area of the same section. H; The beginnings of breakdown was observed in an 
area of decidualised functional stroma (arrowheads). DS; decidualised stromal cells, LE; luminal 
epithelium, BL; basal layer. Scale bars as indicated. Images representative of 3 animals per time-
point. 
Figure 5-6: Morphology of the DHT treated uterine horn 12 hours (A-D) and 24 hours (E-H) after 
the withdrawal of progesterone. A; Uterine morphology 12 hours after progesterone withdrawal in 
untreated mice. B; Uterine morphology in DHT treated mice. C; An intact epithelial layer still lines the 
lumen. D; Cells appear to be breaking down to the left of this image. E; Uterine morphology 24 hours 
after progesterone withdrawal in untreated tissues. F; Uterine morphology 24 hours after 
progesterone withdrawal in DHT treated tissues. G and H; Decidualised cells have not yet detached 
from the underlying basal layer . SC; shed cells, BL; basal layer. Scale bars as indicated. Images 
representative of 3 animals per time-point.  




Figure 5-5: Morphology of the DHT treated uterine horn 4 hours (A-C) and 8 hours (D-F) after the 
withdrawal of progesterone. 




Figure 5-6: Morphology of the DHT treated uterine horn 12 hours (A-C) and 24 hours (D-F) after the 
withdrawal of progesterone. 
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5.3.3 Treatment with DHT appears to alter androgen receptor expression during 
breakdown 
To understand whether DHT could be regulating the delay in breakdown via its cognate 
receptor, the androgen receptor, AR expression was compared in uteri recovered at 4 and 24 
hours in both untreated (-DHT) and DHT treated (+DHT) samples.  
At 4 hours (Figure 5-7, A and B), androgen receptor protein was immunolocalised to the 
nuclei of decidualised stroma cells and stromal fibroblasts in the basal layer. AR expression 
was not detected in the luminal epithelium. In the DHT treated animals, there appeared to be 
an increase in the intensity of immunostaining for AR (Figure 5-7, B) in both the 
decidualised stromal cells and in the stromal cells adjacent to the luminal epithelium, 
consistent with ligand-induced stabilisation of the protein.  
At the 24 hour time-point (Figure 5-7, C and D), in the untreated animals (C), expression of 
AR was sparsely distributed throughout the stromal cell compartment.  In DHT treated 
animals, (Figure 5-7, D) immunostaining for AR appeared to be more intense in the basal 
layer and was localised to the stromal cells adjacent to the luminal epithelium.  
Transcriptional regulation of AR (Ar) was investigated by qRTPCR to determine mRNA 
concentrations at each time-point (Figure 5-8). At 4 hours mRNA concentrations of Ar were 
lower than that of their untreated counterparts (ns, p>0.05), however a trend of an increase 
was observed at 8 hours. Ar mRNA concentrations appeared to increase from the 12 hour to 
the 24 hour time-point, but were not significantly greater than the untreated tissues.  




Figure 5-7: Androgen receptor (AR) expression in untreated and DHT treated animals (4 hours, A 
and B, and 24 hours, C and D after the withdrawal of progesterone).  A; At 4 hours, AR was 
detected in the decidualised stromal cells and stromal cells in the basal layer, whilst it was absent in 
the epithelium, inset AR in intact mouse endometrium. B; At 4 hours after progesterone withdrawal 
in the DHT treated animals, there appeared to be an increase in AR expression in the decidualised 
stroma and in the stroma adjacent to the luminal epithelium. C; By 24 hours weak immunostaining 
for AR is present on the stromal cell compartment, inset negative control. D; In the DHT treated 
animals, strong immunostaining for AR is present in the stromal cells adjacent to the luminal 
epithelium. DS; decidualised stromal cells, LE; luminal epithelium, BL; basal layer. Scale bars as 
indicated. Images representative of 2 animals per time-point. 




Figure 5-8: Androgen receptor (Ar) mRNA concentrations in untreated (black bars) and DHT 
treated animals (blue bars).  mRNA expression for the decidualised horns were normalised against 
the non-decidualised 0hr horn. Statistical analysis was performed by Two WAY ANOVA and 
Bonferroni post hoc testing, comparing each DHT time-point to its respective untreated time-point. 
5.3.4 Administration of DHT delays repair of the endometrium by inhibiting MET 
A role for MET in endometrial repair was discussed in Chapter 4, after dynamic regulation 
of genes involved in the MET pathway were discovered during the window of breakdown 
and repair in our mouse model. Following the initial observation that a single injection of 
DHT delayed the onset of breakdown, the effect of DHT on MET was investigated.  
In uterine samples recovered from mice not treated with DHT (-DHT), evidence of dual 
labelled, vimentin and cytokeratin positive cells were first observed at the myometrial border 
at the 12 hour time-point and at the luminal surface at the 24 hour time-point (see Figure 4-
3). In contrast, dual labelled cells were only detected in the DHT treated animals at the 24 
hour time-point (Figure 5-9, A and B). Unlike in untreated tissues where these cells were 
clustered together, in some DHT treated samples, dual labelled cells were sparsely 
distributed through-out the basal layer adjacent to an area where the decidualised stromal 
cells had not detached from the underlying basal stroma (Figure 5-9, A and B). However 
these were not observed in every animal (Figure 5-9, C). In contrast to data reported in 
chapter 4, no dual labelled were detected in areas near the luminal epithelium (Figure 5-9, 
D). 




Figure 5-9: Evidence of MET in DHT treated tissues.  Epithelial cell marker cytokeratin (green) and 
mesenchymal cell marker vimentin (red). Tissues recovered at the 24 hour time-point, two 
representative uteri are shown in A-C and D. A-D; Stromal cells in the basal layer are positively 
stained for vimentin. The luminal and glandular epithelium are positive for cytokeratin. Dual labelled 
cells (yellow) are identified by the white arrowheads. BL; basal layer, DS; decidualised stroma, LE; 
luminal epithelium, G; glandular epithelium. Images representative of 3 animals per time-point. 
If treatment with DHT was merely delaying the normal onset of endometrial breakdown, as 
evidenced by histological examination, we might expect a rightward shift in mRNA 
concentrations for genes known to regulate MET. In contrast to this hypothesis, 
concentrations of Wt1 mRNA were significantly up-regulated (Figure 5-10) in the DHT 
treated horns compared to the untreated horns at 8 hours (p<0.001) and 12 hours (p<0.001) 
after the withdrawal of progesterone. Concentrations of Snail (Snai1) mRNA were also up-
regulated in the DHT treated horns when compared to their untreated time-points (4 hours; 
p<0.001, 8 hours; p<0.001, 12 hours; p<0.01, 24 hours; p<0.001).  
Interestingly, mRNA concentrations of Slug (Snai2) were decreased in the DHT treatment 
animals in comparison to the untreated animals 4 hours after the withdrawal of progesterone 
(ns, p>0.05). Concentrations of Slug were increased at 12 hours (p<0.001). By 24 hours, no 
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difference in mRNA concentrations of Slug was detected between the DHT treated or 
untreated animals. 
Concentrations for mRNAs for stromal cell markers Cdh2 and vimentin were down-
regulated in the DHT treated group when compared to the untreated time-points (Figure 
5-11). Cdh2 was down regulated at 4 hours (p<0.01) and 8 hours (p<0.05) after progesterone 
withdrawal. Concentrations for vimentin were down-regulated at 4 hours (p<0.05). 
Interestingly, mRNA concentrations for Wnt4 were increased at 4 hours (p<0.001) and 8 
hours (p<0.05) in the DHT group.  
Concentrations for mRNAs for epithelial cell marker Cdh1 were decreased at 4 hours, but 
started to increase at 8 hours, however no significant difference in mRNA concentrations 
were detected at any time-point (Figure 5-11). Similar patterns in mRNA concentrations 
were detected for Wnt7a and Krt8, where mRNAs were decreased at 4 hours, but slowly 
increased towards the 24 hour time-point.  
Taken together these data were suggestive of profound disturbances in the regulation of cell 
identity as a result of DHT exposure following progesterone withdrawal.  
 




Figure 5-10: mRNA concentrations for candidate genes involved in mesenchymal to epithelial 
transition; Wt1, Snail (Snai1) and Slug (Snai2).  mRNA expression for both untreated and DHT 
treated horns was normalised against non-decidualised 0 hour horn. Statistical analysis was 









Figure 5-11: mRNA concentrations for candidate genes involved in mesenchymal to epithelial transition; Cdh2, Wnt4, vimentin, Cdh1, Wnt7a and keratin 8 (Krt8). 
mRNA expression for both untreated and DHT treated horns was normalised against the 0 hour non-decidualised horn. Statistical analysis was performed by Two 
way ANOVA and Bonferroni post hoc testing, where * p<0.05, ** p<0.01 and *** p<0.001. 
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5.3.5 Evidence for an effect of androgens on MET by array analysis 
Additional evaluation of the impact of DHT on MET was investigated using a PCR array 
that profiles 84 key genes that are known to be involved in the EMT/MET pathway. The full 
gene list can be found in Supplementary Table 1. The array utilised uterine samples from 
mice with and without DHT treatment. Samples from the three key time-points (0 (-DHT 
only), 8 and 24 hours) were studied. The differences in fold regulation of gene expression 
were analysed using the ΔΔCT method, where the 8 hour and 24 hour time-points for both 
the untreated and DHT treated samples were compared to the untreated 0 hour time-point, 
uteri recovered at the point of full decidualisation. Additionally, the fold regulation between 
the untreated (-DHT) and DHT treated animals were also analysed e.g. 8 hours -DHT v 8 
hours +DHT. Those genes in which a significant change in fold regulation was observed are 
shown in Table 5-1, Table 5-2 and Table 5-3. 
Notably, a lower number of significant changes in gene expression were observed after 
treatment with DHT (0 v 8 hours -DHT; 24 changes; 0 v 8 hours +DHT; 9 changes, 0 v 24 
hours -DHT; 48 changes, 0 v 24 hours +DHT; 37 gene changes).  
Treatment with DHT resulted in a number of striking gene changes at the 8 hour time-point 
(0 v 8 hours -DHT/+DHT). Integrin beta 1, significantly up-regulated (1.5 fold increase) in 
the -DHT animals was significantly down-regulated after the addition of DHT (36.5 fold 
decrease). Rgs2 (involved in G protein signalling) was decreased 2.7 fold in the -DHT set but 
decreased by 10.8 fold in the +DHT set. Another notable difference was in the regulation of 
Wnt11, 3.4 fold increased in the -DHT set but 19.9 fold increased in the +DHT set. Collagen 
3a1, which was not detected to be significantly regulated in the -DHT set decreased 13.3 fold 
in the DHT treated animals.  
At the 24 hour time-point (0 v24 hours -DHT/+DHT), keratin 19 expression decreased from 
a 7.5 fold increase in -DHT tissues to a 3.5 fold increase in the DHT treated animals. Similar 
changes were also detected in keratin 7, a 28 fold increase to a 7 fold increase and MMP3, a 
61 fold increase to a 9.8 fold increase in the DHT treated group.  
When direct comparisons between -DHT and +DHT animals were analysed a number of 
changes were detected in the 8 hours -DHT v 8 hour +DHT group. Collagens 1a2, 3a1 and 
5a2 were all down-regulated (7.5 fold; 35 fold and 4 fold respectively). Integrin beta 1 was 
down-regulated 104 fold. Cell adhesion molecule osteopontin (Spp1) was down-regulated 25 
fold. Molecules known to be involved in cell migration, moesin (Msn) and Rac1 were also 
significantly down-regulated, 11 fold and 13 fold respectively. Notably, Snail was increased 
by 15.7 fold and Notch1 by 10 fold. 
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At 24 hours, a notable gene change between -DHT and +DHT tissues was the down-
regulation of Mmp-3, by 5 fold.  
0hrs v 8hrs -DHT 
 
0 v 8hrs +DHT 
Gene Name p value Fold Regulation 
 
Gene Name p value 
Fold 
Regulation 
Col5a2 0.014999 1.3733 
 
Col3a1 0.004759 -13.3755 
Fzd7 0.004084 2.112 
 
Itgb1 0.029826 -36.5277 
Gng11 0.027026 -2.0012 
 
Pppde2 0.041858 1.8169 
Igfbp4 0.007334 1.8312 
 
Rac1 0.009679 -7.3429 
Il1rn 0.000873 2.0872 
 
Rgs2 0.001117 -10.8609 
Ilk 0.027785 1.4167 
 
Sparc 0.012026 -11.9256 
Itgb1 0.001503 1.4681 
 
Tfpi2 0.022356 -10.4001 
Krt19 0.000383 1.9973 
 
Twist1 0.029906 8.6303 
Krt7 0.001239 4.8209 
 
Wnt11 0.041917 19.9072 
Mmp2 0.008265 2.0402 
 No. Genes Up Regulated 
No. Genes Down Regulated 
3 
Mmp3 0.013284 3.0056 
 
6 
Mtap1b 0.021019 1.7783 
    
Pdgfrb 0.030445 2.1571 
    
Plek2 0.001445 2.1191 
    
Rgs2 0.001027 -2.7773 
    
Snai2 0.018714 -2.1138 
    
Snai3 0.006822 5.6312 
    
Spp1 0.001467 4.3785 
    
Stat3 0.001286 1.5821 
    
Steap1 0.000673 2.3442 
    
Tfpi2 0.008769 -1.8252 
    
Timp1 0.015419 1.6154 
    
Tmeff1 0.000078 2.3973 
    
Wnt11 0.000277 3.4224 
    
No. Genes Up Regulated 
No. Genes Down Regulated 
20 
    
4 
    
Table 5-1: Significant changes in gene expression 8 hours after progesterone withdrawal in both 
the untreated (left) and DHT treated (right) groups.  Gene changes are displayed as up- or down- 
fold regulation when compared to the 0 hour group, n=6. 
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0hrs v 24hrs -DHT 
 
0 v 24hrs +DHT 
Gene Name p value 
Fold 
Regulation  
Gene Name p value 
Fold 
Regulation 
Akt1 0.004507 1.6241 
 
Akt1 0.021554 1.4004 
Bmp1 0.001376 1.7233 
 
Bmp1 0.004875 1.781 
Bmp7 0.04878 1.8035 
 
Bmp7 0.019901 1.5242 
Cald1 0.006957 2.2812 
 
Cald1 0.041718 1.9679 
Camk2n1 0.04425 4.8329 
 
Camk2n1 0.006771 2.4549 
Cav2 0.03615 1.7465 
 
Cav2 0.039747 1.4628 
Cdh1 0 5.1764 
 
Cdh1 0.012869 2.2448 
Cdh2 0.046312 1.4957 
 
Col1a2 0.035275 1.526 
Dsc2 0.000383 4.734 
 
Dsc2 0.038507 2.5695 
Dsp 0.000257 9.5533 
 
Dsp 0.002195 2.6723 
Esr1 0.032215 1.5223 
 
Esr1 0.015056 1.3194 
Fn1 0.007739 3.0108 
 
Fgfbp1 0.029242 2.4738 
Fzd7 0.011578 2.2833 
 
Fn1 0.021125 2.466 
Gng11 0.016563 -2.7033 
 
Gsc 0.013639 3.1905 
Gsc 0.039591 2.8029 
 
Ilk 0.040806 1.4629 
Gsk3b 0.046881 1.4052 
 
Krt19 0 3.526 
Ilk 0.004121 1.8766 
 
Krt7 0.00039 7.217 
Itgb1 0.006007 1.6552 
 
Mmp2 0.011524 1.9656 
Jag1 0.002575 3.4856 
 
Mmp3 0.026796 9.8823 
Krt19 0.000053 7.5293 
 
Msn 0.024717 1.4358 
Krt7 0.000018 28.178 
 
Ocln 0.008739 2.5191 
Mitf 0.001484 -2.1751 
 
Pdgfrb 0.032017 1.8664 
Mmp2 0.00544 2.7303 
 
Rgs2 0.00053 -3.4636 
Mmp3 0.001871 61.2906 
 
Smad2 0.026931 1.1826 
Msn 0.000728 1.8437 
 
Snai2 0.003658 -1.7138 
Mtap1b 0.000492 2.1494 
 
Spp1 0 13.5539 
Notch1 0.031693 1.6165 
 
Stat3 0.001796 1.7196 
Ocln 0.005327 11.2243 
 
Steap1 0.001172 3.1253 
Pdgfrb 0.000015 4.5738 
 
Tcf7l1 0.00401 -1.7737 
Plek2 0.044301 1.6349 
 
Tgfb1 0.00214 1.8677 
Ptp4a1 0.002475 1.8968 
 
Timp1 0.018738 1.9144 
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0hrs v 24hrs -DHT 
 
0 v 24hrs +DHT 
Gene Name p value 
Fold 
Regulation  
Gene Name p value 
Fold 
Regulation 
Rgs2 0.001014 -4.2015 
 
Tmeff1 0.015332 2.8142 
Smad2 0.005844 1.3823 
 
Tspan13 0.000588 1.8561 
Snai3 0.011681 15.8243 
 
Twist1 0.00685 1.9548 
Spp1 0.000141 23.2021 
 
Vim 0.007273 1.376 
Stat3 0.00232 1.8157 
 
Wnt11 0.001067 3.7167 
Steap1 0.000283 4.6399 
 
Wnt5b 0.021871 -1.4652 
Tcf4 0.001468 1.4002 
 No. Genes Up Regulated 
No. Genes Down Regulated 
33 
Tfpi2 0.002632 -2.1709 
 
4 
Tgfb1 0.004964 1.783 
    
Tgfb2 0.004658 -1.497 
    
Tmeff1 0.000001 4.1575 
    
Tmem132a 0.00069 2.8066 
    
Tspan13 0.00039 3.2687 
    
Twist1 0.00125 3.294 
    
Vim 0.001135 1.7446 
    
Vps13a 0.035245 1.5401 
    
Zeb1 0.000009 2.4496 
    
No. Genes Up Regulated 
No. Genes Down Regulated 
43 
    
5 
    
Table 5-2: Significant changes in gene expression 24 hours after progesterone withdrawal in both 
the untreated (left) and DHT treated (right) groups. Gene changes are displayed as up- or down- 
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8hrs -DHT v 8hrs +DHT 
  
24hrs -DHT v 24hrs +DHT 
Gene Name p value fold regulation 
  
Gene Name p value fold regulation 
Col1a2 0.000052 -7.5768 
  
Bmp1 0.041058 1.2724 
Col3a1 0.000385 -35.8022 
  
Cdh1 0.018099 -1.8729 
Col5a2 0.044721 -4.6694 
  
Cdh2 0.048043 -1.6649 
Itgb1 0.005316 -104.9922 
  
Dsp 0.005709 -2.9035 
Msn 0.006524 -11.4497 
  
Egfr 0.037947 1.6062 
Notch1 0.023339 10.1191 
  
Itga5 0.021464 2.1408 
Ocln 0.047584 2.4584 
  
Jag1 0.013583 -2.2656 
Rac1 0.018337 -13.8268 
  
Krt7 0.028112 -3.1711 
Serpine1 0.035952 -9.2519 
  
Mitf 0.028874 2.2192 
Snai1 0.020913 15.7722 
  
Mmp3 0.030717 -5.0373 
Snai2 0.030825 2.2587 
  
Ocln 0.02128 -3.6188 
Sparc 0.006405 -22.146 
  
Pdgfrb 0.003909 -1.9904 
Spp1 0.003026 -25.388 
  
Ptk2 0.007871 1.2553 
No. Genes Up Regulated 
No. Genes Down Regulated 
4 
  
Serpine1 0.017296 3.6066 
9 
  
Tfpi2 0.000242 3.0199 
     
Wnt5b 0.040307 -1.7319 
     No. Genes Up Regulated 
No. Genes Down Regulated 
7 
     
9 
Table 5-3: Significant changes in gene expression when DHT groups are directly compared to their 
own control time-points at 8 hours (left) and 24 hours (right).  Gene changes are displayed as up- or 
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5.3.5.1 Network analysis of array and qRTPCR data 
To understand the potential regulation of androgens on the MET pathway, the full gene list, 
qRTPCR candiates and the androgen receptor were input into MetaCore™ software. Using 
this software it was possible to identify which genes were known to be downstream of AR. 
The results of this analysis are depicted in Figure 5-12.  
Notably, AR was shown to be upstream of β catenin, involved in the Wnt signalling 
pathway, as well as TGFβ, who along with the Wnts are key regulators of EMT and MET. 
Interestingly, AR is shown to have activatory actions on the epithelial marker keratin 7 
whilst having inhibitory actions on another epithelial marker E cadherin, consistent with a 
decrease in mRNA concentrations at 4 hours (Figure 5-11).  
AR has also been reported to exert activatory effects on extracellular matrix protein 
osteopontin, which is in contrast to the findings in the array where osteopontin (Spp1) was 
down-regulated in the DHT treated animals at 8 hours.  Mesenchymal marker N cadherin has 
also been shown to be activated by AR, which correlates with an increase in mRNA 
concentrations for N cadherin after DHT treatment (Figure 5-11).  
In order to determine a role for DHT and the AR in the regulation of tissue repair a list of 
potential AR-regulated candidates was identified for further investigation and is discussed in 











Figure 5-12: Known interactions of genes from the EMT array that are downstream of the androgen receptor. Arrows indicate direct effects on other genes in the 
pathway. Green arrows indicate activation, whereas red arrows show inhibitory action. Pathway generated using Metacore™ software. 
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5.3.6 DHT maintains the hypoxic response 
Immunohistochemistry for hypoxia was carried out using the Hypoxyprobe® labelling 
system to investigate the effect of DHT on the hypoxic response during the window of 
breakdown and repair, as detailed in section 4.3.3. Hypoxia can be visualised by 
immunohistochemistry, where a brown stain indicates cells under hypoxic conditions. Strong 
staining is indicative of very low oxygen tensions and very hypoxic, weak staining indicates 
cells that are hypoxic, whereas an absence of staining indicates cells under normoxic 
conditions. In Overleaf, Figure 5-13 untreated (-DHT) animals (left) are compared to DHT 
animals (right), at 0, 4, 8 and 24 hours after the withdrawal of progesterone.  
In the DHT group, 4 hours after progesterone withdrawal the beginnings of a hypoxic 
response are observed in the stromal cell compartment close to the lumen, which is similar to 
the immunopositive staining for hypoxia observed in the untreated 0 hour group. At both the 
0 and 4 hour time-points, cells in the basal layer and myometrium are not stained for 
hypoxia. By 8 hours after progesterone withdrawal, the DHT treated animals display a 
phenotype similar to that observed in the 4 hour -DHT group, where the decidualised cell 
mass is strongly immunostained for hypoxia. Weak immunostaining is detected around the 
luminal epithelium at this time; however the basal layer and myometrium remained 
unstained suggesting they are under more normoxic conditions. By 24 hours, staining for 
hypoxia is restricted to the luminal epithelium and the shed cells in the lumen, similar to that 








Overleaf, Figure 5-13: DHT attenuates the hypoxic response. Staining for hypoxia was carried out 
using Hypoxyprobe®. A delay in the breakdown of the endometrium of the DHT treated animals 
(right column) is observed when compared to the untreated (left column). Immunostaining for 
hypoxia shows that the hypoxia response is maintained in the DHT animals, with strong staining 
observed at 8 hours resembling the 4 hour -DHT group. By the 24 hour time-point, shed cells in the 
lumen and the luminal epithelium are positively stained for hypoxia, resembling the phenotype of 
the 8 hour -DHT section. Images representative of 2 animals per time-point. 
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5.3.7 DHT alters key genes involved in angiogenesis and endothelial cell stability 
To investigate whether androgens have an impact on the expression of genes previously 
reported to be regulated by hypoxia in vitro; gene expression was quantified using qRTPCR 
of total tissue extracts (Figure 5-14).  
Concentrations of mRNA encoding Vegfa were increased in the DHT treated group at 4, 8 
and 12 hours after the withdrawal of progesterone, however no significant difference was 
detected. Concentrations then decreased back to levels of those seen in untreated tissues at 
the 24 hour time-point.  
Notably, treatment with DHT attenuated the increase in mRNA concentrations for Cxcl12 
that occurred after progesterone withdrawal at 4 hours (p<0.01) and 24 hours (p<0.001). In 
DHT treated samples concentrations of mRNAs for Pecam-1 were maintained at 4 hours, 
decreased at 8 hours (p<0.05) then were up-regulated at 24 hours (p<0.001) compared to 
their untreated time-points.  
Interestingly, the pattern of expression of both angiopoietins 1 and 2 (Angpt1/Angpt2) was 
similar after treatment with DHT, with no change in expression at 4 and 8 hours when 
compared to the 0 hour time-point. However, significant increases in mRNA concentrations 
at 12 hours (Angpt 1, p<0.05, Angpt 2, p<0.01) and 24 hours (Angpt1/2, p<0.001) were 
detected when compared to the untreated samples. 




Figure 5-14: mRNA concentrations for candidate genes involved in angiogenesis; Vegfa, Cxcl12, Pecam-1, Angpt1, Angpt2. mRNA expression for both untreated 
and DHT treated horns was normalised against the 0 hour non-decidualised horn. Statistical analysis was performed by Two Way ANOVA and Bonferroni post hoc 
testing, where * p<0.05, ** p<0.01 and *** p<0.001. 
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5.3.8 Evidence for an effect of androgens on angiogenesis by array analysis 
Additional evaluation of a role for androgens in vascular function was investigated using a 
PCR array that focuses on genes known to be involved in angiogenesis or vascular 
remodelling. The full gene list can be found in Supplementary Table 2. Samples from three 
time-points (0 hours, 8 hours and 24 hours) were studied as above. Those genes in which a 
significant change in fold regulation was observed are shown in Table 5-4, Table 5-5 and 
Table 5-6.  
As previously noted using the EMT array, a lower number of significant gene changes were 
detected in uteri from mice that had been treated with DHT, (0 hours v 8 hours -DHT; 40 
gene changes, 0 hours v 8 hours +DHT; 28 gene changes, 0 hours v 24 hours -DHT; 45 gene 
changes, 0 hours v 24 hours +DHT; 34 gene changes). In all cases the number of down-
regulated genes exceeded that of the number of up-regulated genes at both time-points in the 
DHT group.  
At the 8 hour time-point, similar fold changes were observed in both the 0 v -DHT and 0 v 
+DHT sets, for example angiopoietin 2 (Angpt2) ~5 fold decrease in -DHT and an ~6 fold 
decrease after DHT treatment. However, Lect1 reported a 6 fold decrease in the untreated 
group but a 10 fold decrease in the +DHT group. Plasminogen (Plg) reported a 3 fold 
increase in the -DHT group but an 8 fold increase in the +DHT group. 
Interestingly, at the 24 hour time-point differences appeared more striking between the -DHT 
and +DHT groups, suggesting that treatment with DHT at 0 hours exerted changes at the 
molecular level in a time-dependent manner.  
When compared to the 0 hour reference sample, treatment with DHT appeared to reduce 
some responses to progesterone withdrawal; for example, Angpt2 reported a 22 fold decrease 
in the -DHT group, but only a 2 fold decrease in the +DHT group; Cxcl5 mRNA was 
reduced to a 2 fold increase in the DHT treated animals (10 fold increase in -DHT group); 
HIF2α (Epas1) was detected to decrease by 3.5 fold (~9 fold in the –DHT group); a 13 fold 
increase in Tnf was detected in the +DHT group; whilst a 24 fold increase had been reported 
in the -DHT set. 
Stark differences were detected in relative changes in expression of Lect1, a 3 fold decrease 
detected in the 24 hour +DHT group (55 fold decrease in untreated samples) and Mmp-9 was 
also differentially regulated, an ~7 fold increase was detected at 24 hours +DHT (28 fold 
increase in the -DHT set). Interleukin 1β was found to increase by 35 fold after the addition 
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of DHT however no significant change in fold regulation was detected in the -DHT set at the 
24 hour time-point.  
In direct time-point comparisons, (8 hours -DHT v 8 hours +DHT) only 5 genes were 
detected to be significantly different at 8 hours. All 5 genes were significantly up-regulated 
in the +DHT group. At the 24 hour time-point, (24 hours -DHT v 24 hours +DHT) 18 genes 
were differentially regulated in the DHT group compared to the -DHT time-point. Angpt2, 
Lect1 and Serpine1 were all up-regulated (8 fold, 16 fold and 5 fold respectively).  
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0hrs v 8hrs -DHT 
 
0hrs v 8hrs +DHT 
Gene Name p value Fold Regulation 
 
Gene Name p value Fold Regulation 
Akt1 0.000137 -2.5842 
 
Akt1 0.000751 -1.5007 
Angpt2 0.00299 -4.9175 
 
Angpt2 0.001059 -5.856 
Bai1 0.048497 -2.5934 
 
Cxcl1 0.022825 2.8975 
Cdh5 0.012848 -4.0682 
 
Cxcl2 0.001759 5.4048 
Csf3 0.025896 2.5198 
 
Edn1 0.000677 3.9095 
Cxcl1 0.004732 4.1928 
 
Eng 0.001462 -1.5005 
Cxcl2 0.006045 4.4648 
 
Epas1 0.002151 -2.6124 
Efnb2 0.001374 -2.8566 
 
Ephb4 0.026111 -1.2138 
Egf 0.005832 -3.4239 
 
Fgf6 0.041569 2.2572 
Eng 0.001554 -2.2298 
 
Fgfr3 0.000333 -2.0865 
Epas1 0.000331 -3.9733 
 
Igf1 0 -3.7126 
Ephb4 0.00026 -1.8575 
 
Il1b 0.008532 2.6909 
Erbb2 0.000141 -2.1867 
 
Itgav 0.026512 -1.6079 
Fgfr3 0.00048 -2.539 
 
Kdr 0.000029 -1.5762 
Flt1 0.009749 -1.804 
 
Lect1 0.00015 -10.0228 
Ifng 0.031845 -2.258 
 
Mapk14 0.004891 -1.4346 
Igf1 0.000008 -3.1822 
 
Mmp9 0.038474 1.8724 
Il1b 0.00072 4.8631 
 
Nos3 0.006988 -1.4408 
Il6 0.041614 1.7567 
 
Plau 0.020667 2.1905 
Itgav 0.015424 -1.6608 
 
Plg 0.000746 8.048 
Kdr 0.000342 -1.7111 
 
Ptgs1 0.005573 -1.9106 
Lect1 0.000234 -6.116 
 
Ptk2 0.001618 -1.429 
Mapk14 0.00171 -1.3964 
 
Sphk1 0.000014 -5.9061 
Mmp9 0.001015 2.1744 
 
Tek 0.046092 -1.375 
Nos3 0.006183 -1.4661 
 
Tgfa 0.000035 -2.8412 
Pecam1 0.0097 -1.5109 
 
Thbs1 0.021062 1.97 
Plau 0.022668 2.7188 
 
Tie1 0.002983 -1.3557 
Plg 0.000315 3.5833 
 
Vegfa 0.037623 1.6257 
Ptgs1 0.000024 -1.6422 
 
Number of genes 
significantly up-regulated 




Ptk2 0.016074 -1.269 
 
18 
Sphk1 0.000006 -4.9733 
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0hrs v 8hrs -DHT 
 
0hrs v 8hrs +DHT 
Gene Name p value Fold Regulation 
 
Gene Name p value Fold Regulation 
Tek 0.000448 -1.4716 
    
Tgfa 0.000068 -3.4111 
    
Thbs1 0.010501 2.4701 
    
Tie1 0.006365 -1.4041 
    
Timp2 0.028328 -1.1885 
    
Tnf 0.003052 2.3139 
    
Vegfa 0.003885 2.1533 
    
Vegfb 0.038244 -1.2515 
    
Vegfc 0.004284 -1.8048 
    
Number of genes 
significantly up-regulated 











Table 5-4: Significant changes in gene expression 8 hours after progesterone withdrawal in both 
the untreated (left) and DHT treated (right) groups.  Gene changes are displayed as up- or down- 
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0hrs v 24hrs -DHT 
 
0hrs v 24 hrs +DHT 
Gene Name p value Fold Regulation 
 
Gene Name p value Fold Regulation 
Angpt1 0.046288 -1.7594 
 
Ang 0.000879 3.8728 
Angpt2 0.000001 -22.9351 
 
Angpt2 0.004513 -2.7053 
Ccl11 0.02758 2.2697 
 
Ctgf 0.034871 2.3 
Ccl2 0.032995 7.0443 
 
Cxcl5 0.025513 2.7626 
Cdh5 0.004155 -3.0425 
 
Edn1 0.001502 12.8259 
Csf3 0.01885 31.9636 
 
Efnb2 0.001274 -2.7987 
Ctgf 0.035697 1.9539 
 
Egf 0.007205 -1.7551 
Cxcl1 0.004845 56.8512 
 
Epas1 0.000205 -3.5014 
Cxcl5 0.001852 10.6539 
 
Ephb4 0.012697 -5.1606 
Edn1 0.006193 6.0435 
 
Erbb2 0.000927 -1.8294 
Efna1 0.043344 1.5754 
 
F2 0.007101 2.8433 
Efnb2 0.003062 -2.6326 
 
F3 0.040744 2.9398 
Egf 0.018678 -1.9777 
 
Fgf1 0.014657 -1.9486 
Eng 0.026026 -1.8363 
 
Fgfr3 0.000086 -3.3566 
Epas1 0.000012 -8.9365 
 
Igf1 0.000141 -2.7399 
Ephb4 0.041566 -1.7025 
 
Il1b 0.045551 35.2507 
F3 0.001286 4.2343 
 
Itgb3 0.001196 2.1481 
Fgfr3 0.000062 -3.4944 
 
Kdr 0.008861 -1.6411 
Flt1 0.006391 -2.0237 
 
Lect1 0.001536 -3.0916 
Hgf 0.006579 2.1842 
 
Mapk14 0.00147 -1.6027 
Igf1 0.000002 -3.1035 
 
Mmp9 0.042146 6.8393 
Il6 0.01492 1.9559 
 
Pgf 0.000032 3.7586 
Jag1 0.00324 1.6671 
 
Plau 0.004478 4.2526 
Kdr 0.00011 -2.471 
 
Plg 0.000159 4.0777 
Lect1 0.000004 -51.9476 
 
Ptgs1 0.000002 -2.6375 
Mapk14 0.011274 -1.4252 
 
Smad5 0.043498 -1.4936 
Mmp14 0.038408 1.4948 
 
Sphk1 0.000005 -3.0822 
Mmp9 0.00972 28.7339 
 
Tek 0.022974 -1.5147 
Nos3 0.003536 -2.0241 
 
Tgfa 0.000008 -3.2086 
Pdgfa 0.000588 2.8488 
 
Tgfb1 0.026449 1.5808 
Pecam1 0.000247 -2.0313 
 
Tgfb2 0.007811 -1.4944 
Plau 0.007907 3.6989 
 
Thbs1 0.024226 3.0517 
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0hrs v 24hrs -DHT 
 
0hrs v 24 hrs +DHT 
Gene Name p value Fold Regulation 
 
Gene Name p value Fold Regulation 
Plg 0.00004 4.7103 
 
Tnf 0.007213 13.5483 
Ptgs1 0.000002 -2.6514 
 
Vegfa 0.000016 3.0398 
Ptk2 0.013642 -1.5107 
 
Vegfc 0.003747 -1.8746 
S1pr1 0.000788 -1.6036 
 
Number of genes 
significantly up-regulated 
Number of genes 
significantly down-regulated 
16 
Sphk1 0 -11.2585 
 
19 
Tek 0.010909 -2.0434 
    
Tgfa 0.000001 -6.0818 
    
Tgfb2 0.000026 -2.7031 
    
Tgfb3 0.025882 -1.9838 
    
Thbs2 0.000037 4.5008 
    
Tie1 0.00304 -2.1991 
    
Timp1 0.040893 -1.9155 
    
Tnf 0.003514 24.461 
    
Number of genes 
significantly up-
regulated 




    
26 
    
      
Table 5-5: Significant changes in gene expression 24 hours after progesterone withdrawal in both 
the untreated (left) and DHT treated (right) groups. Gene changes are displayed as up- or down- 
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8hrs -DHT v 8 hrs +DHT 
 
24hrs -DHT v 24hrs +DHT 
Gene Name p value Fold Regulation 
 
Gene Name p value Fold Regulation 
Akt1 0.044221 1.8404 
 
Ang 0.049399 2.9463 
Efna1 0.02319 2.7301 
 
Angpt2 0.022478 8.3268 
Ephb4 0.028451 1.6355 
 
Cxcl5 0.026708 -3.9265 
Flt1 0.032444 1.4924 
 
Epas1 0.020464 2.5068 
Plg 0.033616 2.4004 
 
Hgf 0.017917 -2.2119 
Number of genes 
significantly up-regulated 





Itgb3 0.012049 2.0497 
0 
 
Jag1 0.029383 -2.124 
    
Lect1 0.009679 16.5037 
    
Nos3 0.035013 1.8536 
    
Pecam1 0.038112 1.7283 
    
S1pr1 0.002801 1.7741 
    
Serpine1 0.006237 5.0798 
    
Sphk1 0.000068 3.5877 
    
Tgfa 0.007621 1.8617 
    
Tgfb2 0.020672 1.7766 
    
Thbs2 0.025847 -3.2965 
    
Timp1 0.023128 2.6099 
    
Vegfa 0.003424 3.3824 
    
Number of genes 
significantly up-regulated 




    
4 
Table 5-6: Significant changes in gene expression when DHT groups are directly compared to their 
own untreated time-points at 8 hours (left) and 24 hours (right). Gene changes are displayed as up- 
or down- fold regulation when compared to the 0 hour group, n=6. 
5.3.8.1 Network analysis of array and qRTPCR data 
To investigate a possible role for direct regulation by androgens through the AR during 
angiogenesis, the full gene list, qRTPCR candidates and AR were input into MetaCore™ 
software to generate a network of known genes interacting with AR (Figure 5-15).  
The network analysis highlighted MMP-9 as a possible downstream target of the AR, which 
would be consistent with the difference in fold regulation that was detected at the 24 hour 
time-point in the -DHT (28.3) and DHT group (6.83). Network analysis also highlights that 
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the AR may have an activatory effect on VEGFa, consistent with a 3 fold increase observed 
at the 24 hour time-point in the array.  
Notably, those genes which were detected to have large differences in fold regulation after 
the addition of DHT, (Lect1, Plg, Angpt2, Il1β, Tnf) were absent from the network and 
therefore may not be directly regulated by androgens acting via direct binding of the AR to 
regulatory sequences in their promoters. Direct or indirect regulation would need to be 
confirmed by chromatin immunoprecipitation (chIP) or other methodology. These genes, 
Lect1, Plg, Angpt2, Il1β, Tnf, were all highlighted for further investigation and a role for 









Figure 5-15: Known interactions of genes from the array that are downstream of the androgen receptor.  Arrows indicate direct effects on other genes in the 
pathway. Green arrows indicate activation, whereas red arrows show inhibitory action. Pathway generated using MetaCore™ software. 
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5.3.9 Evidence that DHT alters factors associated with tissue breakdown and 
repair  
To determine whether treatment with DHT had an effect on mechanisms that contribute to 
repair of the endometrium, additional qRTPCR was conducted to measure mRNAs for 
factors previously identified as being associated with wound healing and tissue remodelling 
(Figure 5-16). 
In untreated (no DHT) tissues, mRNA concentrations of Smad3, previously shown to be 
involved in wound healing, did not change over the window of breakdown and repair (not 
shown). However, treatment with DHT resulted in an increase in total Smad3 mRNA 
concentrations at each time-point with significant up-regulation observed at 8 hours 
(p<0.001) and 12 hours (p<0.001). The highest mRNA concentrations for Smad3 were 
detected at the 8 hour time-point, by 24 hours they were no different to the untreated 
samples.  
Striking changes were detected in mRNA concentrations of connective tissue growth factor 
(Ctgf) in response to DHT treatment, with 20-40 fold increases observed when compared to 
untreated tissues at all time-points (4 hours; p<0.001, 8 hours; p<0.001, 12 hours; p<0.001 
and 24 hours p<0.01). Similarly to Smad3 the highest mRNA concentration for Ctgf was at 8 
hours, concentrations then decreased at 12 and 24 hours.  
In contrast, mRNA concentrations for Pdgfrb were strikingly down-regulated at every time-
point. In contrast to the untreated horns, where mRNA concentrations were increased at 24 
hours, Pdgfrb was down-regulated at the 8 hour time-point (p<0.001) and concentrations 
remained low at 12 hours (p<0.05) and 24 hours (p<0.001). Mmp-3 mRNA concentrations 
were also down-regulated at 24 hours (p<0.01) in comparison to their untreated group.  
 




Figure 5-16: mRNA concentrations for candidate genes involved tissue remodelling; Smad3, Ctgf, 
Pdgfrb, Mmp-3. mRNA expression for both untreated and DHT treated horns was normalised against 
the 0 hour non-decidualised horn. Statistical analysis was performed by Two Way ANOVA and 
Bonferroni post hoc testing, where * p<0.05, ** p<0.01 and *** p<0.001. 
 
5.4 Discussion 
5.4.1 Administration of a single dose of DHT results in changes to normal tissue 
breakdown 
In our refined mouse model, a single dose of DHT at the time of progesterone withdrawal 
was able to delay the onset of breakdown, whilst also delaying repair of the tissue, as 
evidenced by a delay in detachment of the functional layer from the underlying stroma 
(Figure 5-6).   
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5.4.1.1 DHT maintains the decidual response 
The observation that DHT delayed the onset of breakdown of the tissue would be consistent 
with reports that androgens can alter decidual cell function and in mice will maintain the 
decidual response in the absence of progesterone (96, 146, 504). A role for androgens in 
maintenance of pregnancy (maintenance of the deciduoma) has been studied both in vivo and 
in vitro (96, 146, 504, 510). For example, in an in vivo mouse model, decidualisation 
following artificial stimulation was maintained by DHT in the absence of progesterone, this 
effect of DHT was abolished by the addition of flutamide (an AR antagonist) indicating that 
DHT was acting through the AR (146). In vitro studies using primary human endometrial 
stromal cells (hESCs) have also highlighted a role for androgens in decidualisation. 
Decidualisation can be induced in hESCs in vitro following treatment with 8-
bromoadenosine 3'-5'-cyclic adenosine monophosphate (8-Br-cAMP) and progesterone. 
Addition of DHT, enhances the decidual response of these cells by increasing secretion of 
decidual marker prolactin (504).This increase in prolactin is consistent with data from our 
model where mRNA concentrations for prolactin (Prl8) were increased and levels 
maintained across the breakdown and repair window in the DHT treated animals (Figure 
5-3).  
The effects of DHT on decidualised stromal cell morphology have been investigated by 
transmission electron microscopy (TEM) (510). Decidualised stromal cells treated in 
combination with progesterone and DHT are reported to develop intracellular organelles, 
form lipid droplets and display cytoplasmic expansion, in comparison to decidualised 
stromal cells treated with progesterone only (510). This may account for the morphological 
differences in the uterine tissue between the untreated and DHT treated animals at the earlier 
time-points of 4 and 8 hours (Figure 5-5). 
Maintenance of the decidual response, and therefore delay in breakdown, may also involve 
inhibition of apoptosis. Androgens have been proposed to play an anti-apoptotic role in the 
development of prostate cancer, as evidenced in in vitro models of the disease (536–538). A 
recent study has identified an anti-apoptotic role for DHT in the endometrium (144). When 
apoptosis was induced in primary endometrial stromal fibroblasts in vitro, DHT significantly 
reduced caspase activation (144). Further investigation, using our model, into genes that 
regulate apoptosis would complement the data reported; immunostaining for apoptotic 
markers such as caspase 3 would also determine if apoptosis is delayed in the DHT treated 
animals.  
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Injection of DHT at the time of progesterone withdrawal resulted in some significant 
changes in gene expression which were particularly striking at the 8 hour time-point. 
Notably, expression of genes associated with epithelial cell proliferation and adhesion (Spp1, 
integrinβ1) were down-regulated when compared to the control. In contrast, Snail and Slug, 
both of which are known to regulate EMT, were up-regulated following treatment with DHT 
which might have contributed to repression of E cadherin expression. An up-regulation of 
Notch at the 8 hour time-point (8 hours- DHT v 8 hours +DHT) may also contribute to active 
EMT. Activation of Notch is associated with tumour cell migration, and has been shown to 
regulate hypoxia-mediated tumour cell migration (539) in cervical, colon and ovarian cancer 
cell lines in vitro. Androgenic regulation of EMT has not previously been investigated in the 
endometrium. 
Interestingly, a number of striking differences were detected in genes associated with cell 
morphology at the 8 hour time-point in animals treated with DHT. Cell adhesion molecule 
integrinβ1 was down-regulated by 36 fold, consistent with the phenotype of the decidualised 
cell mass at this time (Figure 5-6), where the tissue shows the beginning of breakdown next 
to areas of intact decidualised stroma. DHT has been previously shown to down-regulate cell 
adhesion molecules in in vitro models of prostate cancer (540, 541), whilst also activating 
Snail (542) which promotes cancer invasion and metastasis. Regulatory molecules for cell 
migration, cell shape and cellular remodelling were also down-regulated at the 8 hour time-
point suggesting that DHT maintains the decidualised phenotype by inhibiting these 
molecules. This may result in an overall suppression of cellular remodelling that would 
normally occur in the absence of progesterone.  
5.4.2 DHT has an effect on “normal” tissue repair mechanisms  
MMPs play an integral role in endometrial tissue breakdown during menses as well as in 
tissue remodelling during repair phases (82, 224, 439, 543, 544). The addition of a single 
dose of DHT resulted in dramatic differences in concentrations of Mmp-3 and Mmp-9 
mRNAs in treated and untreated animals (Mmp-3; 61 fold v 9 fold; Mmp-9; 28 fold v 6 fold) 
at the 24 hour time-point. Mmp-3 mRNA concentrations were further investigated by 
qRTPCR, which indicated that the addition of DHT decreased mRNA concentrations at 4, 8 
and 24 hours relative to those females not exposed to DHT. In DHT treated animals mRNA 
concentrations of Mmp-3 began to increase at 12 hours, with the highest concentration 
detected at 24 hours, where the beginnings of breakdown had been observed. However, 
concentrations were not as high as in untreated animals. This DHT induced decrease in 
MMP activity would be consistent with the observed delay in first the breakdown, and then 
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the detachment, of the endometrium by the 24 hour time-point in the DHT treated animals 
(Figure 5-). Differential regulation of MMPs by androgens have been reported in other 
tissues; in the prostate, expression of MMP-2 and MMP-13 are induced by androgens (545, 
546); whilst in vascular smooth muscle cells DHT inhibits MMP-2 activity (547); whilst in 
the skin MMP-2 and MMP-9 were decreased at lower serum androgen concentrations (548). 
Network analysis by MetaCore™ identified both MMP-2 and MMP-9 as being potentially 
downstream of the androgen receptor, suggesting direct regulation of these genes although 
further studies are required to validate this in uterine cells.  
Administration of DHT did not appear to affect the number of macrophages in the uterus 
observed at any time-point (not shown), however the function of macrophages may have 
been indirectly affected by DHT acting on adjacent cell types. For example, as detailed in 
section 4.4.1.3, macrophages have been reported to secrete factors such as tumour necrosis 
factor, osteopontin and VEGF (440, 452, 457), all of which were down-regulated in the 
+DHT group when compared to the -DHT group. Therefore, DHT may not have an effect on 
macrophage proliferation or recruitment but may inhibit secretion of factors that contribute 
to breakdown and repair of the tissue.  
The skin itself is a site of androgen synthesis, and a role for androgens in cutaneous wound 
repair has been investigated (549–551). Much like the repair of the endometrium, cutaneous 
wound repair involves infiltration of immune cells, tissue remodelling and re-
epithelialisation (552–554). A study using an AR knock-out mouse line, reported accelerated 
cutaneous wound healing, suggesting that AR suppresses wound healing activity (549). 
Furthermore, the authors report that in macrophage-specific AR knock-out mice healing and 
tissue remodelling were accelerated whilst re-epithelialisation was unaffected highlighting 
the potential for differential regulation of these two processes. Inhibition of 5α reductase 
accelerates cutaneous wound healing and leads to decreased inflammation in mice, 
implicating a role for DHT in delaying repair (551).  
In the current study, a number of factors previously implicated in wound repair were 
investigated. Increased mRNA concentrations for Smad3 were observed at all DHT treated 
time-points, this is consistent with a previous report, where Smad3 null mice exhibit 
accelerated cutaneous wound healing in comparison to wild type mice (555). Platelet derived 
growth factor beta (PDGFRβ) has also been proposed as a key regulatory factor in cutaneous 
wound repair (556, 557). A study in a mouse model, in which the activity of PDGFRβ was 
inhibited by imatinib mesylate, revealed a delay in wound closure and a decrease in collagen 
synthesis (556). This would be consistent with data reported in this chapter where mRNA 
Chapter 5. A role for androgens in endometrial function. 
197 
 
concentrations for collagens 1a2, 3a1 and 5a2 were significantly lower in the +DHT group 
compared to the -DHT group at 8 hours (Table 5-3), a time-point where Pdgfrb was also 
down-regulated in the +DHT set (Figure 5-16).  In an in vitro model using Cre recombinase 
transfection, to knock out PDGFRβ from dermal fibroblasts, depletion of PDGFRβ led to a 
decrease in cell proliferation and migration (557). In the current study, the addition of DHT 
resulted in a significant decrease in mRNA concentrations for Pdgfrb at 8, 12 and 24 hours, 
suggesting that androgens may be suppressing PDGFRβ-mediated tissue repair, something 
that merits further investigation.  
5.4.3 Androgens and angiogenesis 
In our mouse model the decidualised cell mass is made up of decidualised stromal 
fibroblasts, immune cells and a proliferating vascular compartment (as demonstrated in  
 
Overleaf, Figure 4-13). However, murine endometrial endothelial cells do not express 
androgen receptor (Simitsidellis, unpublished) which may suggest that DHT will not have a 
direct effect on endothelial cells in our model. DHT has also been shown to have no effect 
on the network formation of human endometrial endothelial cells in vitro, suggesting that 
androgens may not regulate endothelial cell migration or proliferation (Greaves, 
unpublished). However, as a number of genes in the angiogenesis array were differentially 
regulated by treatment with DHT in our mouse model, we suggest that DHT indirectly 
regulates endothelial cell stability rather than promoting proliferation and migration. DHT 
may act on AR positive stromal cells that may secrete angiogenic factors that promote 
endothelial cell stability. DHT mediated endothelial stability would also account for the 
delay in breakdown in DHT treated animals.  Vessel stability is normally weakened upon 
progesterone withdrawal; therefore we propose a role for DHT in maintenance of the 
decidual stroma by promoting vessel stability. In support of this, mRNA concentrations of 
Vegfa and Ctgf were increased at 8 hours after treatment with DHT; both factors have been 
implicated in endothelial cell dynamics (558–560).  
5.4.3.1 Direct or indirect regulation by androgens 
Promoter regions of potential AR target genes, identified from the arrays, were assessed for 
putative transcription factor binding sites (TFBS) to investigate direct or indirect regulation 
by androgens. Using bioinformatic software (Mapper CHIP Bioinformatics (561)), promoter 
regions of candidate genes were investigated for the presence of consensus binding sites for 
specificity protein-1 (Sp-1) or activator protein-1 (Ap-1), as well as the androgen response 
element (ARE)  outlined in Table 5-7. 
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Of the 27 genes investigated, 15 contained a potential ARE in their promoter, 22 had a Sp-1 
site and only 3 had an Ap-1 site. Interleukin 1b (Il1b), plasminogen (Plg) and Angiopoietin 1 
(Angpt1) did not contain either an ARE, Sp-1 or Ap-1 site despite a significant change in 
their expression after the addition of DHT and therefore may be indirectly regulated by 
androgens through another transcription factor, such as NFκB or via a more distant enhancer 
element (562, 563). The data gathered from the MAPPER search is by no means definitive 
and further analysis by chromatin immunoprecipitation (chIP) would be necessary to confirm 




Sp-1 site Ap-1 site 
Angpt1 0 0 0 
Angpt2 1 1 0 
Col3a1 0 1 0 
Ctgf 1 2 0 
Cxcl12 1 5 0 
Hif2α/Epas 1 4 0 
Il1b 0 0 0 
Itgb1 1 6 0 
Krt19 2 7 0 
Krt7 2 4 0 
Lect1 0 2 0 
Mmp-2 0 2 0 
Mmp-3 1 0 1 
Mmp-9 0 5 2 
Notch 1 4 0 
Pdgfrb 0 1 2 
Plg 0 0 0 
Rgs2 2 4 0 
Smad3 0 3 0 
Snai1 0 2 0 
Snai2 1 0 0 
Snai3 1 5 0 
Spp1 1 2 0 
Tnf 1 1 0 
Vegfa 0 1 0 
Wnt11 0 1 0 
Wt1 1 3 0 
Table 5-7: Putative transcription factor binding sites in the promoters of candidate genes in the 
mouse. Analysed using Mapper CHIP Bioinformatics (561). 
5.4.4 Androgens as a self-limiting factor in “normal” endometrial function 
Previous animal models of endometrial breakdown focussed solely on the contributions of 
oestradiol and progesterone in normal endometrial function, despite reports of relatively 
constant serum androgen levels across the human menstrual cycle (44, 45). In 
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ovariectomised mouse models only oestradiol and progesterone are replaced by exogenous 
injection or implant and to date no androgens have been administered, despite mice adrenals 
lacking 17α hydroxylase (CYP17) which means mice are unable to synthesise androgens. In 
ovariectomised macaque models of menses, oestradiol and progesterone are administered to 
induce artificial menstrual cycles. However, the effect of exogenous oestradiol and 
progesterone on adrenal androgen production has not been considered, despite recent data 
that demonstrates exogenous hormones increase adrenal secretion of DHEA and DHEAS in 
macaques in comparison to intact controls (564), which may have an effect on the 
endometrium during the artificial menstrual cycles. 
The refined mouse model of breakdown described in this study exhibits rapid shedding, with 
re-epithelialisation complete, or almost so, by 24 hours after the withdrawal of progesterone. 
Previous studies have reported that uterine horns have returned to an ovariectomised, steroid 
depleted morphology by 48 hours (230, 233, 239). The addition of a single dose of DHT was 
enough to delay the onset of breakdown, and extend the breakdown phase, such that by the 
24 hour time-point 100% of mice were bleeding (Figure 5-2), suggestive of a delay in the 
onset of repair mechanisms. Collection of tissues at later time-points (28, 32, 36 hours after 
progesterone withdrawal) would determine whether androgens also had an impact on the 
length of the bleed and therefore initiation of repair. Treating mice with tritiated DHT, would 
also allow analysis of the clearance of DHT by radioimmunoassay, to determine whether 
DHT could still be having an effect at the later time-points.  It is important to consider, 
however, that peripheral concentrations of DHT are not a good measure of target tissue 
concentrations (565).  
Despite these results suggesting that androgens such as DHT may delay onset of bleeding, 
and ultimately impact on repair processes, it is also possible that androgens normally present 
in women as a result of adrenal/peripheral site biosynthesis may play a role in limiting the 
severity of tissue destruction upon progesterone withdrawal. The most recent data shows that 
endometrial shedding occurs in a piecemeal process (169), with scanning electron 
microscopy of menstrual phase endometrium  showing areas of shed tissue adjacent to areas 
of intact epithelium. Therefore, it is possible to speculate that circulating androgens at the 
time of menses may, in part, modulate the breakdown of the endometrium through regulation 
of MMPs to limit tissue destruction and through anti-apoptotic mechanisms to stabilise 
sections of the tissue. Also, it is possible that androgens may regulate immune cell dynamics 
and secretion of factors which contribute to digestion and breakdown of the functional layer 
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of the tissue. Thus, this “self-limiting” regulation may regulate the severity of breakdown 
and reduce blood loss.  
5.4.5 Summary 
In the current study, using our refined mouse model of endometrial breakdown and repair, a 
role for androgens during endometrial repair was investigated. 
The addition of DHT at the time of progesterone withdrawal resulted in a delay in the onset 
of breakdown, whilst also delaying repair. Analysis of genes known to be involved in EMT 
and MET were investigated by a PCR array, dynamic changes were observed at both the 8 
hour (breakdown) and 24 hour (repair) time-points after DHT treatment. An up-regulation in 
known EMT regulator Snail was observed at all time-points, whilst Slug was up-regulated at 
12 hours, whilst cell adhesion markers such as integrinβ1 and osteopontin were down-
regulated. MMPs, involved in breakdown, were also significantly down-regulated, as were a 
number of factors involved in wound repair.  
Potential AR target genes were investigated for putative transcription factor binding sites to 
investigate direct or indirect regulation by androgens, however further analysis by chIP is 
necessary to confirm direct activation of gene expression.  
From the results presented in this chapter it is evident that androgens (DHT) have an effect 
on endometrial function. However, the full impact of androgens on endometrial function and 
a possible role in endometrial pathologies including HMB awaits further elucidation.  
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Chapter 6 Final Discussion 
6.1 Introduction 
The human endometrium is a highly complex, multi-cellular tissue that lines the uterine 
cavity. The endometrium can be divided into two layers; the upper, functional layer and the 
underlying basal layer that is attached to the muscular myometrial layer. The luminal surface 
of the tissue is composed of a layer of epithelial cells, underneath of which is the multi-
cellular stromal cell compartment that is composed of stromal fibroblasts, blood vessels lined 
by endothelial cells, and an immune cell population which contains macrophages, 
neutrophils and uterine natural killer cells. In women of reproductive age, the functional 
layer of the endometrium undergoes dynamic tissue remodelling in response to ovarian-
derived sex steroid hormones, to maintain endometrial receptivity for the possible 
implantation of a blastocyst. Well defined phases of endometrial function have been 
described including; the oestrogen-dominant proliferative phase and the progesterone-
dominant secretory phase which prepares the tissue for a possible pregnancy. In the absence 
of a blastocyst, progesterone levels fall which results in breakdown and clearance of the 
functional layer of the endometrium during menses. The endometrium undergoes tightly 
controlled remodelling resulting in a healed, scar-free tissue ready for the next cycle.  
Endometrial repair occurs concurrently with tissue breakdown (148), at a time when both 
oestradiol and progesterone levels are low, termed a “steroid-depleted” environment. 
Although mice do not spontaneously decidualise or menstruate, regulation of uterine 
function mirrors that in women with cyclical episodes of proliferation. In addition, artificial 
“menstrual” cycles can be induced in the mouse (234), making mouse models an attractive 
model for studying aspects of endometrial function relevant to women’s health. Notably, 
endometrial repair was reported to occur in the absence of oestrogen in a mouse model of 
endometrial breakdown (239). To date, mouse models have been used to study a number of 
factors involved in endometrial breakdown and regeneration (79, 188, 217, 230, 233, 235, 
239, 318–320, 368), however these models have not considered simultaneous breakdown 
and repair, instead focussing on time-points where breakdown has already occurred and 
therefore these studies have investigated a later stage of repair.  
The mechanisms that drive endometrial repair during this steroid-depleted state are not fully 
understood but contributions from the underlying basal glandular epithelium and the basal 
stromal cell compartment as two possible sources of new luminal epithelial cells have been 
suggested. Furthermore, despite low circulating levels of oestrogens and progesterone in 
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women, androgens are maintained across the cycle and therefore may contribute to repair of 
the tissue, either directly or following metabolism to other steroids.  
In the current study we set out to challenge a number of dogmas that surround the study of 
endometrial function, by asking the following questions.  
1. Is it possible to establish a model of menses in the mouse, which mimics menses in 
women, namely; can we model simultaneous breakdown and repair, overt 
menstruation, immune cell influx, tissue necrosis and re-epithelialisation?  
2. Does the stromal cell compartment contribute to endometrial regeneration? 
3. Is there a role, if any, for androgens during endometrial repair? 
We hypothesised that a combination of mechanisms will contribute to re-epithelialisation 
and remodelling of the endometrium during the repair phase. We suggest that epithelial cell 
proliferation will occur but the stromal cell compartment will also contribute to repair, either 
directly through mesenchymal to epithelial transition of stromal fibroblasts or indirectly by 
factors produced by immune cells including tissue resident macrophages.  
6.2 Key findings 
6.2.1 Endometrial breakdown and repair can be broken down into three key 
phases 
In Chapter 3, a previously described mouse model of menses (233) was refined in order to 
develop a model that more closely mimics menses in women. A number of novel findings 
were identified using our refined model. Firstly, collection of uterine tissues at time-points 
earlier than those previously published identified an “early” window of repair, one where 
both breakdown and repair mechanisms were initiated. Immunohistological and molecular 
analysis identified three phases of the repair process; tissue stabilisation, tissue restoration 
and tissue remodelling (outlined in Table 6-1).  
  
Chapter 6. Final Discussion. 
203 
 
4-8 hours PW/D 12 hours PW/D 24 hours PW/D onwards 
Circulating progesterone falls to 
~30% 
Circulating progesterone falls to 
~25% 
Circulating progesterone falls to 
≤10% 
Stromal cell proliferation in 
basal layer 
Increased epithelial cell 
proliferation 
Basal gland epithelial cell 
proliferation 
Endothelial cell proliferation in 
decidualised cell mass  (4 
hours) 
 
Apoptotic shed cells. Apoptotic shed cells 
Exposed blood vessels adjacent 
to lumen  (8 hours) 
Blood vessels appear “sealed” 
Endothelial cell proliferation in 
basal layer 
Hypoxia localised to 
decidualised cells; increase in 
hypoxia-regulated VEGF 
Hypoxia localised to shed cells 
and luminal epithelium 
Hypoxia localised to shed cells 
and luminal epithelium 
Increase in stromal cell markers 
Decrease in stromal markers, 
increase in epithelial markers 
Increase in epithelial markers 
Genes associated with EMT up-
regulated 
Switch in markers associated 
with EMT to MET 
Genes associated with MET up-
regulated 
MMPs suppressed by 
progesterone 
Increase in MMPs associated 
with tissue breakdown 
Increase in MMPs associated 
with tissue remodelling 
Macrophages are identified in 
the decidualised stroma 
Macrophages are associated 
with the luminal epithelium 
Increase in no. of macrophages, 
localised to luminal epithelium 
& stroma 
  
Potential pericyte activation 
Conditions favour stromal cell 
compartment 
Stromal → Epithelial switch 
Conditions favour epithelial cell 
compartment 
Tissue Stabilisation Tissue Restoration Tissue Remodelling 
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6.2.2 Tissue stabilisation controls breakdown and initiates repair 
Endometrial breakdown occurred within 4 hours of the withdrawal of progesterone, 
consistent with a 70% decrease in serum progesterone concentrations and evidence of blood 
in the vaginal smear. This is the first study to report breakdown and bleeding within 4 hours, 
suggesting that the mechanisms contributing to tissue breakdown are tightly regulated by 
progesterone and that the rapid fall in serum progesterone levels trigger initiation of tissue 
destruction. In a previously published mouse model of menses, a critical period of 
progesterone withdrawal precedes endometrial breakdown (235), this finding supports 
studies in the macaque (356) and the human (164, 566). In the mouse, replacement of 
progesterone after 12-16 hours was sufficient to reverse the effects of progesterone 
withdrawal. However, the authors do not report any evidence of endometrial bleeding until 
12 hours after the withdrawal of progesterone, despite a reported drop in progesterone 
concentrations from ~128ng/ml to ~14ng/ml in the first 8 hours (235). Therefore, it is not the 
drop in progesterone that must trigger breakdown but a minimal threshold, once the level has 
dropped below it, recovery is not possible. For example, in our model, circulating 
progesterone concentrations are maximal prior to progesterone pellet removal at ~12ng/ml, 
bleeding is recorded at 4 hours when progesterone concentrations are ~3ng/ml. Therefore it 
is likely in our model that progesterone would have to be replaced by 4 hours to prevent the 
degree of tissue destruction observed at our 8 hour time-point.  
In the first 8 hours after progesterone withdrawal, a large number of stromal cells in the basal 
compartment were positive for BrdU, indicative of stromal proliferation. In addition, 
endothelial cell proliferation in the decidual cell mass was also detected. Stromal cell 
markers and genes associated with EMT were increased as well as induction of hypoxia 
across the decidualised cell mass. The molecular and cellular dynamics observed at 4-8 
hours after the withdrawal of progesterone suggest that the stromal cell compartment is 
favoured over the epithelial compartment. We believe that the molecular and cellular 
mechanisms that occur during this time frame (up to 8 hours after the withdrawal of 
progesterone), in response to falling progesterone concentrations, stabilise the tissue in 
preparation for endometrial shedding so that only the functional layer of the endometrium is 
shed. Shedding of the basal layer of the endometrium has been linked to the establishment of 
lesions in the pathology of endometriosis (567) and the mechanisms by which the 
endometrium only sheds its functional layer are unknown.  
As the decidualised functional layer sheds, it is possible that it secretes factors that initiate 
repair. In our mouse model, progressive shedding of the decidualised functional stroma was 
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observed (8 hours after progesterone withdrawal); in addition to this, residual round luminal 
epithelial cells were observed to be lining the lumen adjacent to sites of newly exposed 
endometrium. We postulate that as the endometrium detaches from the underlying basal 
stroma, it secretes factors that promote repair. A study by Gaide-Chevronnay et al., on 
human tissues, supports a role for the degenerating endometrium supporting its own repair; 
an increase in leukocyte chemokines, extracellular matrix (ECM) proteins and enzymes 
involved in prostaglandin synthesis were detected in the functional layer of menstrual phase 
tissue (462). Furthermore, an SEM study by Garry et al., observed that immediately after 
shedding, a fibrinous matrix appears to “seal” the endometrium prior to re-epithelisation 
(148). In support of this finding a previous mouse model of breakdown has shown that extra-
cellular matrix proteins were detected to be increased at the time of repair and were localised 
to the luminal edge of the uterine horn (79). We suggest that the shed material in our newly 
refined model may be supporting endometrial repair by secreting factors that promote the 
establishment of the ECM. The degenerating stroma is hypoxic and hypoxia has been shown 
to regulate immune cell function, and therefore may mediate macrophage migration to 
endometrium during remodelling (492, 496).  
A role for the degenerating functional stroma in endometrial repair has not been widely 
studied. Although, it is tempting to speculate that it may play a role in the pathology of 
endometrial disorders. For example, women with heavy menstrual bleeding may have a 
dysfunctional stroma that does not secrete repair factors, resulting in delayed repair and a 
longer bleed. Or, in women with endometriosis, the functional layer could promote its own 
survival by secreting factors that enable establishment of lesions, such as ECM proteins, and 
therefore the dissociated, shed tissue observed in our model warrant further study. 
Consistent with studies in human tissues, or in human cells in vitro, the cellular changes 
observed in our model by 8 hours are similar to those seen in women within the first 24 
hours of progesterone withdrawal (148, 193, 237, 439, 544); where hypoxia-induced up-
regulation of VEGF is observed (193), MMPs are still low (439, 544) and the beginnings of 
breakdown can be seen (148, 237). 
6.2.3 Initiation of early repair mechanisms contributes to tissue restoration 
By the 24 hour time-point, blood was not detected in the vaginal smear of any of the animals 
investigated. However, endometrial-like tissue was detected in the lumen of these animals 
upon dissection. These mice were considered to have ceased bleeding by this time, which 
suggests that stabilisation of the blood vessels in the underlying basal layer had occurred. 
Interestingly, as re-epithelialisation of the uterine horn was not observed in every animal at 
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this time-point, we suggest that vessel stabilisation occurs rapidly to reduce blood loss 
preceding completion of re-epithelialisation. This finding is consistent with SEM studies in 
menstruating women, where blood vessels appeared to be “sealed” prior to re-
epithelialisation of the uterine surface (148).  
In our model, tissue restoration was associated with an increase in epithelial cell proliferation 
and MMP expression. The decidualised functional stroma was apoptotic (detected by 
caspase 3, not shown) and was detected to no longer express steroid receptors (not shown), 
which would suggest that by this time-point it would not be capable of driving any further 
repair mechanisms and was not contributing to the overall mRNA concentrations detected in 
qRTPCR or PCR arrays. Hypoxia was localised to the shed cells, consistent with breakdown 
of blood vessels, and the luminal epithelium only. The underlying stromal cell compartment 
was under more “normoxic” conditions, suggesting that hypoxia may not regulate tissue 
restoration from the stroma but may play a key role in initiating early repair mechanisms 
during the tissue stabilisation period; this will be further discussed in section 6.2.5.  
In our model, the addition of DHT at the time of progesterone withdrawal was associated 
with a delay in breakdown and also a delay in repair. Delayed repair mechanisms, either 
involving vessel stabilisation or re-epithelialisation, have been implicated in the aetiology of 
heavy menstrual bleeding (HMB). Furthermore, expression of a number of factors, including 
vascular endothelial growth factor (VEGF) and connective tissue growth factor (CTGF) 
(193, 423) have been investigated as potential regulators of normal repair. Women with 
HMB have lower levels of VEGF (275) and increased prostaglandin synthesis (568), which 
are thought to contribute to a delay in repair by inhibiting endothelial stability and increasing 
inflammatory mediators.  
In our model, administration of DHT at the time of progesterone withdrawal significantly 
up-regulated Ctgf at all time-points, whilst also increasing mRNA concentrations of Vegfa, 
which suggests that despite delaying breakdown androgens may mediate initial repair 
mechanisms by encouraging vessel stability. Conversely, DHT administration resulted in 
increased Smad3 expression, which is associated with delayed wound repair in the skin 
(555).  Danazol (an anti-oestrogenic, anti-progestagenic, androgenic compound) has been 
used to treat women with HMB (569), with the success of treatment attributed to its anti-
proliferative effects, which may limit endometrial growth and therefore reduce the thickness 
of the tissue to be shed. However, it is also interesting to speculate that Danazol’s androgenic 
and glucocorticoid effects may also aid endometrial repair by regulating repair mechanisms.  
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Endometrial tissues from women with HMB have been widely studied in the context of 
tissue repair factors (193, 423, 570) however, a possible role for androgens in regulating 
repair has not been studied. In women, circulating oestrogen concentrations fall during 
menopause resulting in an increased androgen to oestrogen ratio (571, 572), as observed 
during menses. Post-menopausal women report slower wound healing; topical application of 
exogenous oestrogens has been shown to aid wound repair (573–576). This would suggest 
that during the menstrual cycle, when oestrogen levels are greater than androgens this may 
aid repair and remodelling of the tissue, which would be consistent with the morphological 
changes observed in the endometrium during the early proliferative phase (previously 
described in section 1.6.1). It is possible that in “normal” women cyclical fluctuations in the 
androgen to oestrogen ratio are such that tissue repair proceeds unimpeded. However, in 
women with HMB there may be an imbalance in this ratio, as observed in post-menopausal 
women, which leads to dysfunctional repair and a delay in tissue remodelling. This would be 
consistent with women with PCOS, who have increased androgen levels, who report long 
and heavy menstrual periods. However, the impact of androgens on endometrial function and 
endometrial pathologies including HMB awaits further elucidation.  
In our mouse model we report differential regulation of matrix metalloproteinases (MMPs). 
MMPs play an integral role in endometrial breakdown (219), and increased expression of 
MMPs has been detected during menses in women and during tissue breakdown in mouse 
models of menses (220, 221, 223, 227, 230, 544). Despite the significant drop in circulating 
progesterone levels during tissue stabilisation (4-8 hours), mRNA concentrations for Mmp-2, 
Mmp-3 and Mmp-9 do not increase dramatically at this time, suggesting that progesterone 
levels are still high enough to inhibit MMP activity. These results are consistent with reports 
in human tissues that identify a role for progesterone in MMP inhibition (425, 577–579).  
Mmp-3 was significantly up-regulated at 8 hours, whilst the tissue was observed to be 
breaking down, consistent with reports of increased MMP-3 activity during tissue 
breakdown in women at menses (215, 222). A dramatic increase (61 fold) was detected in 
the PCR array at 24 hours suggesting that MMP-3 is also involved in tissue remodelling and 
re-epithelialisation. This dual role for MMP-3 has been previously reported with cells 
immunopositive for MMP-3 identified in both the decidualised stroma and in areas of re-
epithelialisation in a mouse model of menses (230).  
Interestingly, whilst Mmp-9 was significantly up-regulated at 8 hours (2 fold) it was greatly 
increased at 24 hours (28 fold increase), consistent with previous data from Kaitu’u-Lino et 
al., (230) who also detected a significant increase in Mmp-9 mRNA at this time. We suggest 
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that MMP-9 may play a role in tissue remodelling rather than tissue breakdown, consistent 
with data from wound healing studies where MMP-9 has been shown to be involved in 
keratinocyte migration and granulation tissue (580). MMP-9 knock-out mice display delayed 
wound healing due to delayed re-epithelialisation and an increase in fibrin clotting (580). 
Human endometrial expression of MMP-9 is at its highest during the mid-secretory phase of 
the menstrual cycle, where the tissue is undergoing decidualisation, consistent with a role for 
MMP-9 in tissue remodelling (226).  A decrease in MMP-2 and MMP-9 expression has been 
associated with women with HMB (275), who are suspected to have deregulated repair 
mechanisms in comparison to normal women.  
6.2.4 The stromal cell compartment contributes to tissue restoration and tissue 
remodelling 
The basal glandular epithelium is considered to be the source of the new luminal epithelium 
(154, 201, 237, 241), and a label retaining study in a mouse model of breakdown supports 
this theory (318), suggesting that a “stem-like” population maintains the luminal epithelial 
layer. However, in our study, evidence of basal gland epithelial proliferation was only 
observed in a few animals and not until the 24 hour time-point; therefore we suggest that the 
basal gland contribution to regeneration is not an early repair mechanism. 
 A recent study, using human endometrium recovered during the menstrual phase, failed to 
detect any significant number of Ki-67 (proliferation marker) positive cells in either the 
stromal or epithelial cell compartments, which the authors suggest means that repair in 
women may not occur by mitotic division (169). Notably, these samples were taken from 
women with known gynaecological conditions (including adenomyosis and poor fertility) 
and therefore may not clearly represent the cellular dynamics in normal women. The 
evidence of both stromal and epithelial cell proliferation at all time-points in our mouse 
model implies that mitotic division does contribute to endometrial repair. 
In Chapter 3, pan cytokeratin positive stromal cells were identified close to the luminal 
surface at the 24 hour time-point, suggesting that these cells were in a transition-like state 
and may contribute to the new luminal epithelium via mesenchymal to epithelial transition 
(MET). Further investigation presented in Chapter 4, identified dual labelled pan cytokeratin 
and vimentin (definitive epithelial and mesenchymal markers, respectively) cells in the 
stromal cell compartment at the endometrial-myometrial ridge, 12 hours after the withdrawal 
of progesterone, at a time where the tissue was still breaking down. Dual labelled cells were 
then identified at the luminal edge at the 24 hour time-point in tissues collected from animals 
where full re-epithelialisation was not yet complete, suggesting that these dual labelled cells 
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migrate from the endometrial-myometrial border to contribute to the luminal epithelium. 
However, as there is a 12 hour interval between the last two time-points investigated, it 
would be of interest to collect tissues at 16 and/or 20 hours after progesterone withdrawal to 
determine whether these cells do migrate and can be identified interspersed throughout the 
stromal cell compartment.  
The possible contribution of the stromal cell compartment to endometrial function has been 
investigated in two models of post-partum repair (375, 376). Both models incorporated 
mesenchymal cell-labelled mouse lines, which were used for lineage tracing studies. In intact 
virgin mice, epithelial cells did not contain any cells that were of mesenchymal origin, 
however after three pregnancies both luminal and glandular epithelium contained cells that 
were mesenchymal-derived (375).  The identification of mesenchymal-derived cells in the 
epithelium is in support with a pilot study in our lab, using PDGFRβ-GFP labelled mice 
(which labelled stromal fibroblasts), which has identified PDGFRβ positive cells in the 
epithelium of intact, cycling mice (Simitsidellis, unpublished). This would suggest that not 
only does the stromal cell compartment contribute to the extensive remodelling observed 
during post-partum repair in the mouse, but it also contributes to overall tissue function in a 
non-menstruating species, that displays endometrial resorption (315) instead of endometrial 
shedding. To investigate this further, the PDGFRβ-GFP labelled mouse line will be 
incorporated into our refined mouse model of breakdown to study stromal cell dynamics. 
PDGFRβ is expressed by stromal fibroblasts in the endometrium and has also been proposed 
as a marker for putative endometrial stem cells known as pericytes (251).  
Re-epithelialisation of the endometrium by MET, has implications in the pathology of 
endometriosis, where endometrial tissue establishes itself outside of the uterine cavity (290, 
581). A role for MET in the regulation of endometrial tissue has not been studied intensively, 
whereas EMT has been proposed as a mechanism in the pathogenesis of endometriosis. A 
study published in 2003, by Demir et al. (582), was the first to suggest a role for EMT during 
establishment of peritoneal lesions in endometriosis. In their study, menstrual effluent was 
found to have an effect on the expression of mesenchymal and epithelial markers in 
mesothelial cells in vitro. Up-regulation of mRNA concentrations of the mesenchymal 
marker vimentin and down-regulation of the epithelial marker E cadherin were observed. 
Furthermore, disruptions to cell-cell adhesion between mesothelial cells  in vitro was 
reported, suggesting that factors in menstrual effluent may aid the manifestation of 
endometriotic lesions (582).   
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A more recent study in 2012, by Matsuzaki and Darcha, investigated a role for MET in the 
development of different types of endometriotic lesions, as cytokeratin has been reported in 
the stromal cell compartment of lesions from  women with endometriosis (581). Deep 
infiltrating and “black” peritoneal lesions expressed increased levels of cytokeratin markers 
and lower levels of mesenchymal markers than normal endometrium, suggesting MET as a 
process that enables lesion establishment. However, “red” peritoneal lesions and ovarian 
endometriotic tissue expressed higher levels of mesenchymal markers when compared to 
normal endometrium. This suggests that EMT plays a role in the establishment of these types 
of lesions. In both cases, expression of all markers may simply reflect changes in proportions 
of cell types in the lesions when compared to eutopic endometrium. 
The adult stem cell niche has been studied in a number of tissues;  like the endometrium, the 
intestine is a highly regenerative tissue capable of rapid regeneration after injury meaning 
that the intestinal crypt has been extensively studied (244, 247–249). It is likely that the 
endometrium also contains a stem cell population which contributes to restoration of tissue 
integrity during each menstrual cycle. The clonogenicity of endometrial stroma and 
epithelial cells has been studied in vitro (257, 259), and putative endometrial stem cells have 
been investigated in mouse models of breakdown (318, 368), using a label retaining method, 
which identified stromal and epithelial label retaining cells suggestive of stem cell niches for 
each compartment.  
Putative human endometrial stem cells have been identified using two markers CD146 and 
PDGFRβ, these dual labelled putative pericytes, once cell sorted, are multipotent and can 
differentiate into mesenchymal lineages (251, 461). CD146+ PDGFRβ+ cells have been 
identified at perivascular sites in the endometrium of intact mice (Simitsidellis, unpublished). 
The number of human endometrial pericytes is reported to be higher in the basal layer 
compared to the functional layer (583), and pericytes are reported to be essential for blood 
vessel formation and stabilisation (584) and therefore may be  contributing to repair of the 
murine endometrium. Pdgfrb mRNA concentrations increase during the repair phase in 
control mice (24 hours after progesterone withdrawal, not shown) but were decreased after 
the addition of DHT, which may suggest that androgens regulate pericyte activation and their 
possible contribution to repair.  
The contribution of bone marrow progenitors as a potential new source of epithelial cells has 
been investigated in mouse models (266, 267, 585) where GFP-labelled bone marrow from 
donor males was injected into female mice. GFP-labelled bone marrow derivatives were 
identified in both endometrial stromal and epithelial compartments of intact cycling mice. In 
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support of this theory, in our mouse model, a significant increase in mRNA concentrations 
for Snai3 were detected in the array (5 fold at 8 hours, 15 fold at 24 hours). In contrast to 
Snai1 and Snai2, little is known about Snai3 however it is expressed in high concentrations 
in the thymus and is thought to regulate haematopoietic stem cell differentiation (586). Over 
expression of Snai3 is also thought to be associated with decreased lymphocyte development 
and increased myeloid cell development (precursors for granulocytes) (586, 587). The 
increase in Snai3 observed in our model during tissue remodelling may be indicative of 
recruitment of bone marrow progenitors, and therefore may be an important factor for future 
study. The addition of DHT led to a decrease in mRNA concentration for Snai3 at all time-
points, which may implicate androgens as a regulator of stem cell recruitment. However, it is 
possible that due to the overall delay in breakdown and changes in other genes in the EMT 
pathway that this may be a downstream effect of DHT. Also, MAPPER analysis revealed 
that Snai3 does contain a putative androgen response element (561) so could be directly 
regulated by androgens. As Snai3 has not been investigated in the endometrium or widely 
studied in many other tissues, there is the potential to investigate a new candidate that could 
regulate repair. Identifying Snai3 protein in the endometrium, by immunohistochemistry or 
by western blot would be invaluable.  
The presence and regulation of endometrial stem cells also has implications in 
endometriosis. It is postulated that endometriosis occurs through retrograde menstruation, 
where endometrial tissue is flushed into the peritoneal cavity, which adheres to the 
peritoneum (292). It is thought that women with endometriosis will shed some of the basal 
layer of the endometrium during menstruation (567, 588), and that this tissue will contain 
endometrial stem cells that will contribute to the establishment of lesions (589). Bone 
marrow progenitors have also been implicated as a contributor to lesion formation in 
endometriosis (266, 267), and therefore both potential mechanisms warrant further study.  
6.2.5 Hypoxia as an initiator of repair mechanisms 
In our mouse model, hypoxia was detected in the decidualised cell mass during breakdown 
and in the luminal epithelium, whilst the basal stromal compartment remained unstained and 
under more normoxic conditions. Hypoxia has been shown to regulate genes involved in 
angiogenesis in vitro (191, 193), consistent with these data, an increase in hypoxia was 
associated with an increase in VEGF and a decrease in CXCL12. Downstream targets of 
HIF1α, as identified by MetaCore™, were found to be significantly up- or down-regulated at 
8 hours, when staining for hypoxia was at its strongest, suggesting direct regulation. A 
number of genes including Cxcl1, Cxcl5, Lect1 were reported to be significantly regulated 
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between 8 and 24 hours, where hypoxia in the uterine horn was localised to the shed cell 
mass and the luminal epithelium. These genes had not been identified as downstream targets 
of HIF1α and therefore may be indirectly regulated by HIF1α or by a HIF1α-independent 
mechanism.    
A potential role for hypoxia during endometrial repair has been investigated (188, 191, 193, 
321, 439), however the debate over its importance as a driver of repair remains. Hypoxic 
regulation of endometrial neo-angiogenesis has been implicated (188, 191, 193, 439), 
however no evidence of hypoxia was detected in a xenograft mouse model, where human 
explants were exposed to repeated cycles of oestrogen and progesterone withdrawal (321). 
Hypoxia has been shown to suppress MMP expression in stromal cells in vitro, (439) where 
a return to normoxic conditions removed this inhibition, therefore this may account for 
increased MMP expression at the 8 and 24 hour time-points when the hypoxic response was 
not as strong as at 4 hours.  
Whilst the debate over hypoxia mediated endometrial repair continues, hypoxia mediated 
metastasis has been widely studied in a number of tissues including the liver (590), the 
pancreas (591) and the breast (393). Whilst a role for hypoxia in proliferation of epithelial 
cells in endometrial carcinoma has recently been elucidated (464, 468), hypoxia has also 
been implicated in VEGF-dependent tumour angiogenesis in both the endometrium (592) 
and the ovary (470). Hypoxia has been reported to regulate EMT (and therefore cancer 
metastasis) by direct or indirect regulation of Snail, Slug and Twist (464, 590). 
Administration of androgens resulted in a maintenance of the decidual response and a 
prolonged exposure to hypoxic conditions that may have initiated the process of EMT, 
consistent with a 15 fold increase in Snail at 8 hours +DHT compared to 8 hours -DHT, and 
an 8 fold increase in Twist at 8 hours +DHT compared to the 0 hour -DHT group. Prolonged 
exposure to hypoxia- mediated EMT may account for the phenotypic differences observed 
during the 24 hour window between -DHT and +DHT groups.  
A rat adenocarcinoma model highlights oxygen as a key regulator of EMT and MET, where 
tumours treated under hyperoxic conditions showed regression due to initiation of MET 
processes (593). This would suggest that a switch in oxygen tension is capable of 
suppressing EMT regulators and activating MET regulatory molecules, which would be 
consistent with the initiation of MET in our model as the uterus returns to more normoxic 
conditions. However, the rat model was carried out at very high oxygen concentrations, 
which are unlikely to have been replicated at any time-point in our model; furthermore this is 
the only study to link high oxygen concentrations to MET.  
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It is likely that hypoxia is a key initiator of endometrial breakdown, and may set in motion 
repair mechanisms that are observed at the later time-points in our model. However, the 
absence of immunostaining for hypoxia in the underlying basal stroma at all time-points 
suggests that it does not directly regulate the stromal cell compartment, although a role for 
hypoxia in endometrial mesenchymal stem cell differentiation has been postulated (461).  
Hypoxia was observed in the decidualised stroma during breakdown which suggests that if 
the functional stromal compartment does contribute to repair by secreting factors (462) that 
this may be regulated by hypoxia. Evidence of hypoxia in the repairing luminal epithelial 
may also be regulating repair of this cell type and therefore, further investigation is required.  
Understanding the mechanisms of hypoxia-mediated endometrial breakdown, and whether it 
does contribute to repair, may also provide an insight into endometrial cancer, further work 
is needed to determine whether hypoxia regulates these mechanisms in a HIF-dependent or 
HIF-independent manner.  
6.2.6 Androgens disrupt normal repair mechanisms 
In our refined mouse model a single injection of DHT at the time of progesterone withdrawal 
delayed the onset of endometrial breakdown whilst delaying repair mechanisms so that these 
two processes did not occur concurrently. Collection of uterine tissues at 28, 32 and 36 hours 
after the withdrawal of progesterone (and addition of DHT) should identify a time-point 
where repair mechanisms are initiated in the DHT treated animals.  
In the absence of progesterone, androgens were able to maintain the decidual cell mass to 
delay the onset of breakdown by regulating factors that drive EMT, evidenced by the up-
regulation of Wt1 and Snail and down-regulation of E cadherin. A number of genes known to 
be involved in MET/EMT and angiogenesis/inflammation were found to be differentially 
regulated following treatment with DHT. Further analysis using MAPPER identified putative 
androgen response elements, Sp-1 and Ap-1 binding sites in the promoters of 24 of the 27 
candidate genes investigated.  
At the time of menses, circulating testosterone and androstenedione levels are relatively high 
(44, 45). Evidence for strong immunostaining for 5α reductase in the human endometrium at 
the secretory phase (499) suggests that local synthesis of DHT is occurring during this time. 
These data suggest that androgens are present and are contributing to tissue function during 
menses. Further analysis of the impact of DHT on endometrial function is required.  
Analysis of the uterine samples by chromatin immunoprecipitation would provide a more 
definitive list of androgen regulated genes. Incorporation of the PDGFRβ-GFP mice into the 
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mouse model and utilisation of in vivo imaging would allow investigation into the effects of 
DHT on pericyte migration.  
6.3 Future studies 
From the studies in this thesis it is evident that the stromal cell compartment contributes 
either directly or indirectly to endometrial repair and therefore there are a number of 
potential targets to focus on. 
In this study, mRNA concentrations were determined from whole tissue lysates. Laser 
capture micro-dissection would allow for isolation of specific cell types, which would 
provide further insight into the dynamics of each cellular compartment. More specifically it 
would allow investigation into the regulation of MET regulated genes and those of cell 
identity at key time-points (8 hours and 24 hours).  
A number of in vitro cell culture methods are available to study cellular dynamics. Utilising 
3D co-culture models with primary endometrial epithelial and stromal cells will enable 
investigation of cell-cell interactions in a model that recapitulates the multi-cellular 
morphology of the human endometrium. It is evident that stromal cell compartment 
contributes to repair; manipulation of the stromal cell compartment in these models would 
allow elucidation of its effect on the epithelial cell compartment. In vitro studies using cell 
conditioned media would also allow investigation of how each cell type interacts with 
another, for example, whether decidualised stromal cells undergoing progesterone 
withdrawal have an effect on epithelial cell or immune cell dynamics. 
In order to delineate a role for MET in epithelial repair, future work should focus on fate 
mapping studies to determine the presence and lineage of stromal cells undergoing MET. 
Labelled mouse lines and collection of tissues at more frequent time points (16, 20, 28 hours 
after progesterone withdrawal) would enable tracking of cells from the myometrial ridge to 
the luminal surface, if this is indeed the source of these cells. Recent acquisition of a 
PDGFRβ labelled mouse line will enable detection of cells that have/or are currently 
expressing the stromal cell marker. The effect of androgens, more specifically DHT, on 
breakdown and repair can also be studied in these mice using live in vivo imaging. DHT was 
shown to down-regulated PDGFRβ mRNA concentrations at all time-points and therefore, 
may be having an effect on the migration of cells.  
It is possible that the degenerating functional stroma may also play a role in repair and 
utilising laser capture technology would enable investigation of candidate genes that may be 
secreted by the functional stroma, such as integrins, adherens, MMPs and chemokines. In 
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addition, in vitro cell culture using human stromal cell conditioned media in a wound healing 
assay, utilising primary human epithelial cells, would allow further investigation of potential 
stromal secreted factors during breakdown and how they affect epithelial cell proliferation or 
migration.  
Neutralising antibodies to candidate targets would also maximise the output of this mouse 
model. For example, further investigation of MMP regulation in our refined model would 
confirm their role in the rapid onset of breakdown and tissue remodelling. DHT was shown 
to down-regulate Mmp-3 mRNA concentrations consistent with a dealy in shedding and 
separation of the functional layer from the basal layer.  Giving specific MMP inhibitors at 
the time of progesterone withdrawal would delineate potential roles for MMP-3 and MMP-9 
at different points in the early repair process. Macrophages were shown to increase during 
tissue remodelling; inhibition of macrophages by neutralisation antibodies would delineate 
their importance in this process. In vitro culture of macrophages with conditioned media 
would also enhance our knowledge on the factors that may regulate their recruitment.  
The mouse model focuses on a very short time frame, where repair mechanisms are initiated 
within 24 hours of progesterone withdrawal. In women, re-epithelialisation (in the absence 
of oestrogen) is complete by around day 3 of the average cycle, at this time ovarian derived 
oestrogen biosynthesis occurs to drive endometrial proliferation which contributes to overall 
remodelling of the tissue. One limitation of our model is that we have not investigated the 
effect of oestrogen on remodelling in our mouse model; administration of oestradiol at the 24 
hour time-point would enable investigation of how it contributes to restoration of tissue 
integrity and overall tissue homeostasis.  
Finally, androgens have been shown to have an effect on the “normal” breakdown and repair 
mechanisms in our mouse model and therefore their role at menses merits further study. 
Preliminary work, outlined in this thesis, has highlighted that a single dose of DHT is 
sufficient to disturb the dynamics of breakdown and repair. DHT appeared to maintain the 
decidual response; however it is unknown whether DHT is acting through the androgen 
receptor or through the progesterone receptor. Furthermore, it is unknown whether the 
changes in gene expression identified in Chapter 5 are through direct or indirect action of the 
androgen receptor. Utilising chromatin immunoprecipitation (chIP) will allow for 
identification of those genes which contain an androgen response element and therefore may 
be regulated directly or those that may be regulated indirectly through an Sp-1 or Ap-1 
binding site (outlined in Table 5-7) or another transcription factor. The list of candidate 
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genes will also be investigated for the presence of a progesterone response element to 
provide further insight into how DHT may be regulating these genes.  
6.4 Conclusions 
The data presented in this thesis provides evidence of a more relevant mouse model where 
breakdown and repair occur simultaneously, as in women. A previously unrecognised role 
for mesenchymal to epithelial transition was investigated, along with a putative role for 
androgens during endometrial repair. The results presented in this thesis have implications 
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Symbol Description Gene names 












Thymoma viral proto-oncogene 
1 
Akt/PKB/PKB/Akt/PKBalpha/Rac AKT(PKB) Mm.6645 NM_009652 
Bmp1 Bone morphogenetic protein 1 Pcp/Tld BMP1 Mm.27757 NM_009755 
Bmp7 Bone morphogenetic protein 7 OP1 BMP7 Mm.595 NM_007557 
Cald1 Caldesmon 1 
4833423D12Rik/AI195384/AV071549/AW53
6160/C920027I18Rik/MGC30319 
- Mm.308134 NM_145575 
Camk2n1 
Calcium/calmodulin-dependent 
protein kinase II inhibitor 1 
1810006K23Rik/AI848599/AI891706 - Mm.41603 NM_025451 
Cav2 Caveolin 2 AI447843 - Mm.396075 NM_016900 
Cdh1 Cadherin 1 
AA960649/Ecad/L-
CAM/MGC107495/UVO/Um 
E-cadherin  Mm.35605 NM_009864 
Cdh2 Cadherin 2 CDHN/N-cadherin/Ncad N-cadherin Mm.257437 NM_007664 
Col1a2 Collagen, type I, alpha 2 
AA960264/AI325291/Col1a-2/Cola-
2/Cola2/oim 
Collagen I Mm.277792 NM_007743 
Col3a1 Collagen, type III, alpha 1 
AW550625/Col3a-1/KIAA4231/MMS10-
W/Ms10w/mKIAA4231 
Collagen III Mm.249555 NM_009930 
Col5a2 Collagen, type V, alpha 2 1110014L14Rik/D230017N05 Collagen V Mm.10299 NM_007737 
Ctnnb1 
Catenin (cadherin associated 
protein), beta 1 
Bfc/Catnb/Mesc β-catenin Mm.291928 NM_007614 
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EGFR Mm.8534 NM_007912 
Erbb3 
V-erb-b2 erythroblastic 
leukemia viral oncogene 
homolog 3 (avian) 
C76256/Erbb-3/Erbb3r/Her3/MGC117742 - Mm.373043 NM_010153 




ESR Mm.9213 NM_007956 
F11r F11 receptor 
9130004G24/AA638916/ESTM33/JAM/JAM
-1/JAM-A/Jcam/Jcam1/Ly106 
- Mm.294882 NM_172647 
Fgfbp1 
Fibroblast growth factor 
binding protein 1 
FGF-BP - Mm.46053 NM_008009 
Fn1 Fibronectin 1 E330027I09/Fn/Fn-1/MGC117493 Fibronectin Mm.193099 NM_010233 
Foxc2 Forkhead box C2 Fkh14/Hfhbf3/MFH-1/Mfh1 FOXC1/2 Mm.14092 NM_013519 
Fzd7 
Frizzled homolog 7 
(Drosophila) 
Fz7 Frizzled Mm.297906 NM_008057 
Gng11 
Guanine nucleotide binding 
protein (G protein), gamma 11 
0610037B21Rik - Mm.25547 NM_025331 
Gsc Goosecoid homeobox - - Mm.129 NM_010351 
Gsk3b 




- Mm.394930 NM_019827 
Igfbp4 
Insulin-like growth factor 
binding protein 4 
AI875747/Deb2/IGFBP-4 - Mm.233799 NM_010517 
Il1rn 
Interleukin 1 receptor 
antagonist 
F630041P17Rik/IL-1ra - Mm.882 NM_031167 
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Integrin alpha 5 (fibronectin 
receptor alpha) 
Cd49e/Fnra/VLA5 - Mm.16234 NM_010577 
Itgav Integrin alpha V 
1110004F14Rik/2610028E01Rik/CD51/D430
040G12Rik 
- Mm.227 NM_008402 
Itgb1 





alpha-8/beta-1 integrin Mm.263396 NM_010578 
Jag1 Jagged 1 Htu/Ozz/Ser-1 Jagged1 Mm.22398 NM_013822 
Krt14 Keratin 14 AI626930/K14/Krt-1.14/Krt1-14 - Mm.439898 NM_016958 
Krt19 Keratin 19 
AI663979/EndoC/K19/Krt-1.19/Krt1-
19/MGC25344 
Keratin 19 Mm.439699 NM_008471 






MITF Mm.333284 NM_008601 
Mmp2 Matrix metallopeptidase 2 Clg4a/GelA/MMP-2 MMP-2 Mm.29564 NM_008610 
Mmp3 Matrix metallopeptidase 3 SLN-1/SLN1/STR-1/Stmy1/Str1 Stromelysin-1 Mm.4993 NM_010809 
Mmp9 Matrix metallopeptidase 9 
AW743869/B/MMP9/Clg4b/MMP-9/pro-
MMP-9 
MMP-9 Mm.4406 NM_013599 
Msn Moesin C78546 - Mm.138876 NM_010833 
Mst1r 
Macrophage stimulating 1 
receptor (c-met-related tyrosine 
kinase) 










Symbol Description Gene names 
Gene Name used in Metacore™ 
analysis 
Unigene Refseq 
Nodal Nodal Tg.413d NODAL Mm.57195 NM_013611 
Notch1 
Notch gene homolog 1 
(Drosophila) 
9930111A19Rik/Mis6/Tan1/lin-12 Notch (and Notch1 receptor) Mm.290610 NM_008714 
Nudt13 
Nudix (nucleoside diphosphate 
linked moiety X)-type motif 13 
4933433B15Rik - Mm.317636 NM_026341 
Ocln Occludin AI503564/Ocl Occludin Mm.4807 NM_008756 
Pdgfrb 
Platelet derived growth factor 
receptor, beta polypeptide 
AI528809/CD140b/Pdgfr PDGF receptor Mm.4146 NM_008809 
Plek2 Pleckstrin 2 - - Mm.103380 NM_013738 
Pppde2 
PPPDE peptidase domain 
containing 2 
AI427858/AI850401/D15Wsu75e/Fam152b - Mm.474453 NM_134095 
Ptk2 PTK2 protein tyrosine kinase 2 FAK/FRNK/Fadk/KIAA4203/mKIAA4203 FAK1 Mm.254494 NM_007982 
Ptp4a1 




- Mm.374437 NM_011200 
Rac1 
RAS-related C3 botulinum 
substrate 1 
AL023026/D5Ertd559e Rac1 Mm.292510 NM_009007 
Rgs2 
Regulator of G-protein 
signaling 2 
GOS8  Mm.28262 NM_009061 
Serpine1 
Serine (or cysteine) peptidase 
inhibitor, clade E, member 1 
PAI-1/PAI1/Planh1 - Mm.250422 NM_008871 
Sip1 
Survival of motor neuron 
protein interacting protein 1 
1700012N19Rik/Gemin2 SIP1 (ZFHX1B) Mm.35353 NM_025656 
Smad2 MAD homolog 2 (Drosophila) Madh2/Madr2 SMAD2 Mm.391091 NM_010754 
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Gene Name used in Metacore™ 
analysis 
Unigene Refseq 
Snai2 Snail homolog 2 (Drosophila) Slug/Slugh/Snail2 SLUG Mm.4272 NM_011415 
Snai3 Snail homolog 3 (Drosophila) AI643946/Smuc/Zfp293 - Mm.103673 NM_013914 
Sox10 SRY-box containing gene 10 Dom/Sox21 - Mm.276739 NM_011437 
Sparc 
Secreted acidic cysteine rich 
glycoprotein 
AA517111/BM-40 Osteonectin Mm.291442 NM_009242 
Spp1 Secreted phosphoprotein 1 
2AR/Apl-1/BNSP/BSPI/Bsp/ETA-
1/Eta/OP/Opn/Opnl/Ric/Spp-1 
Osteopontin Mm.288474 NM_009263 
Stat3 
Signal transducer and activator 
of transcription 3 
1110034C02Rik/AW109958/Aprf - Mm.249934 NM_011486 
Steap1 
Six transmembrane epithelial 
antigen of the prostate 1 
2410007B19Rik/Prss24/Steap - Mm.85429 NM_027399 




ITF2 Mm.4269 NM_013685 
      
Tcf7l1 
Transcription factor 7-like 1 (T-
cell specific, HMG box) 
Tcf-3/Tcf3/bHLHb21 - Mm.440067 NM_009332 
Tfpi2 
Tissue factor pathway inhibitor 
2 
AV000670/PP5/TFPI-2 TFPI-2 Mm.25612 NM_009364 
Tgfb1 
Transforming growth factor, 
beta 1 
TGF-beta1/TGFbeta1/Tgfb/Tgfb-1 TGF Beta Mm.248380 NM_011577 
Tgfb2 
Transforming growth factor, 
beta 2 
BB105277/Tgf-beta2/Tgfb-2 TGF beta Mm.18213 NM_009367 
Tgfb3 
Transforming growth factor, 
beta 3 
MGC118722/Tgfb-3 TGF beta Mm.3992 NM_009368 
Timp1 
Tissue inhibitor of 
metalloproteinase 1 
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Transmembrane protein with 
EGF-like and two follistatin-
like domains 1 
A830033E11/M7365/Tr1 - Mm.422686 NM_021436 
Tmem13
2a 
Transmembrane protein 132A 6720481D13Rik/Hspa5bp1/Orai1/R74613 - Mm.27387 NM_133804 
Tspan13 Tetraspanin 13 1100001I23Rik/NET-6/Tm4sf13 - Mm.254663 NM_025359 








Versican proteoglycan Mm.158700 
NM_0010812
49 
Vim Vimentin MGC102095 Vimentin Mm.268000 NM_011701 
Vps13a 





- Mm.211963 NM_173028 
Wnt11 
Wingless-related MMTV 
integration site 11 
- WNT Mm.22182 NM_009519 
Wnt5a 
Wingless-related MMTV 
integration site 5A 
8030457G12Rik/Wnt-5a WNT Mm.287544 NM_009524 
Wnt5b 
Wingless-related MMTV 
integration site 5B 
AW545702/Wnt-5b WNT Mm.321818 NM_009525 
Zeb1 





TCF8 Mm.3929 NM_011546 
Zeb2 




- Mm.440702 NM_015753 
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Thymoma viral proto-oncogene 
1 
Akt/PKB/PKB/Akt/PKBalpha/Rac AKT (PKB) Mm.6645 NM_009652 
Ang 
Angiogenin, ribonuclease, 
RNase A family, 5 
AI385586/Ang1/Rnase5/Rnase5a - N/A NM_007447 
Angpt1 Angiopoietin 1 1110046O21Rik/Ang-1/Ang1 Angiopoietin 1 Mm.309336 NM_009640 










- Mm.43133 NM_174991 
Ccl11 
Chemokine (C-C motif) ligand 
11 
Scya11/eotaxin Eotaxin Mm.4686 NM_011330 
Ccl2 




- Mm.290320 NM_011333 
Cdh5 Cadherin 5 
7B4/AA408225/Cd144/VE-
Cad/VECD/VEcad/Vec 
VE-cadherin Mm.21767 NM_009868 
Col18a1 Collagen, type XVIII, alpha 1 - Endostatin Mm.4352 NM_009929 
Col4a3 Collagen, type IV, alpha 3 [a]3(IV)/alpha3(IV) Collagen IV Mm.389135 NM_007734 
Csf3 
Colony stimulating factor 3 
(granulocyte) 
Csfg/G-CSF/MGI-IG - Mm.1238 NM_009971 
Ctgf Connective tissue growth factor Ccn2/Fisp12/Hcs24/fisp-12 CTGF Mm.390287 NM_010217 
Cxcl1 
Chemokine (C-X-C motif) 
ligand 1 
Fsp/Gro1/KC/Mgsa/N51/Scyb1/gro - Mm.21013 NM_008176 
Cxcl2 
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Chemokine (C-X-C motif) 
ligand 5 
AMCF-II/ENA-78/GCP-2/LIX/Scyb5/Scyb6 - Mm.4660 NM_009141 
Edn1 Endothelin 1 ET-1/preproET Endothelin-1 Mm.14543 NM_010104 
Efna1 Ephrin A1 AI325262/B61/Efl1/Epl1/Eplg1/Lerk1 - Mm.15675 NM_010107 
Efnb2 Ephrin B2 
ELF-2/Epl5/Eplg5/Htk-L/LERK-
5/Lerk5/NLERK-1 
- Mm.209813 NM_010111 
Egf Epidermal growth factor AI790464 - Mm.252481 NM_010113 
Eng Endoglin AI528660/AI662476/CD105/S-endoglin Endoglin Mm.225297 NM_007932 
Epas1 




EPAS1/ARNT Mm.1415 NM_010137 
Ephb4 Eph receptor B4 AI042935/Htk/MDK2/Myk1/Tyro11 - Mm.34533 NM_010144 
Erbb2 
V-erb-b2 erythroblastic 
leukemia viral oncogene 
homolog 2, neuro/glioblastoma 







F2 Coagulation factor II Cf-2/Cf2/FII/thrombin Thrombin Mm.89048 NM_010168 
F3 Coagulation factor III AA409063/CD142/Cf-3/Cf3/TF Tissue Factor Mm.273188 NM_010171 
Fgf1 Fibroblast growth factor 1 Dffrx/Fam/Fgf-1/Fgfa FGF1 Mm.241282 NM_010197 




Symbol Description Gene Names 
Gene Name used in Metacore™ 
analysis 
Unigene Refseq 
Fgf6 Fibroblast growth factor 6 Fgf-6/HSTF-2 - Mm.3403 NM_010204 
Fgfr3 
Fibroblast growth factor 
receptor 3 
CD333/FR3/Fgfr-3/Flg-2/HBGFR/Mfr3/sam3 FGFR3 Mm.6904 NM_008010 
Figf C-fos induced growth factor AI325264/VEGF-D/Vegfd VEGF-D Mm.297978 NM_010216 
Flt1 FMS-like tyrosine kinase 1 AI323757/Flt-1/VEGFR-1/VEGFR1/sFlt1 VEGFR1 Mm.389712 NM_010228 
Fn1 Fibronectin 1 E330027I09/Fn/Fn-1/MGC117493 Fibronectin Mm.193099 NM_010233 
Hgf Hepatocyte growth factor C230052L06Rik/HGF/SF/NK1/NK2/SF/HGF HGF Mm.267078 NM_010427 
Hif1a 
Hypoxia inducible factor 1, 
alpha subunit 
AA959795/HIF1alpha/MOP1/bHLHe78 HIF1A/ARNT2 Mm.3879 NM_010431 
Ifng Interferon gamma IFN-g/Ifg - Mm.240327 NM_008337 
Igf1 Insulin-like growth factor 1 C730016P09Rik/Igf-1/Igf-I IGF-1 Mm.268521 NM_010512 
Il1b Interleukin 1 beta IL-1beta/Il-1b - Mm.222830 NM_008361 
Il6 Interleukin 6 Il-6 IL-6 Mm.1019 NM_031168 
Itgav Integrin alpha V 
1110004F14Rik/2610028E01Rik/CD51/D430
040G12Rik 
Alpha-V/beta-1 integrin Mm.227 NM_008402 
Itgb3 Integrin beta 3 
CD61/GP3A/INGRB3/MGC159221/MGC159
223 
- Mm.87150 NM_016780 
Jag1 Jagged 1 Htu/Ozz/Ser-1 Jagged1 Mm.22398 NM_013822 
Kdr 
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Leukocyte cell derived 
chemotaxin 1 
ChM-I - Mm.46561 NM_010701 







p38 MAPK Mm.311337 NM_011951 
Mdk Midkine MK/Mek - Mm.906 NM_010784 
Mmp14 
Matrix metallopeptidase 14 
(membrane-inserted) 
AI325305/MT-MMP-1/MT1-MMP MMP-14 Mm.280175 NM_008608 
Mmp19 Matrix metallopeptidase 19 MGC123370 MMP-19 Mm.131266 NM_021412 
Mmp2 Matrix metallopeptidase 2 Clg4a/GelA/MMP-2 MMP-2 Mm.29564 NM_008610 
Mmp9 Matrix metallopeptidase 9 
AW743869/B/MMP9/Clg4b/MMP-9/pro-
MMP-9 
MMP-9 Mm.4406 NM_013599 
Nos3 
Nitric oxide synthase 3, 
endothelial cell 
2310065A03Rik/Nos-3/eNOS/ecNOS eNOS Mm.258415 NM_008713 
Nrp1 Neuropilin 1 C530029I03/NP-1/NPN-1/Npn1/Nrp Neuropilin Mm.271745 NM_008737 
Nrp2 Neuropilin 2 1110048P06Rik/Np-2/Np2/Npn-2/Npn2 - Mm.266341 NM_010939 
Pdgfa 
Platelet derived growth factor, 
alpha 
- - Mm.2675 NM_008808 
Pecam1 
Platelet/endothelial cell 
adhesion molecule 1 
C85791/Cd31/MGC102160/PECAM-1/Pecam PECAM-1 Mm.343951 NM_008816 
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COX1/Cox-1/Cox-3/Pghs1 - Mm.275434 NM_008969 




AI849002/Edg1/Lpb1/S1p/S1p1 S1P1 receptor Mm.982 NM_007901 
Serpine1 
Serine (or cysteine) peptidase 
inhibitor, clade E, member 1 
PAI-1/PAI1/Planh1 - Mm.250422 NM_008871 
Serpinf1 
Serine (or cysteine) peptidase 
inhibitor, clade F, member 1 
AI195227/EPC-1/Pedf/Pedfl/Sdf3 - Mm.2044 NM_011340 
Smad5 MAD homolog 5 (Drosophila) 
1110051M15Rik/AI451355/Dwf-
C/Madh5/MusMLP 
SMAD5 Mm.272920 NM_008541 
Sphk1 Sphingosine kinase 1 1110006G24Rik/Sk1/Spk1 SPHK1 Mm.20944 NM_025367 




AA517024/Cd202b/Hyk/Tie2/tie-2 Tie2 Mm.14313 NM_013690 
Tgfa 
Transforming growth factor 
alpha 
wa-1/wa1 - Mm.137222 NM_031199 
Tgfb1 
Transforming growth factor, 
beta 1 
TGF-beta1/TGFbeta1/Tgfb/Tgfb-1 TGF-beta Mm.248380 NM_011577 
Tgfb2 
Transforming growth factor, 
beta 2 
BB105277/Tgf-beta2/Tgfb-2 TGF-beta Mm.18213 NM_009367 
Tgfb3 
Transforming growth factor, 
beta 3 
MGC118722/Tgfb-3 TGF-beta Mm.3992 NM_009368 
Tgfbr1 
Transforming growth factor, 
beta receptor I 
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Thbs1 Thrombospondin 1 TSP-1/TSP1/Thbs-1/tbsp1 Thrombospondin 1 Mm.4159 NM_011580 
Thbs2 Thrombospondin 2 TSP2/Thbs-2 - Mm.26688 NM_011581 
Tie1 
Tyrosine kinase with 
immunoglobulin-like and EGF-
like domains 1 
D430008P04Rik/TIE/tie-1 TIE Mm.4345 NM_011587 
Timp1 
Tissue inhibitor of 
metalloproteinase 1 
Clgi/MGC7143/TIMP-1/Timp TIMP1 Mm.8245 NM_011593 
Timp2 
Tissue inhibitor of 
metalloproteinase 2 
D11Bwg1104e/Timp-2 TIMP2 Mm.206505 NM_011594 
Tnf Tumor necrosis factor 
DIF/MGC151434/TNF-
alpha/TNFSF2/TNFalpha/Tnfa/Tnfsf1a 
- Mm.1293 NM_013693 
Tnfsf12 
Tumor necrosis factor (ligand) 
superfamily, member 12 
Apo3l/Dr3l/Dr3lg/Tweak - Mm.344820 NM_011614 
Tymp Thymidine phosphorylase 
2900072D10Rik/Ecgf1/PD-
ECGF/PDECGF/Pdgfec 
- Mm.287977 NM_138302 
Vegfa 
Vascular endothelial growth 
factor A 
Vegf/Vegf120/Vegf164/Vegf188/Vpf VEGF-A Mm.282184 NM_009505 
Vegfb 
Vascular endothelial growth 
factor B 
VEGF-B/Vrf VEGF-B Mm.15607 NM_011697 
Vegfc 
Vascular endothelial growth 
factor C 
AW228853/VEGF-C VEGF-C Mm.1402 NM_009506 
Supplementary Table 2: Angiogenesis array gene list. 
 
